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Introduction
Human immunodeﬁ ciency virus 
Patients living with the acquired immunodeﬁ enciency syndrome (AIDS) are 
infected with the human immunodeﬁ ciency virus (HIV). HIV belongs to the class 
of retroviruses and destructs the patients’ immune response. Th e virus depletes T 
lymphocytes, expressing the CD4 phenotypic marker. Th is destruction takes place 
gradually and in the late stage of the disease, with CD4 cells dropping below 200 per 
µl, there is an increasing chance for opportunistic infections, if no medical treatment 
is given1. Several pathways transmit HIV, such as unprotected sexual intercourse, 
sharing of contaminated injection needles, receipt of contaminated blood products 
and mother-to-child transmission. Mother-to-child transmission can occur in uterus, 
which is rare, during delivery, or post partum when the newborn is breastfed. In the 
ﬁ ght against the spread of HIV, consciousness of these pathways is very important. 
Worldwide around 40 million people are infected with HIV-1, this number includes 
around 4 million children living with HIV infection2. A distinction is made between 
HIV-1 and HIV-2, the latter being less virulent and pathogenic. HIV-2 has a lower 
prevalence than HIV-1 and is seen primarily in West-Africa3,4. Th e treatment of HIV 
as studied in this thesis concerns HIV-1 infection. Although the treatment of children 
with HIV remains challenging5, this thesis deals with HIV-1 infection in adults. 
Antiretroviral agents
Antiretroviral agents play a key-role in the treatment of HIV-1-infected persons. In 
contrast to the early days of HIV treatment where single agents were used, nowadays 
combinations of several agents have high success rates6-8. Th e success rate of highly 
active antiretroviral therapy (HAART) however is not 100%. HAART can inhibit 
replication of the virus, but cannot eradicate it. For this reason patients with HIV 
infection need to continue their medication life-long to suppress the virus. To monitor 
the eﬀ ect of therapy the viral load is measured. Th e viral load is the number of viral 
RNA copies per ml, in the blood of the patient. Th erapy is considered successful if 
the viral load is undetectable on an ongoing basis. With current techniques the lower 
limit of detection for the viral load is 50 copies/ml. A detectable viral load is a sign 
for virological failure or treatment failure9. Reasons for treatment failure can be very 
divers and involve the trias of patient, virus and drug10.
Nowadays, more than 20 years after the start of the pandemic of HIV there are 18 
diﬀ erent antiretroviral agents available. Th ese agents are divided over ﬁ ve diﬀ erent 
groups. In Table 1 an overview of the available antiretrovirals is provided.
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Table 1. Overview of available antiretroviral agents by group.
Clinical pharmacology
Th e popular medical science search engine pub med (www.pubmed.com) reported 
more than 30,000 hits, at the time that this thesis was written, when the keywords 
“pharmacology” and “HIV” were used. Th e oldest hits were from the ﬁ rst days of the 
HIV epidemic in the beginning of the 80’s. Th is ﬁ nding represents an impressive 
number of articles published with regard to the studies of drugs (pharmacology11) in 
the era of HIV. Th is number also represents the complexity of clinical pharmacology 
(studies of drugs in men12) of antiretroviral drugs. Apparently, after all these years 
of hard work there is still need for more knowledge of the ever-changing HAART 
regimens. 
Clinical pharmacology can be divided in a pharmacokinetic and a pharmacodynamic 
part. Pharmacokinetics is the knowledge about the eﬀ ects of the human body on the 
drug, whereas pharmacodynamics describes what the drug is doing to the body. In 
clinical pharmacology of antiretroviral agents there is a central role for the relationship 
between concentration of the drugs in blood and their eﬃ  cacy and toxicity. 
With the development of new drugs new questions arise with regard to 
pharmacokinetics and pharmacodynamics. Fields of interest with regard to clinical 
pharmacology of antiretroviral agents are: drug interactions, dose optimization and 
additional parameters like gender, race and pharmacogenetics. 
NRTIs NtRTI NNRTIs PIs Fusion inhibitors
zidovudine tenofovir nevirapine amprenavir enfuvirtide 
stavudine  efavirenz fosamprenavir  
lamivudine  delarvidine indinavir  
abacavir   nelfinavir  
emtricitabine   saquinavir  
didanosine   lopinavir  
zalcitabine   ritonavir  
   atazanavir  
NRTIs : Nucleoside reverse transcriptase inhibitors, NtRTI : Nucleotide reverse transcriptase inhibitor, 
NNRTIs : Non nucleoside reverse transcriptase inhibitors, PIs : Protease inhibitors. 
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Drug interactions
Drug interactions are common in HAART regimens. Th e protease inhibitors as well 
as the NNRTIs are susceptible to pharmacokinetic drug interactions. Metabolism 
of these agents greatly depends on Cytochrome P450 (CYP) isoenzymes. CYP 
isoenzymes are known to be vulnerable to induction or inhibition by other drugs. Two 
well known examples are rifampin, a tuberculostatic agent, for its inducing eﬀ ect on 
CYP3A413,14 and ritonavir, a protease inhibitor, for its inhibiting eﬀ ect on the same 
isoenzyme15. In practice co-administration of rifampin will greatly accelerate CYP3A4 
metabolism of several drugs such as lopinavir16 and saquinavir17, whereas ritonavir 
will slow down the metabolism of the same drugs. Drug interactions were studied in 
Chapter 1 for lopinavir/ritonavir combined with rifampin and in Chapter 6 for the 
combination of nelﬁ navir/ritonavir and efavirenz.
Interactions can also occur between food and drugs. Th e protease inhibitors lopinavir 
and nelﬁ navir have to be taken with a meal to ensure a good absorption from the 
gastrointestinal tract18,19. Other drugs such as didanosine are susceptible for acid from 
the stomach and are therefore preferably not combined with food20. Drug interactions 
and food eﬀ ects were studied in a combination of indinavir/ritonavir with didanosine 
in Chapter 4.
Drug interactions can have a pharmacodynamic background as well. Combining drugs 
that exhibit synergism can be useful in the treatment of patients, as the combined 
antiviral activity of the two drugs is higher than the sum of the activity of the two 
independent drugs. Synergism of antiretroviral activity has been reported for lopinavir 
and saquinavir21. Other combinations of drugs can antagonize each other’s activity, 
leading to less activity than the sum of the activity of each drug. In Chapter 2 the 
pharmacokinetics, tolerability and eﬃ  cacy of lopinavir combined with saquinavir 
were studied.
Dose optimization
In the development of new antiretroviral agents, as in the development of any other 
drug, studies are undertaken to ﬁ nd a dose at which patients experience an optimal 
eﬀ ect of the medication, without suﬀ ering from adverse events. In clinical practice 
however, situations might occur in which the recommended dose does not have the 
desired eﬀ ect. Th is might be the case when drug interactions are expected, or when 
dose frequency is changed, or if unexpected toxicity or inactivity occurs. 
Knowledge of drug interactions can give reasons for dose optimizations to ensure equal 
exposure to the drug aﬀ ected by the interacting drug. For example rifampin is known 
to induce lopinavir metabolism, leading to subtherapeutic blood concentrations of 
lopinavir16. In this particular situation an adjusted dose of lopinavir might compensate 
for the accelerated metabolism. Dose adjustments of lopinavir/ritonavir to compensate 
Introduction
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for the inducing eﬀ ect of rifampin were studied in Chapter 1.
Dose frequency is an important factor in the development of HAART regimens. 
Currently most HAART regimens allow for twice daily dosing. For the patient it can 
be more convenient and probably more easily to adhere to if dose frequency is less 
frequent22,23. For some agents it seems reasonable to give the daily dose in one dose rather 
than divided over two doses24. Nevertheless this should be tested with pharmacokinetic 
proﬁ les to study the exposure to the drug. If necessary, dose adjustments can be made 
to ﬁ nd the right dose in each patient. Chapter 3 is the reﬂ ection of a study in which 
dose adjustments were made subsequently to reducing dose frequency from twice daily 
to once daily for lopinavir/ritonavir.
Th e occurrence of adverse events sometimes compels to a more balanced optimum 
between eﬃ  cacy and toxicity. Th e protease inhibitor indinavir is normally given with 
ritonavir dosed as 800/100 mg twice daily25. It was found that patients receiving this 
combination stopped their medication for reasons of toxicity more often than for a 
lack of eﬃ  cacy26. A dose reduction of indinavir to 600 or 400 mg might lead to less 
adverse events, without losing antiviral activity. Chapter 5 presents a study in healthy 
subjects exploring the pharmacokinetic proﬁ le of these reduced doses in order to 
predict indinavir exposure in patients.
Th erapeutic drug monitoring in individual patients can detect drug concentrations 
that are too low to be antiviral active. In such cases an intervention is necessary. In 
some cases a dose increase will result in the desired eﬀ ect, nevertheless there are very 
few data that support such measures. In Chapter 7 the eﬀ ect of dose increases in 
patients with low plasma nelﬁ navir concentrations was evaluated.
 
Other parameters in clinical pharmacology
Gender, race and pharmacogenetics are three other parameters that can have their 
inﬂ uence on the clinical pharmacology of antiretroviral agents. 
Several studies have shown pharmacokinetic diﬀ erences between males and 
females27-29, and between patients of diﬀ erent ethnicity30-33. Th e observed diﬀ erences 
are not always large and considerable numbers of patients should be studied to observe 
these diﬀ erences. In general, drug exposure, with same dosage for males and females, 
seems to be higher in females. Th is might put females at higher risk for toxicity. In 
Chapter 8 gender and race diﬀ erences for nevirapine pharmacokinetics were studied.
Pharmacogenetic studies evaluate the eﬀ ect of genetic polymorphism on clinical 
pharmacology. Single nucleotide polymorphisms (SNPs) leading to genetic 
heterogeneity can cause variability in disposition of P450 isoenzymes34-36. Diﬀ erent 
genotypes of P450 isoenzymes, due to SNPs, could result in an altered drug metabolism 
in individual patients37. Currently SNPs and their eﬀ ects on drug disposition are subject 
of research and the knowledge of SNPs is therefore expanding. Th e antiretrovirals of 
the NNRTI and PI groups are supposed to be vulnerable for this source of variability, 
16
Introduction
as they greatly depend on P450 isoenzyme mediated metabolism. A pharmacogenetic 
study for efavirenz is described in Chapter 9.
Objectives of this thesis
Th is thesis is a presentation of studies that were undertaken to shed more light on the 
clinical pharmacology of antiretroviral agents. In particular drug interactions and dose 
optimizations were studied. Additionally, studies were performed to learn about the 
role of gender, race and pharmacogenetics in the clinical pharmacology of antiretroviral 
agents. Multiple objectives were studied in some of the chapters in this thesis, whereas 
single objectives were studied in others. Studies with the protease inhibitors lopinavir, 
indinavir and nelﬁ navir are presented in Parts I, II and III, respectively. Part IV 
focuses on the group of non-nucleoside reverse transcriptase inhibitors. Finally, a 
general discussion is presented.
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Lopinavir
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lopinavir/ritonavir combined with 
rifampin in healthy volunteers
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Abstract
Coadministration of lopinavir/ritonavir, an antiretroviral protease inhibitor, at 
the standard dose (400/100 mg twice a day [BID]) with the antituberculous agent 
rifampin is contraindicated because of a signiﬁ cant pharmacokinetic interaction due 
to induction of cytochrome P450 3A by rifampin. In the present study, two adjusted-
dose regimens of lopinavir/ritonavir were tested in combination with rifampin. 
Th irty-two healthy subjects participated in a randomized, two-arm, open-label, 
multiple-dose, within-subject controlled study. All subjects were treated with lopinavir/
ritonavir at 400/100 mg BID from days 1 to 15. From days 16 to 24, the subjects in arm 
1 received lopinavir/ritonavir at 800/200 mg BID in a dose titration, and the subjects 
in arm 2 received lopinavir/ritonavir at 400/400 mg BID in a dose titration. Rifampin 
was given at 600 mg once daily to all subjects from days 11 to 24. Th e multiple-dose 
pharmacokinetics of lopinavir, ritonavir, and rifampin were assessed. 
Twelve of 32 subjects withdrew from the study. For nine subjects lopinavir/ritonavir 
combined with rifampin resulted in liver enzyme level elevations. Pharmacokinetic 
data for 19 subjects were evaluable. Geometric mean ratios for the lopinavir minimum 
concentration in serum and the maximum concentration in serum (Cmax) on day 24 
versus that on day 10 were 0.43 (90% conﬁ dence interval [CI], 0.19 to 0.96) and 1.02 
(90% CI, 0.85 to 1.23), respectively, for arm 1 (n=10) and 1.03 (90% CI, 0.68 to 1.56) 
and 0.93 (90% CI, 0.81 to 1.07), respectively, for arm 2 (n=9). Ritonavir exposure 
increased from days 10 to 24 in both arms. Th e geometric mean Cmax of rifampin was 
13.5 mg/liter (day 24) and was similar between the two arms. 
Adjusted dose regimens of lopinavir/ritonavir in combination with therapeutic drug 
monitoring and monitoring of liver function may allow concomitant use of rifampin. 
Lopinavir/ritonavir combined with rifampin
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Introduction
Th e treatment of human immunodeﬁ ciency virus (HIV)-infected individuals has 
improved greatly over the past several years. With the development of antiretroviral 
agents in diﬀ erent classes, more options for the eﬀ ective suppression of the virus have 
become available1. However, many problems remain to be solved. One of them is the 
treatment of patients presenting with HIV infection and coinfections. Tuberculosis 
is a signiﬁ cant opportunistic infection in HIV-infected individuals in developing 
countries and, to a lesser extent, in developed countries2-5. For public health reasons, 
active tuberculosis must be treated immediately5. Th e treatment of HIV infection can 
be postponed on the basis of CD4 cell counts and the viral load. However, depending on 
the clinical and biochemical parameters for coinfected patients, simultaneous treatment 
of both infections can become indicated in particular situations. Th e combination 
of antiretroviral therapy with therapy with antituberculous agents is complex. In 
particular, the use of rifampin is hampered due to signiﬁ cant drug drug interactions. 
Rifampin is a ﬁ rst-line antibacterial agent for the treatment of tuberculosis and acts by 
inhibiting the DNA-dependent RNA polymerase of the microorganism6. Rifampin is 
a strong inducer of cytochrome P450 (CYP)-mediated metabolism of other agents; in 
particular, the CYP3A isoenzyme is subject to induction. Rifampin metabolism itself 
is not dependent on CYP3A; nevertheless, autoinduction of cholinesterase- and B 
esterase-mediated metabolism of rifampin has been shown6. 
Because of its CYP3A-inducing eﬀ ects, rifampin is known to produce signiﬁ cant 
pharmacokinetic interactions with HIV protease inhibitors (PIs) and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs)7. Th ese pharmacokinetic interactions may 
lead to subtherapeutic levels of these antiretroviral agents in plasma, and for this reason, 
rifampin in combination with most PIs and NNRTIs is contraindicated. Th is clearly 
limits the options for highly active antiretroviral therapy in Mycobacterium tuberculosis-
coinfected HIV-infected patients. Data on the adjusted dosages that generally result 
in therapeutic levels of the antiretrovirals in plasma have been published for the PI 
saquinavir8 and the NNRTI efavirenz9. Pharmacokinetic interactions between 
rifampin and nucleoside reverse transcriptase inhibitors (NRTIs) are less pronounced, 
since these agents do not undergo appreciable oxidative metabolism10,11. A study of 
the interaction of rifampin with T-20 (enfuvirtide) did not reveal clinically signiﬁ cant 
changes in the pharmacokinetics of T-2012. 
Lopinavir/ritonavir is a formulation of two PIs approved for the treatment of HIV 
infection at a standard dosage of 400/100 mg twice a day (BID) in combination with 
other antiretrovirals. Th e coformulation of lopinavir/ritonavir is available as capsules 
with a dose of 133 mg of lopinavir and 33 mg of ritonavir per capsule. Lopinavir is 
mainly dependent on CYP3A for its metabolism, and ritonavir is a strong inhibitor 
of CYP3A. For this reason, ritonavir is coformulated with lopinavir13, resulting in 
sustained and elevated plasma lopinavir levels. Th e pharmacokinetic interaction 
between rifampin and lopinavir/ritonavir has been studied previously14. Th e area 
under the concentration-time curve (AUC) and the minimum concentration in 
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plasma (Cmin) for lopinavir in healthy subjects were reduced 75 and 99%, respectively, 
as a result of coadministration of rifampin at 600 mg once daily (QD) with lopinavir/
ritonavir at 400/100 mg BID. Th is is the direct result of the strong induction of 
CYP3A by rifampin, which overcomes the inhibition of CYP3A by low-dose ritonavir. 
Th erefore, rifampin combined with lopinavir/ritonavir in the standard-dose regimen 
is contraindicated. Th e objective of the present study was to investigate in healthy 
subjects the pharmacokinetics of two adjusted-dose regimens of lopinavir/ritonavir in 
combination with rifampin in comparison to the standard dose of lopinavir/ritonavir 
without rifampin.
Materials and methods
Study design
Th e study was designed as a randomized, phase I, open-label, two-arm, within-subject 
controlled study with 32 healthy subjects, both males and females. See Table 1 for 
details of the study design. Th e study consisted of a run-in period of 10 days in which 
lopinavir/ritonavir at the standard dose (400/100 mg BID as three coformulated 
capsules) was given to all subjects. On study day 10, the steady-state pharmacokinetics 
of lopinavir and ritonavir were determined over the daytime 12-h dosing interval. 
During study days 11 to 15, subjects were dosed with lopinavir/ritonavir at the 
standard dosage, and rifampin at 600 mg QD was added to the regimen. After study 
day 15, subjects were randomized to either arm 1 or arm 2. From day 16, a dose-
titration phase was started in order to diminish dose-related toxicity. In the last phase 
of the study (study days 18 to 24), the subjects in arm 1 were dosed with lopinavir/
ritonavir at 800/200 mg BID plus rifampin at 600 mg QD, while subjects in arm 2 
were dosed with lopinavir/ritonavir at 400/400 mg BID plus rifampin at 600 mg QD. 
Th e steady-state pharmacokinetics of lopinavir, ritonavir, and rifampin were studied 
on study day 24. 
During the study both rifampin and lopinavir/ritonavir were to be taken together 
immediately after breakfast in the morning; 12 h later, lopinavir/ritonavir was to be 
taken after dinner. For the pharmacokinetic analysis, the study subjects were conﬁ ned 
on the day prior to blood draw (days 9 and 23) until after the last blood draw on 
study days 10 and 24. From the day before the start of conﬁ nement, the subjects were 
not allowed to consume alcohol. During conﬁ nement, subjects consumed only the 
standardized scheduled meals and beverages provided at the research unit. Th e subjects 
fasted from midnight on study days 9 and 23 to the time of breakfast on study days 
10 and 24. Water intake was not allowed from 1 h before until 2 h after drug intake. 
Th e study medication was taken orally after breakfast (550 kcal, 28% fat) with 200 
ml of noncarbonated water. After the intake of medication the subjects had to remain 
in an upright position for at least 2 h. After dosing, the subjects continued fasting (no 
food or beverages) until 5 h after drug intake, at which time the subjects received a 
Lopinavir/ritonavir combined with rifampin
27
standardized lunch. Th e subjects received a standardized snack at 9 h following drug 
ingestion, and dinner was served after the last blood draw. Beverages (i.e., water, orange 
juice, apple juice, coﬀ ee, tea, and milk) were allowed ad libitum from 5 h after dosing 
until the end of the conﬁ nement period.
Table 1. Study design
Selection of subjects
Th is study was performed with healthy subjects. Th e inclusion criteria were the ability 
to sign voluntary informed consent; age 18 years or older; good health (i.e., the subject 
was not suﬀ ering from an acute or chronic illness and was not using medications); and 
a body mass index (BMI) lower than 30.0 for men and lower than 28.6 for women 
(body mass index is equal to weight [in kilograms]/height2 [in square meters]). Female 
subjects could not be of childbearing potential, deﬁ ned as being postmenopausal for at 
least 1 year or surgically sterile (by bilateral tubal ligation, bilateral oophorectomy, or 
hysterectomy), or could be of childbearing potential but practicing one of the following 
methods of birth control: condoms, sponge, foams, jellies, diaphragm or intrauterine 
device, vasectomy for the sexual partner, or total abstinence from sexual intercourse. 
Exclusion criteria were as follows: known hypersensitivity to lopinavir, ritonavir, or 
rifampin; positive test result for HIV; positive test result for hepatitis B or C virus; 
a tuberculin skin test reaction of more than 15 mm or a tuberculin skin test reaction 
of 1 to 15 mm with a chest X-ray with abnormalities consistent with tuberculosis; 
pregnancy or breastfeeding; body weight <50 kg; use of contact lenses; a history of 
pancreatitis; a history of alcohol abuse; and one or more of the following laboratory 
Timescale (Days) 
1–10a 11–15 randomisation 16 17 18–24a
Arm 1 
LPV/r 533/133 mg 
BID, RIF 
600 mg QD 
LPV/r 
667/167 mg BID 
RIF 
600 mg QD 
LPV/r  
800/200 mg BID 
RIF 
600 mg QD 
LPV/r 
400/100 mg 
BIDb
LPV/r 
400/100 mg 
BID, RIF 
600 mg QDc
Arm 2 
LPV/r 400/200 mg 
BIDd, RIF 
600 mg QD 
LPV/r 
400/300 mg BIDd
RIF 
600 mg QD 
LPV/r  
400/400 mg BIDd
RIF 
600 mg QD 
 
LPV/r: lopinavir/ritonavir, RIF: rifampin 
aon days 10 and 24, blood sampling was performed up to 12 hours post ingestion. 
b LPV/r was coformulated in capsules containing 133 mg lopinavir and 33 mg ritonavir each. A dose of 400/100 
mg lopinavir/ritonavir BID therefore consisted of 3 capsules. 
c RIF was dosed as 2 capsules of containing 300 mg rifampin each. 
d In the combinations LPV/r 400/200 mg BID, LPV/r 400/300 mg BID and LPV/r 400/400 mg BID the extra 
ritonavir was dosed as 100 mg capsules ritonavir, in addition to the normal LPV/r 400/100 mg combination. 
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test results: hemoglobin concentration, <7.5 mM; leukocyte count, <3 x 109/liter; 
aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) levels 
more than two times the upper limit of normal (ULN); γ-glutamyltransferase (GGT) 
levels more than two times the ULN; alkaline phosphatase levels more than two times 
the ULN; serum creatinine levels more than 1.5 times the ULN; (pancreatic) amylase 
levels more than two times the ULN; or total bilirubin levels more than two times 
the ULN.
Blood sampling procedure
For determination of lopinavir and ritonavir concentrations, blood samples (5 
ml) were collected predosing and at 2, 4, 6, 8, 10, and 12 h postingestion on days 
10 and 24. Rifampin concentrations were determined with the same samples used 
for determination of lopinavir and ritonavir concentrations on day 24. However, 
additional blood samples (5 ml) for the more precise determination of the maximum 
concentration in plasma (Cmax) for rifampin were drawn at 1 and 3 h postingestion on 
day 24. Th e subjects returned to the study location on study days 1, 3, 7, 13, 16, 17, 
18, 20, and 22 for predose blood sampling (5 ml) for determination of lopinavir and 
ritonavir concentrations. Blood samples were centrifuged at approximately 1,000 x g 
for 10 min at 4°C. Plasma for determination of lopinavir and ritonavir concentrations 
was transferred to a labeled polypropylene tube and stored at ≤–18°C within 2 h after 
collection. Plasma for determination of rifampin concentrations was transferred to a 
labeled polypropylene tube containing ascorbic acid and was stored at ≤–80°C within 
2 h after collection. 
Bioanalysis 
Plasma lopinavir and ritonavir levels were determined by a validated high-performance 
liquid chromatography (HPLC) method, which was a modiﬁ ed version of a previously 
published method15. Th e modiﬁ cation consisted of a switch of the UV detection 
wavelength from 245 to 215 nm at 15.5 min, with retention times of 14.4 min for 
ritonavir and 15.8 min for lopinavir. Th e concentration of each agent could be measured 
without interference from the other drug. Th e lopinavir and ritonavir calibration curves 
were linear over a range of 0.045 to 30.0 mg/liter. Th e lower limit of quantiﬁ cation was 
0.04 mg/liter for both lopinavir and ritonavir. Rates of recovery after extraction from 
plasma were 95% for lopinavir and 94% for ritonavir. Th e accuracies ranged from 99 
to 101% for lopinavir and from 92 to 100% for ritonavir, and the intraday precisions 
ranged from 0.92 to 5.16% for lopinavir and from 1.51 to 5.14% for ritonavir. Th e 
interday precisions ranged from 0 to 1.57% for lopinavir and from 0 to 5.00% for 
ritonavir. 
Plasma rifampin levels were measured by a validated HPLC method that was developed 
in the University Medical Centre Nijmegen but that has not yet been published. Th e 
method consisted of protein precipitation followed by reversedphase HPLC with UV 
detection. Two hundred microliters of acetonitrile was added to 200 µl of plasma to 
precipitate protein. Th is mixture was vortexed for 20 s, and afterwards the mixture 
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was centrifuged for 5 min. Fifty microliters of the clear supernatant was used for 
injection. Chromatographic analysis was performed on an Inertsil 5 ODS 2 analytical 
column (250 by 4.6 mm [inner diameter]; Varian, Bergen op Zoom, Th e Netherlands) 
protected with a Chromguard HPLC column (10 by 3 mm[inner diameter]; Varian). 
Th e mobile phase was a mixture of 0.01 M potassium dihydrogen phosphate (62%) and 
acetonitrile (38%). Th e ﬂ ow rate was 1 ml/min, and the wavelength for UV detection 
was 334 nm. Th e rifampin retention time was 7.3 min. Th e rifampin calibration curve 
was linear over a range of 0.50 to 30.0 mg/liter. Th e lower limit of quantiﬁ cation 
for rifampin was 0.50 mg/liter. Recovery after extraction from plasma was 108.5%. 
Accuracy ranged from 101.3 to 102.2%, and intraday and interday precisions ranged 
from 2.84 to 3.65% and from 1.59 to 3.68%, respectively.
Safety monitoring and laboratory safety
Th e medical history, vital signs, a physical examination, and an electrocardiogram for 
each subject were obtained at screening. Laboratory tests were done at screening and all 
study visits (days 1, 3, 7, 10, 13, 16, 17, 18, 20, 22, and 24). Laboratory tests included 
tests for sodium, potassium, creatinine, total bilirubin, cholesterol, triglycerides, 
glucose, alkaline phosphatase, ASAT, ALAT, GGT, and amylase (pancreatic) levels; a 
wholeblood cell count; and urinalysis.
Additionally, subjects were asked about the occurrence of adverse events at each visit. 
Adverse events were assessed for intensity, according to the AIDS Clinical Trials 
Group classiﬁ cations, mild (symptoms do not interfere with daily activities), moderate 
(symptoms interfere with daily activities), and severe (symptoms markedly interrupt 
daily activities), and seriousness. Serious adverse events were deﬁ ned as any untoward 
medical occurrence that at any dose resulted in death, that was life threatening, that 
required in-patient hospitalization or prolongation of existing hospitalization, that 
resulted in a persistent or signiﬁ cant disability or incapacity, or that was a congenital 
anomaly or birth defect. During the study, the occurrence of grade 2 toxicity, according 
to World Health Organization scales, would result in discontinuation of a subject 
from the study medication. For cholesterol and triglycerides, grade 3 toxicity was a 
reason to discontinue study medication.
Pharmacokinetic analysis
Values for the pharmacokinetic parameters of lopinavir, ritonavir, and rifampin were 
estimated by noncompartmental methods. Th e Cmax and the time to Cmax (Tmax) were 
determined directly from the plasma concentration-time data. Cmin and the morning 
predosing observed trough concentration in plasma (C0) were also determined directly 
from the plasma concentration-time data. Th e area under the plasma concentration-
time curve from time zero to 12 h postdosing (AUC12) was calculated by use of 
the linear trapezoidal rule. Th e value of the peak-to-trough rate constant (β) was 
obtained from the slope of the least-squares regression of the logarithms of the plasma 
concentration-versus-time data for the 12-h interval, which was then used to calculate 
the half-life (T1/2). Th e dosing interval or peak-to-trough T1/2 was calculated as ln 
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2/β. Th e apparent oral clearance value (CL/F), where F is the bioavailability, was 
calculated by dividing the administered dose in a dosing interval by AUC12. CL/F was 
normalized for body weight (CL/F.kg) by dividing by the weight (in kilograms). Th e 
apparent volume of distribution (V/F) was calculated by dividing CL/F by β. V/F 
was normalized for body weight (V/F.kg) by dividing by the weight (in kilograms).
Statistical analysis
Th e pharmacokinetic data for lopinavir, ritonavir, and rifampin are presented as 
arithmetic means ± standard deviations and geometric means. Th e data were 
logarithmically transformed for the calculation of geometric means. Th e median and 
interquartile ranges are presented for Tmax. Th e change in a pharmacokinetic variable 
for lopinavir or ritonavir from the administration of lopinavir/ritonavir alone to the 
administration of the combination regimen with rifampin was analyzed by a paired 
t test for each of the study arms. A Wilcoxon signed-ranks test was used for Tmax. 
P values less than 0.05 were considered statistically signiﬁ cant. Variables included 
logarithmically transformed AUC12, Cmin, C0, and Cmax and nontransformed Tmax and 
T1/2. Th e bioavailability ratio for the combination regimen relative to that for lopinavir 
alone was assessed by the two one-sided-tests procedure with 90% conﬁ dence intervals 
for AUC12, Cmin, C0, and Cmax. For this purpose geometric mean ratios were calculated 
by dividing the geometric mean values for study day 24 by the geometric mean values 
for study day 10. Th e 90% conﬁ dence intervals of the geometric mean ratios were 
obtained by exponentiating the conﬁ dence limits for the diﬀ erences in logarithmic 
means. Th e geometric mean ratios together with the 90% conﬁ dence intervals were 
compared to the range of 0.80 to 1.25 to determine whether the lopinavir/ritonavir 
dose regimens combined with rifampin met the criteria for bioequivalence to the 
standard clinical dose of lopinavir/ritonavir.
Additionally, lopinavir C0s on study day 7 versus those on study day 10 and lopinavir 
C0s on study day 22 versus those on study day 24 were tested by the paired-samples t 
test to evaluate whether steady state was achieved. A power calculation was performed 
in the development phase of the study. Th e calculation, based on the lopinavir C0, 
indicated that data for nine subjects were needed in each study arm. As a dropout rate 
of 40 to 50% was assumed, 16 subjects were included in each study arm. 
Results
Subjects
Th irty-two subjects (18 males, 14 females) were included in the study, of which 20 
completed the study. Twelve subjects dropped out for reasons of adverse events or 
laboratory abnormalities. Data for all 32 subjects participating in the study were included 
in the safety analyses. Pharmacokinetic data for 1 of the 20 subjects who completed 
the study were not evaluable due to vomiting shortly after drug administration on 
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day 24. For this reason, statistical analyses for pharmacokinetics were performed with 
data for 19 subjects, 10 in arm 1 and 9 in arm 2. Th e 10 subjects in arm 1 (4 males, 
6 females) had a mean age of 37 years (range, 22 to 70 years), a mean height of 1.70 
m (range, 1.61 to 1.85 m), and a mean weight of 70.6 kg (range, 61.5 to 77.0 kg). Of 
these 10 subjects, 1 was black; all others were Caucasian. Th e nine subjects in arm 2 (7 
males, 2 females) had a mean age of 36 years (range, 25 to 47 years), a mean height of 
1.80 m (range, 1.58 to 1.90 m), and a mean weight of 75.4 kg (range, 60.5 to 85.4 kg). 
All nine subjects in arm 2 were Caucasian. 
Lopinavir pharmacokinetics
Figure 1 shows the arithmetic mean ± standard deviation trough lopinavir levels in 
plasma in the morning obtained during the study. Trough lopinavir levels in plasma 
were not statistically diﬀ erent between days 7 and 10, suggesting that in both arms 
steady state was reached after 10 days of treatment with lopinavir/ritonavir at 400/100 
mg BID (P = 0.5 and P = 0.5 for comparison of C0s on day 7 versus that on day 10 for 
arms 1 and 2, respectively). 
Figure 1. Lopinavir trough levels throughout the study
Study day
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16 Arm 1 (n=10)
Arm 2 (n=9)
Day 1-10; lopinavir/ritonavir (LPV/r) 400/100 mg BID; Day 11-15; LPV/r 400/
100 mg BID + rifampin (RIF); Day 16-17; LPV/r dose escalation + RIF; Day 18-24; 
Arm 1: LPV/r 800/200 mg BID + RIF, Arm 2: LPV/r 400/400 mg BID + RIF. 
Data are presented as aritmetic mean values with standard deviations in error bars.
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Table 2. Summary of steady state pharmacokinetics of lopinavir
On study day 16 (when lopinavir/ritonavir at 400/100 mg BID was combined with 
rifampin at 600 mg QD), trough lopinavir levels decreased 93% in arm 1 and 90% 
in arm 2 in comparison to those on study day 10. Trough lopinavir levels increased 
in both study arms after lopinavir/ritonavir dosages were titrated to 800/200 mg 
BID in arm 1 and 400/400 mg BID in arm 2 and administered in combination with 
rifampin at 600 mg QD (days 18, 20, 22, and 24). Trough lopinavir levels in plasma 
were not statistically diﬀ erent between days 22 and 24, suggesting that steady state 
was reached (P = 0.7 and P = 0.15 for comparison of C0s on day 22 versus those on 
Parametera Aritmetic mean r standard deviation (Geometric mean) P-valueb 
 Study day 10 Study day 24  
Geometric mean ratio 
(day 24 / day 10) 
and 90% CIc 
Arm 1d  (n=10)     
AUC12 (h.mg/L) 111.8 ± 19.03 (110.1) 104.5 ± 46.86 (92.3) 0.27 0.84 [0.64-1.10] 
Cmin (mg/L) 6.5 ± 1.83 (6.2) 5.1 ± 4.17 (2.7) 0.08 0.43 [0.19-0.96] 
C0 (mg/L) 7.6 ± 2.36 (7.3) 7.0 ± 6.11 (3.4) 0.14 0.46 [0.19-1.10] 
Cmax (mg/L) 12.9 ± 2.50 (12.6) 13.8 ± 4.89 (12.9) 0.84 1.02 [0.85-1.23] 
Tmax (h) 4.0 (4.0-5.4)e 4.1 (4.0-6.0)e 0.40f - 
T1/2 (h) 6.8 ± 1.81 (6.6) 7.2 ± 4.28 (6.1) 0.72 - 
Cl/F.kg (L/h.kg) 0.06 ± 0.01 (0.06) 0.18 ± 0.18 (0.13) - - 
Vd/F.kg (L/kg) 0.56 ± 0.15 (0.55) 2.16 ± 3.77 (1.13) - - 
Arm 2d  (n=9)     
AUC12 (h.mg/L) 102.9 ± 26.09 (99.9) 100.7 ± 26.81 (97.4) 0.81 0.98 [0.81-1.17] 
Cmin (mg/L) 5.2 ± 1.88 (4.9) 5.9 ± 2.73 (5.1) 0.91 1.03 [0.68-1.56] 
C0 (mg/L) 6.9 ± 2.33 (6.5) 7.0 ± 3.50 (5.8) 0.64 0.89 [0.56-1.40] 
Cmax (mg/L) 12.3 ± 3.22 (11.9) 11.5 ± 3.07 (11.1) 0.35 0.93 [0.81-1.07] 
Tmax (h) 4.0 (4.0-6.0)e 6.0 (4.0-6.0)e 0.12f - 
T1/2 (h) 6.2 ± 2.41 (5.8) 8.4 ± 3.34 (7.9) 0.05 - 
Cl/F.kg (L/h.kg) 0.06 ± 0.01 (0.06) 0.06 ± 0.02 (0.06) - - 
Vd/F.kg (L/kg) 0.51 ± 0.18 (0.48) 0.72 ± 0.32 (0.66) - - 
 
a AUC12: the area under the plasma concentration-time curve from time 0 to 12 hours post-dose, Cmin: the 
minimum observed plasma concentration, C0: the pre-dose observed plasma concentration, Cmax: the maximum 
observed plasma concentration, Tmax: the time to Cmax, T1/2: the dosing interval or peak to trough half-life, 
CL/F.kg: the apparent oral clearance value normalized for body weight, Vd/F.kg: volume of distribution corrected 
for body weight.  
b P-value for the difference between the 2 study periods, two-sided t-test for paired data. 
c CI: confidence interval  
d Arm 1 (n=10): lopinavir/ritonavir 800/200 mg BID, Arm 2 (n=9): lopinavir/ritonavir 400/400 mg BID 
e median and interquartile range 
f Wilcoxon signed-ranks test  
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day 24 for arms 1 and 2, respectively). Th e values for the lopinavir pharmacokinetic 
parameters are summarized in Table 2. Arithmetic means ± standard deviations and 
geometric means are included for study days 10 and 24 for both arm 1 and arm 2. 
Note that these geometric means result in values diﬀ erent from the arithmetic means 
in Figure 1 and 2. Th e P values for the within-subject diﬀ erences between days 10 and 
24 are presented in Table 2 as well. Table 2 also presents the geometric mean ratio 
(day 24/day 10) and the 90% conﬁ dence interval for AUC12, Cmin, C0, and Cmax. For 
arm 1 (n = 10; lopinavir/ritonavir at 800/200 mg BID in combination with rifampin 
at 600 mg QD), no statistically signiﬁ cant diﬀ erences were observed between the 
values of the pharmacokinetic parameters for days 10 and 24. Due to intersubject 
variability, the geometric mean ratio and matching conﬁ dence interval met the criteria 
for bioequivalence only for Cmax. Geometric mean ratios for Cmin and C0 showed 
decreases of 57 and 54%, respectively, from days 10 to 24, and the lopinavir AUC12 for 
arm 1 decreased by 16%. Th e total variability (coeﬃ  cient of variation) in the lopinavir 
Cmin in arm 1 was 28% on day 10, whereas it was 81% on day 24. 
Figure 2. Lopinavir steady-state concentration-time proﬁ les
Data are presented as aritmetic mean values with standard deviations in error bars
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Arm 1(n=10); lopinavir/ritonavir 400/100 mg BID (Day 10)
Arm 1(n=10); lopinavir/ritonavir 800/200 mg BID + rifampin (Day 24)
Arm 2 (n=9); lopinavir/ritonavir 400/100 mg BID (Day 10)
Arm 2 (n=9); lopinavir/ritonavir 400/400 mg BID + rifampin (Day 24)
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Figure 2 displays the arithmetic mean plasma-concentration time proﬁ les for lopinavir 
in arm 1 for both study day 10 and study day 24. Th e error bars in Figure 2 show this 
larger variability on day 24. In arm 2 (n = 9; lopinavir/ritonavir at 400/400 mg BID 
in combination with rifampin at 600 mg QD), the geometric mean ratios and their 
matching conﬁ dence intervals meet the criteria for bioequivalence for AUC12 and Cmax 
(Table 2). Although the geometric mean ratios are within 11% of unity for Cmin (+3%) 
and C0 (–11%), the 90% conﬁ dence intervals for the geometric mean ratios of Cmin 
and C0 exceed both the upper and the lower limits of the predeﬁ ned bioequivalence 
range of 0.80 to 1.25. No statistically signiﬁ cant diﬀ erences between the values of the 
pharmacokinetic parameters obtained on days 10 and 24 were observed. Th e total 
variabilities (coeﬃ  cients of variation) in lopinavir Cmins in arm 2 on days 10 and 24 were 
36 and 46%, respectively. Figure 2 displays the arithmetic mean plasma-concentration 
time proﬁ les for lopinavir in arm 2 for both study day 10 and study day 24. Th e error 
bars in Figure 2 represent the standard deviation of the mean and show variabilities of 
the same magnitude on both study days. 
Ritonavir pharmacokinetics
Th e values of the steady-state pharmacokinetic parameters for ritonavir are summarized 
in Table 3. Arithmetic means ± standard deviations and geometric means are included 
for study days 10 and 24 for both arm 1 and arm 2. Th e P values for the within-subject 
diﬀ erences between days 10 and 24 are displayed as well. Th e geometric mean ratio 
(day 24/day 10) and 90% conﬁ dence interval are given for AUC12, Cmin, C0, and Cmax. 
Geometric mean ratios in arm 1 showed increases in AUC12, Cmin, C0, and Cmax of 
42, 11, 17, and 75%, respectively, with an increase in the ritonavir dosage from 100 to 
200 mg BID from days 10 to 24. A statistically signiﬁ cant diﬀ erence in the ritonavir 
Cmax was found between study days 10 and 24 (P = 0.01). No statistically signiﬁ cant 
diﬀ erences in Cmin, C0, and AUC12 were observed. In arm 2, geometric mean ratios 
showed increases in the ritonavir AUC12, Cmin, C0, and Cmax of 7.1-, 4.9-, 4.7-, and 
8.4-fold, respectively, with the increase in the ritonavir dosage from 100 to 400 mg 
BID from days 10 to 24. Th ese diﬀ erences were statistically signiﬁ cant for AUC12, 
Cmin, C0, and Cmax from days 10 to 24 (P < 0.001 for all comparisons) (Table 3). No 
signiﬁ cant diﬀ erences in Tmax or T1/2 were observed in either arm.
Rifampin pharmacokinetics
Th e values of the steady-state pharmacokinetic parameters for rifampin on day 24 are 
presented in Table 4. Arithmetic means ± standard deviations and geometric means 
are displayed. Data are grouped by study arm; arm 1 denotes lopinavir/ritonavir at 
800/200 mg BID in combination with rifampin at 600 mg QD, and arm 2 denotes 
lopinavir/ritonavir at 400/400 mg BID in combination with rifampin at 600 mg QD. 
No statistically signiﬁ cant diﬀ erences in rifampin pharmacokinetics between arms 1 
and 2 were found.
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Table 3. Summary of steady state pharmacokinetics of ritonavir
Parametera Aritmetic mean r standard deviation (Geometric mean) P-valueb 
 Study day 10 Study day 24  
Geometric mean ratio 
(day 24 / day 10) 
and 90% CIc 
Arm 1d  (n=10)     
AUC12 (h.mg/L) 6.6 ± 2.26 (6.3) 10.7 ± 5.83 (8.9) 0.05 1.42 [1.07-1.90] 
Cmin (mg/L) 0.19 ± 0.10 (0.17) 0.24 ± 0.32 (0.18) 0.67 1.11 [0.72-1.73] 
C0 (mg/L) 0.28 ± 0.15 (0.24) 0.47 ± 0.58 (0.28) 0.64 1.17 [0.65-2.13] 
Cmax (mg/L) 1.37 ± 0.73 (1.20) 2.50 ± 1.37 (2.10) 0.01 1.75 [1.31-2.34] 
Tmax (h) 4.0 (4.0-5.4)e 4.0 (4.0-5.5)e 0.67f - 
T1/2 (h) 2.7 ± 1.09 (2.6) 2.7 ± 1.58 (2.3) 0.56 - 
Cl/F.kg (L/h.kg) 0.25 ± 0.09 (0.24) 0.40 ± 0.30 (0.31) - - 
Vd/F.kg (L/kg) 0.98 ± 0.37 (0.89) 1.26 ± 0.80 (1.03) - - 
Arm 2d  (n=9)     
AUC12 (h.mg/L) 5.6 ± 1.92 (5.3) 41.5 ± 16.83 (37.9) <0.001 7.12 [5.85-8.66] 
Cmin (mg/L) 0.17 ± 0.05 (0.16) 0.96 ± 0.57 (0.79) <0.001 4.89 [3.22-7.43] 
C0 (mg/L) 0.24 ± 0.09 (0.22) 1.39 ± 0.97 (1.06) <0.001 4.73 [2.89-7.73] 
Cmax (mg/L) 1.16 ± 0.60 (1.01) 9.63 ± 4.86 (8.47) <0.001 8.38 [6.59-10.64] 
Tmax (h) 4.0 (4.0-6.0)e 4.0 (4.0-4.0)e 0.52f - 
T1/2 (h) 3.1 ± 0.71 (3.1) 2.3 ± 0.99 (2.2) 0.07 - 
Cl/F.kg (L/h.kg) 0.29 ± 0.14 (0.27) 0.16 ± 0.10 (0.14) - - 
Vd/F.kg (L/kg) 1.39 ± 0.90 (1.18) 0.56 ± 0.43 (0.46) - - 
 
a AUC12: the area under the plasma concentration-time curve from time 0 to 12 hours post-dose, Cmin: the 
minimum observed plasma concentration, C0: the pre-dose observed plasma concentration, Cmax: the maximum 
observed plasma concentration, Tmax: the time to Cmax, T1/2: the dosing interval or peak to trough half-life, 
CL/F.kg: the apparent oral clearance value normalized for body weight, Vd/F.kg: volume of distribution corrected 
for body weight.  
b P-value for the difference between the 2 study periods, two-sided t-test for paired data. 
c CI: confidence interval 
d Arm 1 (n=10): lopinavir/ritonavir 800/200 mg BID, Arm 2 (n=9): lopinavir/ritonavir 400/400 mg BID 
e median and interquartile range 
f Wilcoxon signed-ranks test 
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Table 4. Steady state pharmacokinetics of rifampin on study day 24
Adverse events
Most (87%) of the adverse events were mild. Th ree adverse events (not related to a study 
medication) were reported to be severe; these were cases of gastroenteritis, inﬂ uenza, 
and headache. Serious adverse events did not occur. Twelve of 32 subjects (38%) were 
prematurely discontinued from the study; 3 of these subjects discontinued the study 
prior to randomization (while receiving lopinavir/ritonavir at 400/100 mg BID alone). 
One subject was prematurely discontinued from the study for grade 2 total bilirubin 
level elevations (>31 µmol/liter), which predominantly consisted of indirect bilirubin. 
However, this subject did not have concurrent grade 2+ ALAT, ASAT, or alkaline 
phosphatase level elevations. One additional subject was prematurely discontinued 
from the study for grade 3 elevations in cholesterol levels (>7.77 mmol/liter) and 
triglyceride levels (>8.48 mmol/liter), both of which subsequently declined to below 
grade 3 elevations following discontinuation of the study medication. A third subject 
was prematurely discontinued from the study for a complex of vomiting and abdominal 
pain. Th ese complaints disappeared after the study medication was discontinued. Th ere 
were half as many subject discontinuations in arm 1 (lopinavir/ritonavir at 800/200 
mg BID and rifampin at 600 mg QD; three subjects discontinued the medication; one 
subject developed grade 2 elevations in ASAT, ALAT, and GGT levels; one subject 
developed a grade 2 elevation in ASAT levels and a grade 3 elevation in ALAT levels; 
and one subject suﬀ ered from vomiting and diarrhoea) as in arm 2 (lopinavir/ritonavir 
at 400/400 mg BID with rifampin at 600 mg QD; six subjects discontinued the 
medication; three subjects developed grade 2 elevations in ASAT and ALAT levels; 
two subjects developed grade 2 elevations in ALAT levels; and one subject suﬀ ered 
from nausea, abdominal pain, fatigue, shivers, and increased sweating). 
Parametera Aritmetic mean r standard deviation (Geometric mean) 
 Arm 1b (n=10) Arm 2b (n=9) 
AUC12 (h.mg/L) 79.2 ± 33.84 (72.2) 76.6 ± 31.87 (70.3) 
Cmax (mg/L) 14.2 ± 5.61 (13.0) 15.0 ± 3.80 (14.5) 
Tmax (h) 4.0 (3.0-4.0)c 4.0 (3.0-4.0)c 
T1/2 (h) 3.12 ± 1.75 (2.8) 2.5 ± 1.33 (2.2) 
Cl/F.kg (L/h.kg) 0.12 ± 0.06 (0.11) 0.11 ± 0.06 (0.10) 
Vd/F.kg (L/kg) 0.45 ± 0.16 (0.43) 0.34 ± 0.10 (0.33)  
 
a AUC12: the area under the plasma concentration-time curve from time 0 to 12 hours post-dose, Cmax: the 
maximum observed plasma concentration, Tmax: the time to Cmax, T1/2: the dosing interval or peak to trough half-
life, CL/F.kg: the apparent oral clearance value normalized for body weight, Vd/F.kg: volume of distribution 
corrected for body weight.  
b Arm 1 (n=10): lopinavir/ritonavir 800/200 mg BID, Arm 2 (n=9): lopinavir/ritonavir 400/400 mg BID 
c median and interquartile range 
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During the study, six subjects (two in arm 1, four in arm 2) had grade 2 elevations in 
ALAT levels (>2.6 times the ULN) and three subjects (one in arm 1, two in arm 2) 
had grade 3 elevations in ALAT levels (>5.1 times the ULN). Five of these subjects 
experienced concurrent grade 2 elevations in ASAT levels (>2.6 times the ULN). 
Seven of the nine subjects with grade 2 to 3 elevations in ALAT levels (two in arm 1, 
ﬁ ve in arm 2) were prematurely discontinued from the study. Th e other two subjects 
developed elevations in liver enzyme levels on or after study day 24. Th e onset of all 
grade 2 or 3 elevations in ALAT and ASAT levels was after the initiation of rifampin 
treatment, but none of these were associated with grade 2+ elevations in total bilirubin 
or alkaline phosphatase levels. After discontinuation of the study medication, all such 
elevations declined below those for grade 2 toxicity, with only two remaining above the 
ULN at the ﬁ nal study evaluation. 
Laboratory measurements
Th e mean change from the baseline values to the maximum values as well as the mean 
change from the baseline values to the ﬁ nal values was determined for a number of 
laboratory parameters. Th e baseline was day 1 for the period from day 1 to 10, and the 
baseline was day 10 for the period from days 11 to 24. For ASAT, the mean changes 
from the baseline value (day 10) to the maximum value (ﬁ nal value) were 39.9 (2.4) and 
39.9 (1.1) IU/liter in arms 1 and 2, respectively, for study days 11 to 24. For ALAT, 
the mean changes from the baseline value (day 10) to the maximum value (ﬁ nal value) 
were 72.6 (13.5) and 89.3 (6.9) IU/liter in arms 1 and 2, respectively, for study days 11 
to 24. For alkaline phosphatase, the mean changes from the baseline value (day 10) to 
the maximum value (ﬁ nal value) were 12.9 (3.0) and 16.3 (5.0) IU/liter in arms 1 and 
2, respectively, for study days 11 to 24. No clinically relevant changes in ASAT, ALAT, 
and alkaline phosphatase levels were seen on study days 1 to 10 (lopinavir/ritonavir at 
400/100 mg BID alone). For total bilirubin, the mean change from the baseline value 
(day 1) to the maximum value (ﬁ nal value) was 10 (4.7) µmol/liter for study days 1 
to 10. For study days 11 to 24, the mean changes in the total bilirubin level from the 
baseline value (day 10) to the maximum value (ﬁ nal value) were 0.9 (–9.1) and 1.3 
(–3.9) µmol/ liter in study arms 1 and 2, respectively.
Discussion
In the present study, two adjusted-dose regimens of lopinavir/ritonavir in combination 
with rifampin were compared to the standard dose of lopinavir/ritonavir without 
rifampin. Th e steady-state pharmacokinetics of lopinavir and ritonavir were determined 
after 10 days of treatment with the standard dose of lopinavir/ritonavir (400/100 mg 
BID). In the second part of the study, the steady-state pharmacokinetics of lopinavir/
ritonavir at 800/200 mg BID with rifampin at 600 mg QD (arm 1) and lopinavir/
ritonavir at 400/400 mg BID with rifampin at 600 mg QD (arm 2) were assessed. 
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Lopinavir
Lopinavir exposure was substantially higher in both study arms compared to the 
historical data obtained for lopinavir/ritonavir at 400/100 mg BID in combination 
with rifampin at 600 mg QD. Th is historical interaction study with a standard dose 
of lopinavir/ritonavir with rifampin was conducted with 22 healthy subjects to assess 
the eﬀ ects of multiple doses of rifampin at 600 mg QD on the pharmacokinetics of 
lopinavir after treatment with lopinavir/ritonavir at 400/100 mg BID. Th e values 
of the pharmacokinetic parameters for lopinavir were substantially reduced by the 
coadministration of lopinavir/ritonavir with rifampin, as follows: Cmax by 45%, AUC 
by 75%, and Cmin by 99%14. 
While the concentrations of lopinavir are dramatically increased when lopinavir/
ritonavir is used in combination with rifampin with both of the dosing regimens, it 
could not be demonstrated that the adjusted-dose regimens with rifampin evaluated 
in the present study were equivalent, particularly with respect to Cmin, to the standard 
dose of lopinavir/ritonavir without rifampin. Th is indicates that the adjusted-dose 
regimens may in some cases not be capable of completely compensating for the 
accelerated metabolism of lopinavir by rifampin. Data are also limited by the relatively 
small number of subjects who completed the study and for whom pharmacokinetic data 
were evaluable. However, the level of lopinavir exposure in arm 2 was more comparable 
to that obtained with a standard dose lopinavir/ritonavir without rifampin than was 
the level of lopinavir exposure in arm 1. Th e pharmacokinetics of lopinavir in arm 1 
were more variable than those in arm 2. It could be that the higher dose of ritonavir 
given in arm 2 (400 mg BID) resulted in a more consistent inhibition of lopinavir 
metabolism compared to that achieved with the ritonavir dose given in arm 1 (200 
mg BID). Note that on study day 24, a total of 4 of 10 subjects (40%) in arm 1 had a 
Cmin lower than the lowest value observed on study day 10 (Cmin, <3.7 mg/liter). In 
contrast, only one of the nine subjects (11%) in arm 2 had a Cmin lower than the lowest 
value observed on study day 10 (Cmin, <3.1 mg/liter). Th e study was not designed 
to show a diﬀ erence in lopinavir exposures between study arms. However, by taking 
into account the greater variability in lopinavir pharmacokinetics in arm 1, therapeutic 
drug monitoring might prove to be useful in clinical practice to monitor for possible 
subtherapeutic Cmins of lopinavir in plasma and individually optimize the lopinavir/
ritonavir dosing regimen in a given patient. In arm 2, the Cmins of lopinavir in plasma 
tended to be higher, possibly making therapeutic drug monitoring of less importance.
Ritonavir
For ritonavir, it is apparent that in arm 1 a twofold increase in the ritonavir dose from 
200 mg/day in the absence of rifampin to 400 mg/day in the presence of rifampin 
resulted in a less than proportional increase in plasma ritonavir concentrations. In arm 
2, considerably higher plasma ritonavir concentrations were achieved during treatment 
with lopinavir/ritonavir at 400/400 mg BID in combination with rifampin compared 
to those achieved with lopinavir/ritonavir at 400/100 mg BID alone. In fact, when 
ritonavir is administered in combination with lopinavir, the ritonavir Cmax and AUC12 
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increase more than proportionally due to nonlinear pharmacokinetics16 when the total 
daily dose is increased fourfold from 200 mg/day in the absence of rifampin to 800 
mg/day in the presence of rifampin. Th e ritonavir AUC12 was approximately fourfold 
higher when lopinavir/ritonavir at 400/400 mg BID was coadministered with rifampin 
than when lopinavir/ritonavir at 800/200 mg BID was coadministered with rifampin. 
Th ese observed eﬀ ects of ritonavir exposure indicate that the inhibition of CYP3A by 
ritonavir is more complete and less subject to induction by rifampin when ritonavir is 
dosed at 400 mg BID than when it is dosed at 200 mg BID. 
Rifampin
Data for rifampin in the literature6 report a mean Cmax and a mean AUC of 8 to 20 
mg/liter and 60 to 80 mg x h/liter, respectively. Th e mean values for Cmax and AUC 
observed in this study are within these ranges (Table 4). Th is indicates that lopinavir/
ritonavir does not aﬀ ect the pharmacokinetics of rifampin. Th e fact that no statistically 
signiﬁ cant diﬀ erences in the pharmacokinetic parameters for rifampin were observed 
between arm 1 and arm 2, as shown in Table 4, provides further evidence that these 
diﬀ erent doses of lopinavir and ritonavir had no inﬂ uence on rifampin exposure. Th e 
literature also reports6,17 that rifampin intake with food can decrease the rifampin Cmax. 
It is noteworthy that in the present study rifampin was administered with lopinavir/
ritonavir at breakfast (550 kcal, 28% fat). Nevertheless, in this study the rifampin Cmax 
did not show the decrease that has been reported before. Data in the literature indicate 
that the Tmax is 1.5 to 2.0 h under fasting conditions. In a trial studying the single-
dose pharmacokinetics of rifampin under fasting conditions17, with food, and with 
antacids, the observed Tmax was 4.43 h after a high-fat breakfast (792 kcal, 57% fat). 
In the present study, the median Tmax was about 4 h in both study arms; this delay 
of Tmax was probably the result of the intake with food. However, in clinical practice, 
the rifampin Cmax is the main pharmacokinetic parameter of interest6. Th erefore, the 
clinical relevance of the delay in Tmax is limited, as in the present study the mean Cmaxs 
were well within the previously reported ranges6. 
Safety
Th e most common adverse events, reported by 50% of subjects, included urine 
discoloration, which is a known eﬀ ect of rifampin therapy18; nausea; headache; 
diarrhoea; abdominal pain and cramps; and fatigue. Th e majority of all adverse events 
were mild (87%), with approximately 13% judged to be of moderate severity and only 
three events (gastroenteritis, inﬂ uenza, and headache) reported to be severe. None of 
the adverse events met the regulatory deﬁ nition of serious. A number of subjects had 
to discontinue the study prematurely due to elevations in liver function test results, 
with the onset of the elevations occurring after the initiation of combination lopinavir/
ritonavir and rifampin dosing. A greater number of discontinuations occurred among 
the subjects in the arm receiving lopinavir/ritonavir at 400/400 mg BID plus rifampin 
at 600 mg QD. However, the study design did not allow an assessment of whether 
the frequency or magnitude of the elevations in the liver function test results seen 
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with lopinavir/ritonavir in combination with rifampin was diﬀ erent between the 
study arms. No clinically signiﬁ cant hematology or urinalysis values were observed in 
the study. 
Overall, tolerability limitations were observed with the coadministration of lopinavir/
ritonavir and rifampin in healthy subjects. Th e high rate of discontinuations observed 
was primarily a result of the elevations in the liver function test results that occurred 
after the initiation of lopinavir/ritonavir and rifampin coadministration. However, 
there was no dosing segment with rifampin alone to allow determination of whether 
the liver function test abnormalities observed during combination lopinavir/ritonavir 
and rifampin treatment were of a greater magnitude or incidence than would have been 
observed with rifampin administration alone to healthy subjects. Nevertheless, the 
increased rate of elevations in hepatic transaminase levels seen in both combination-
treatment arms warrants the use of caution when these two drugs are administered 
concurrently to patients infected with both HIV and M. tuberculosis. 
Conclusions
Th e present recommendations from the Centers for Disease Control and Prevention 
indicate that rifampin can be used in conjunction with efavirenz at 800 mg QD10. 
Th e combination of efavirenz with rifampin has been studied in a group of 24 HIV-
infected patients coinfected with M. tuberculosis9. Other combination regimens 
that have been considered for use for the simultaneous treatment of HIV and M. 
tuberculosis infections are limited. 
Th e combination of saquinavir/ritonavir at 400/400 mg BID with rifampin, as 
mentioned in the Introduction, has its parallels with the combination evaluated in the 
present study. However, the data for the saquinavir/ritonavir combination were only 
presented as a case report. 
Th e product Trizivir combines three NRTIs, namely, zidovudine, lamivudine, and 
abacavir, and could be an option for use in combination with rifampin. Nevertheless, 
the pharmacokinetics of this combination of NRTIs in combination with rifampin 
were not studied, and recently, this combination of NRTIs was shown to be less 
eﬀ ective than an efavirenz-based regimen19 and therefore will not be an option of 
ﬁ rst choice. 
Centers for Disease Control and Prevention guidelines also suggest the use of 
rifabutin5,10. However, complex bidirectional interactions are to be expected when 
rifabutin is combined with PIs6. To compensate for these interactions, rifabutin 
doses must be decreased in some cases, or the PIs should be given at higher doses 
to compensate for accelerated metabolism. Th e combination of rifabutin with the 
NNRTIs efavirenz and delavirdine results in pharmacokinetic interactions as well10; 
however, nevirapine can be used in combination with rifabutin, although no data from 
clinical studies have been published10. It was reported from a study with HIV-infected 
inmates during a tuberculosis outbreak in a prison that, regardless of the rifabutin 
dosage, rifabutin concentrations are highly unpredictable, probably due to drug-drug 
interactions20. 
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From these data it becomes clear that the combination of rifabutin with PIs or 
NNRTIs remains a therapeutic challenge. 
Th e presently studied combination of lopinavir/ritonavir, dosed as either 800/200 
mg BID or 400/400 mg BID with rifampin, may be considered for the treatment of 
HIV-infected persons who are coinfected with M. tuberculosis. Th e toxicity observed 
when higher-dose lopinavir/ritonavir and rifampin were administered together led 
to discontinuation in 31% (9 of 29) of the healthy subjects during this study. When 
these drugs are used to treat patients who use other hepatically metabolized drugs, 
who are receiving long-term chronic treatment, and who have concomitant disease, 
the adverse event proﬁ le observed in the present study might even worsen. Th erefore, 
the treatment of HIV-infected patients with tuberculosis with these agents should 
be approached with caution, and close monitoring of liver function will be needed. 
Th erapeutic monitoring of the pharmacokinetics of lopinavir may be useful for the 
detection of minimal levels in plasma that are markedly below the expected mean, 
particularly in those patients treated with 800/200 mg BID, as well as to optimize the 
dosing regimen of lopinavir/ritonavir in combination with rifampin. If therapeutic 
drug monitoring is not possible, the combination of lopinavir and ritonavir at 400/400 
mg BID may be preferred, although the rates of elevations in liver function test results 
achieved with that regimen tended to be higher than those achieved with the lopinavir/
ritonavir regimen of 800/200 mg BID.
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Abstract
Patients receiving a lopinavir/ritonavir and saquinavir dual protease inhibitor-based 
antiretroviral salvage regimen were studied to evaluate the pharmacokinetics, tolerability 
and eﬃ  cacy of the regimen. Pharmacokinetic curves were obtained for lopinavir and 
saquinavir. Patient records were studied for adverse events and eﬃ  cacy data. Th e 
pharmacokinetics of lopinavir and saquinavir were comparable with literature data, 
except for the saquinavir 0–12 h area under the curve and maximum concentration. 
Th e tolerability of the regimen was good and eﬃ  cacy was encouraging.
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Introduction
HIV-infected patients are treated with highly active antiretroviral therapy (HAART) 
for longer periods. Second-line and further regimens are seen more often, as patients 
fail their initial HAART regimen. Th is development underlines the need for more 
options in salvage therapies. Dual protease inhibitor (PI)-based HAART might 
lead to a powerful suppression of HIV infection and improve outcomes in salvage 
therapy. Accordingly, a combination of lopinavir/ritonavir and saquinavir in standard 
dosages could be used in the treatment of heavily pre-treated HIV-1-infected 
patients. Combining saquinavir with lopinavir/ritonavir has the advantage that 
ritonavir has a ‘double boosting’ function for both lopinavir and saquinavir. Another 
advantage of this combination might be the described in-vitro synergy of lopinavir 
and saquinavir1. Negative pharmacokinetic interactions, as seen for lopinavir/ritonavir 
plus amprenavir2, are not expected for lopinavir/ritonavir plus saquinavir. Increasing 
interest in the combination of lopinavir/ritonavir and saquinavir for the treatment of 
HIV infection has led to several studies on this combination of drugs. However, only 
sparse data have so far been published. Th e objectives of the study were to evaluate the 
pharmacokinetics, tolerability and eﬃ  cacy of salvage regimens containing lopinavir/
ritonavir plus saquinavir.
Methods
Patients older than 18 years who had failed at least three previous antiretroviral 
regimens including non-nucleoside reverse transcriptase inhibitors and PI were eligible. 
Selected patients were treated with lopinavir/ritonavir 400/100 mg twice a day and 
saquinavir soft gel capsules (Fortovase) 1000 mg twice a day; backbone therapy was at 
the physician’s discretion. All patients had been on the current treatment for at least 
4 weeks before the pharmacokinetics were studied. To evaluate the pharmacokinetics 
of lopinavir and saquinavir, patients received a morning dose together with standard 
breakfast at the clinic. Blood samples were drawn immediately before and up to 
12 h after dosing. All available plasma samples were measured using a modiﬁ ed 
version of a validated high-performance liquid chromatography method3. Non-
compartmental methods were used to evaluate drug concentration versus time data. 
Th e pharmacokinetic parameters evaluated were: area under the curve (AUC0–12h), 
maximum concentration (Cmax), minimum concentration (Cmin), apparent clearance 
(Cl/F) and half-life (T1/2). Pharmacokinetic data were compared with literature data 
of lopinavir/ritonavir dosed as 400/100 mg twice a day and saquinavir plus ritonavir 
dosed as 1000/100 mg twice a day. Patient characteristics including concomitant 
medication and data on viral loads and CD4 cell counts were obtained from patient 
records in the hospital. All viral loads were quantiﬁ ed using the Versant HIV-1 RNA 
3.0 test kit (Bayer Diagnostics, Leverkusen, Germany). 
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Results
Seven male patients with a mean age of 45 years (range 32–55) were included, all 
were in Centers for Disease Control and Prevention (CDC) class C3. Lamivudine was 
part of the backbone therapy for all patients; six patients also used tenofovir and ﬁ ve 
patients used T20. Th ree patients used stavudine. Abacavir, didanosine and zidovudine 
were used by one patient each.
Six out of seven patients used concomitant medication (ﬂ uconazol, pyrimethamin, 
sulfadiazin, folinate, loperamide, ganciclovir, alprazolam, bezaﬁ brate and L-thyroxine). 
None of these medications are known to interact with either lopinavir or saquinavir.
For lopinavir the median and interquartile ranges (IQR) of pharmacokinetic parameters 
were: AUC0–12h 88.0 h.mg/L (68.6–118.9 h.mg/L), Cmax 9.9 mg/L (7.9–12.5 mg/L), 
Cmin 4.8 mg/L (3.9–5.6 mg/L), Cl/F 5.8 l/h (4.3–6.1 l/h) and T1/2 5.0 h (4.7–9.8 h). 
See Figure 1 for individual plasma concentration-time proﬁ les of lopinavir. Lopinavir 
product information4 reported similar mean AUC0–12h 82.8 h.mg/L, Cmax 9.6 mg/
L, Cmin 5.5 mg/L, Cl/F 6–7 l/h and T1/2 5–6 h. Other studies5,6 also reported that 
lopinavir levels were not negatively aﬀ ected by saquinavir when co-administered.
For saquinavir the median and IQR of pharmacokinetic parameters were: AUC0–12h 
9.8 h.mg/L (8.3–24.5 h.mg/L), Cmax 1.6 mg/L (1.4–3.9 mg/L), Cmin 0.40 mg/L 
(0.22–0.93 mg/L), Cl/F 105.8 l/h (67.7– 121.8 L/h) and T1/2 3.6 h (2.9–4.1 h). 
Figure 1 gives an overview of individual saquinavir plasma concentration- time proﬁ les. 
Veldkamp et al.7 reported a higher median AUC0–12h and Cmax of: 18.8 h.mg/L and 
3.7 mg/L, a similar median Cmin and T1/2: 0.40 mg/L and 3.0 h. Th e median Cl/F was 
lower at 54.4 l/h. Ribera et al.6 reported higher values, Kurowski et al.8 reported higher 
AUC0–12h but similar Cmin. Stephan et al.5 reported that lopinavir/ritonavir was able 
to boost saquinavir levels as eﬀ ectively as ritonavir alone.
Adverse events reported by ﬁ ve out of seven patients were mainly gastrointestinal and 
mild in nature (vomiting, two; nausea, one; diarrhoea, one; heartburn, one; herpes 
labialis, one; exanthema, one; cutaneous herpes zoster, one). It has to be taken into 
account that the patients studied were experienced with regard to antiretroviral 
therapy. Good tolerability of this combination was also reported in other studies9,10.
Th e median and IQR of the viral load in log10 copies/ml at baseline, week 12 and 
week 24 were 5.2 (4.9–5.5), 4.5 (2.9–5.0) and 3.9 (2.7–4.9). Two patients reached 
an undetectable viral load (< 400 copies/ml), one at week 12 the other at week 24. 
Five out of seven patients showed a decreased viral load (> 0.5 log) during 24 weeks 
of treatment. 
Th e median and IQR of the CD4 cell counts x 106/l at baseline, week 12 and week 24 
were 72 (31–109), 194 (59–242) and 134 (44–238). All patients showed an increased 
CD4 cell count during the ﬁ rst 12 weeks of treatment. 
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Conclusion
Th e chosen dosages for lopinavir/ritonavir and saquinavir may be used for the 
combination of these agents in a dual PI-based antiretroviral regimen. Th e 
pharmacokinetic data of seven patients obtained from this study corresponded 
with literature data for lopinavir4,5 and saquinavir5,7,8 when used separately, with the 
exception of saquinavir AUC0–12h and Cmax, which appeared to be somewhat lower 
in this study. Th erapeutic drug monitoring remains an important tool in regimens 
like this, with or without concomitant medications. Th e tolerability of the studied 
treatment was good. Th e eﬃ  cacy of this regimen, measured as a decline in viral load 
and an increase in CD4 cell count was encouraging, as also reported by others9-11.
References
1.  Molla, A., H. Mo, S. Vasavanonda, L. Han, C. T. Lin, A. Hsu, and D. J. Kempf. 2002. In vitro 
antiviral interaction of lopinavir with other protease inhibitors. Antimicrob.Agents Chemother. 
46:2249-2253.
2.  Bertz, R. J., Foit, C., Ashbrenner, E., Burt, D., Williams, L. A., Chira, T., Bernstein, B., 
Wieboldt, R., Tillmann, E., Heuser, R., Rode, R., Hsu, A., Granneman, R., and Sun, E. Eﬀ ect 
of amprenavir on the steady-state pharmacokinetics of lopinavir/ritonavir in HIV+ and healthy 
subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-
30, 2002, San Diego, CA, USA, Abstract A-1823. 2002. 
3.  Hugen, P. W. H., C. P. W. G. M. Verwey-van Wissen, D. M. Burger, E. W. Wuis, P. P. 
Koopmans, and Y. A. Hekster. 1999. Simultaneous determination of the HIV-protease inhibitors 
indinavir, nelﬁ navir, saquinavir and ritonavir in human plasma by reversed-phase high-performance 
liquid chromatography. Journal of Chromatography B Biomed Sci Appl 727:139-149.
4.  Kaletra® Summary of Product Characteristics. 2000. Abbott, Chicago, IL, USA.
5.  Stephan, C. J., Lutz, T., Kurowski, M., Gute, P., and Staszewski, S. [TuPeB4561] Lopinavir/
Ritonavir versus Rinonavir boosted Saquinavir plasma levels. XIV International AIDS 
Conference. 2002.
6.  Ribera, E., Diaz, M., Pou, L., Ruiz, L., Ruiz, I., Ocana, I., and Falco, V. [TuPeB4545] Steady-
state Pharmaccokinetics of double boosting regimen of Lopinavir, plus Minidose Ritonavir, plus 
Saquinavir Soft-Gel in HIV-infected adults. XIV International AIDS Conference . 2002.
 7.  Veldkamp, A. I., R. P. van Heeswijk, J. W. Mulder, P. L. Meenhorst, G. Schreij, G. S. van der, J. 
M. Lange, J. H. Beijnen, and R. M. Hoetelmans. 2001. Steady-state pharmacokinetics of twice-
daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J.Acquir.Immune.Deﬁ c.
Syndr. 27:344-349.
8.  Kurowski, M., A. Arslan, K. Arasteh, C. Moecklinghoﬀ , and A. Hill. 2001. Comparative 
pharmacokinetics of twice daily Fortovase/ritonavir and Invirase/ritonavir. 2nd International 
Workshop on Clinical Pharmacology of HIV Th erapy, April 2-4, 2001.Noordwijk, the 
Netherlands [abstract 3.2].
9.  Smith, G. H. R., Klien, M. B., Murphy, T., Macleod, J. D., Routy, J. P., LeBlanc, R. P., Rene, 
P., Gilmore, N., and Lalonde, R. G. [TuPeB4547] Double, boosted salvage therapy with 
lopinavir(LOP)/ritonavir(RIT) and saquinavir-sgc(SQR) in HIV-1 infected patients having failed 
3 antiretroviral classes. XIV International AIDS Conference . 2002. 
Lopinavir/ritonavir plus saquinavir
51
10.  Zala, C., Patterson, P., Coll, P., Bouzas, M. B., Kaufman, S., Gun, A., Perez, H., and Cahn, P. 
[TuPeB4492] Virological response and safety at 48 weeks of double boosted protease inhibitors 
with Lopinavir/R plus either Saquinavir or Amprenavir in heavily pretreated HIV infected 
patients. XIV International AIDS Conference . 2002. 
11.  Staszewski, S., Dauer, B., Stephan, C., Gute, P., Klauke, S., and Sturmer, M. [TuPeB4474] 
Switch to a simple boosted double protease inhibitor regimen of lopinavir/r and saquinavir without 
reverse transcriptase inhibitors after multiple therapy failures. XIV International AIDS 
Conference. 2002. 

Chapter 3
Pharmacokinetics of once daily 
lopinavir/ritonavir as part of 
a regimen also containing two 
nucleosides administered once daily:
the inﬂ uence of dose modiﬁ cations
C.J.L. la Porte1,2, E.F. Schippers3, M.E. van der Ende4, P.P. Koopmans5,2, 
W.L. Blok6, R.H. Kauﬀ mann7, F.P. Kroon3, D.M. Burger 1,2
1 Department of Clinical Pharmacy, University Medical Centre 
Nijmegen, Th e Netherlands.
2 Nijmegen University Centre for Infectious Diseases, 
Th e Netherlands.
3 Department of Infectious Diseases, Leiden University Medical 
Center, Th e Netherlands.
4 Erasmus Medical Centre Rotterdam, Th e Netherlands.
5 Department of General Medicine, University Medical Centre 
Nijmegen, Th e Netherlands.
6 Walcheren Hospital, Vlissingen, Th e Netherlands.
7 Leyenburg Hospital, Th e Hague, Th e Netherlands.
Submitted
Chapter 3
54
Abstract
Background: Th ere is an increasing interest in once daily highly active antiretroviral 
therapy (HAART) regimens. For lopinavir/ritonavir, only sparse data are available on 
the pharmacokinetic proﬁ le and interpatient variability of once daily administration. 
No data have been reported so far that evaluate the eﬀ ect of dose modiﬁ cations in case 
of subtherapeutic exposure to lopinavir.
Methods: 20 HIV-1-infected patients (1 female), 10 of whom were treatment-naive, 
were started on a once daily HAART regimen consisting of lopinavir/ritonavir 
800/200 mg once daily and two nucleosides once daily (didanosine/lamivudine: 13; 
didanosine/tenofovir: 3; lamivudine/tenofovir: 3; abacavir/lamivudine: 1 patient). A 
24h pharmacokinetic curve was recorded after at least 2 weeks of treatment. Plasma 
samples for lopinavir were analyzed by a validated HPLC method.
Results: Th e mean ± standard deviation AUC24, Cmax, and Ctrough for lopinavir were 
197.9 ± 64.5 mg/L.h, 12.94 ± 4.47 mg/L, and 2.94 ± 2.48 mg/L, respectively. Th ese 
values are 120%, 135%, and 53% of the respective pharmacokinetic parameters of 
lopinavir in the licensed dose of 400/100 mg twice daily. Th e data were similar with 
data presented on once daily lopinavir/ritonavir with nucleosides administered twice 
daily. We found no signiﬁ cant correlation between body weight and lopinavir exposure 
in our patients. In 6/20 (30%) patients a lopinavir Ctrough below the target threshold 
of 1.0 mg/L was observed; these patients were eligible for a dose modiﬁ cation. From 
two patients no follow-up sample was available. Despite the increased dosage of 7 
lopinavir/ritonavir capsules once daily, none of the other 4 patients met the target 
lopinavir threshold of 1.0 mg/L. In three patients the dose was increased further to 
8 lopinavir/ritonavir capsules, only 1 patient reached a lopinavir plasma trough level 
above 1.0 mg/L (1.7 mg/L). Data on viral load, CD4 cell counts and adverse events 
were available for the 10 naive patients.
Conclusions: once daily administration of lopinavir/ritonavir results in exposure to 
lopinavir that is on average similar to twice daily administration with the exception of 
a somewhat lower Ctrough. Th erapeutic drug monitoring may be helpful in identifying 
patients with lower-than-expected lopinavir exposure. However, dose modiﬁ cations 
will not lead to Ctrough levels above 1.0 mg/L in the majority of the patients.
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Introduction
Th e treatment of HIV-infected patients has gained success with the introduction 
of HAART1,2. Combinations of two nucleoside reverse transcriptase inhibitors 
(NRTIs) with either a protease inhibitor (PI) or a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) have become standard of care nowadays3. 
Adverse events, both short- and long-term, and complexity of the regimen are 
important predictors of non-compliance4,5, and subsequent virological failure6. 
Once daily (QD) dosed HAART regimens contribute to the development of less 
complex regimens.
Lopinavir/ritonavir is a formulation of two PIs that is approved for the treatment 
of HIV infection at a standard dose of 400/100 mg twice daily (BID)7. Ritonavir 
is an inhibitor of cytochrome-P450-isoenzyme CYP3A48. Lopinavir is metabolised 
by CYP3A4 and inhibition of CYP3A4 by ritonavir results in higher plasma 
concentrations of lopinavir. 
Recently, a study comparing lopinavir/ritonavir 800/200 mg QD with 400/100 
mg BID in 38 antiretroviral-naive HIV-infected patients has been published9. 
Pharmacokinetics were studied in both treatment groups as well as antiviral activity and 
adverse events. A number of patients receiving lopinavir/ritonavir 800/200 mg QD 
had lower lopinavir trough concentrations (Ctrough) as compared to patients receiving 
lopinavir/ritonavir 400/100 mg BID. Nevertheless, no dose adjustments were made 
to achieve higher lopinavir plasma concentrations in these particular patients. No 
statistically signiﬁ cant diﬀ erences were observed in antiviral activity between the BID 
and QD treatment groups, up to 72 weeks of treatment10.
Th e inhibitory quotient (IQ) has been shown to be a predictor of virological response 
to HIV therapy11. Th e inhibitory quotient is calculated by dividing the lopinavir 
trough concentration (Ctrough) by the concentration needed to suppress the virus for 
50% (IC50) in vitro, corrected for protein binding. In experienced patients receiving 
HAART consisting of lopinavir/ritonavir 400/100 mg BID with efavirenz and 
NRTIs, IQ values for lopinavir were determined. It was shown that patients with 
IQ >15 showed 100% response (<400 HIV-RNA copies at week 24). Taking an IQ 
of 15 as starting point, in patients infected with wild-type virus (IC50 estimated at 
0.07 mg/L), the target Ctrough of lopinavir can be calculated by the same formula; 
Target Ctrough = IQ x IC50 = 15 x 0.07 = 1.0 mg/L. Based on this calculation, for 
antiretroviral-naive patients a target lopinavir Ctrough of 1.0 mg/L has been proposed12. 
One could hypothesize that a QD dose of lopinavir/ritonavir 800/200 mg should 
have a target Ctrough level of at least 1.0 mg/L to ensure antiviral activity.
In the present study the primary objective was to study the pharmacokinetics of 
lopinavir/ritonavir dosed as 800/200 mg QD. Furthermore, the eﬀ ect of a dose 
increase in patients with lopinavir Ctrough plasma concentrations below 1.0 mg/L 
was studied. Antiviral activity and safety of the studied regimen were considered 
secondary objectives. 
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Methods
Study design
Th is study was a 48-week, open-label, uncontrolled, multi-centre study in 10 HIV-
1 infected patients with an indication to start HAART. Patients were treated with 
lopinavir/ritonavir 800/200 mg QD in combination with two nucleosides, which 
were dosed QD as well. After at least 14 days of treatment the patients were admitted 
for 24 hour blood sampling. Upon admission, study medication was taken with a 
standard breakfast. Blood samples were drawn at 0, 1, 2, 3, 4, 5, 6, 7, 8, and 24 hours 
after observed intake of the drugs. In some patients additional blood samples were 
drawn at 10, 12, 16 and 20 hours after intake of medication, for a better estimation of 
terminal half-life.
Th e target for Ctrough was 1.0 mg/L. Dosage increase by 1 lopinavir/ritonavir 133/33 
mg capsule, in addition to the daily dosage, was made when the target Ctrough level of 
1.0 mg/L was not reached. After another 2 weeks a Ctrough was again measured. If 
the Ctrough was again below 1.0 mg/L the procedure of dosage adjustment could be 
repeated (up to 3 times).
Patients were followed for 48 weeks after inclusion in the study. Visits were planned 
at weeks 4, 8, 12, 24, 36 and 48 after start of treatment. Upon these visits, blood 
samples were collected for routine measurements and lopinavir plasma concentrations. 
Additionally the occurrence of adverse events was evaluated during each visit.
Subsequently 10 non-naive patients were included to extend the pharmacokinetic 
information of this study.
Selection of patients
Naive patients were selected on the basis of the following inclusion criteria: able and 
willing to sign informed consent, age 18 years or older, documented HIV-1 infection, 
CD4 cell count ≤ 500 cells/mm3. Th e following exclusion criteria were applicable: 
pregnancy or breast-feeding, known hypersensitivity to lopinavir or ritonavir, 
concomitant use of ﬂ ecainide, propafenone, astemizole, terfenadine, rifampin, 
ergotamine, dihydoergotamine, ergonovine, methylergonovine, cisapride, lovastatin, 
simvastatin, pimozide, midazolam, triazolam, carbamazepine, phenobarbital, 
phenytoin, one or more of the following laboratory results: haemoglobin < 6 mM 
(≅ < 90 g/L), leukocytes < 2.109/L, ASAT or ALAT > 10 times upper limit of normal, 
serum creatinine > 2 times upper limit of normal, active opportunistic infection.
Non-naive patients were selected on their preference for a once daily regimen at the 
discretion of the treating physician.
Bioanalysis
Plasma levels of lopinavir were determined using a validated high performance liquid 
chromatography method, that was previously published13. Th e lopinavir calibration 
curve was linear over a range of 0.10 to 30.0 mg/L. Th e lower limit of quantiﬁ cation 
was 0.10 mg/L for lopinavir. Recovery after extraction from plasma was 95%. Accuracy 
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ranged from 99% to 101% and intra-day precision ranged from 0.92% to 5.16%. Th e 
inter-day precision of lopinavir ranged from 0% to 1.57%.
Pharmacokinetic analysis
Values for the pharmacokinetic parameters of lopinavir were estimated using 
noncompartmental methods. Th e maximum observed plasma concentration (Cmax) and 
the time to Cmax (Tmax) were determined directly from the plasma concentration-time 
data. Th e plasma concentration observed 24 hours after intake of lopinavir (Ctrough) 
was also determined directly from the plasma concentration-time data. Th e area under 
the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC24) was 
calculated by the linear trapezoidal rule. Th e value of the peak to trough rate constant 
(β) was obtained from the slope of the least squares regression of the logarithms of the 
plasma concentration versus time data for the 24-hour interval, which was then used 
to calculate half-life (T1/2). Th e dosing interval or peak to trough T1/2 was calculated 
as ln(2)/β. Th e apparent oral clearance value (CL/F), where F is the bioavailability, was 
calculated by dividing the administered dose in a dosing interval by AUC24. CL/F was 
normalized for body weight by dividing by the weight in kg (CL/F.kg). Th e apparent 
volume of distribution (Vd/F) was calculated by dividing the CL/F by β. Vd/F was 
normalized for body weight by dividing by the weight in kg (Vd/F.kg).
Safety
During the scheduled study visits, blood samples were drawn for the determination 
of laboratory safety parameters. Additionally, patients were asked for the occurrence 
of adverse events during the past period on each study visit. For this purpose a 
questionnaire was used. Adverse events were assessed for intensity according to 
AIDS Clinical Trial Group (ACTG) classiﬁ cations: mild (symptoms do not interfere 
with daily activities), moderate (symptoms interfere with daily activities) or severe 
(symptoms markedly interrupt daily activities).
Results
Patient characteristics
A total of 20 patients, at ﬁ ve diﬀ erent study centres, were included in the study. One 
of them was female, 10 patients were treatment naive and 10 were experienced. Th e 
mean age was 38 ± 7 years, the mean weight and length was 74 ± 15 kg and 1.79 
± 0.09 m, respectively. Th e route of transmission was homosexual in 15 patients, 
heterosexual in 2 patients, iv-drug use in 3 patients. Backbone therapy consisted of 
2 nucleosides QD (didanosine/lamivudine in 13 patients; didanosine/tenofovir in 3 
patients; lamivudine/tenofovir in 3 patients; and abacavir/lamivudine in 1 patient). 
Out of the 10 naive patients, 3 discontinued study medication during the 48-week 
follow-up. One patient discontinued between week 12 and 24 for reasons of severe 
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diarrhoea. A second patient discontinued between week 12 and 24 due to the large 
pill load as a result of 2 dose adjustments. A third patient discontinued because of a 
persisting detectable viral load up to week 36.
Lopinavir pharmacokinetics
In Table 1, lopinavir pharmacokinetic parameters are summarized. Furthermore, 
the pharmacokinetic parameters of lopinavir once daily from a previous study9 are 
presented as comparison. In Figure 1 the mean lopinavir concentration-time plot for 
all 20 patients is presented. 
Th e mean ± standard deviation AUC24, Cmax, and Ctrough for lopinavir were 197.9 ± 
64.5 mg/L.h, 12.94 ± 4.47 mg/L, and 2.94 ± 2.48 mg/L, respectively. Th ese values 
are 120%, 135%, and 53% of the respective pharmacokinetic parameters of lopinavir 
in the licensed dose of 400/100 mg BID7. Th e data were similar to data presented on 
QD lopinavir/ritonavir with nucleosides administered BID9. 
Figure 1. Mean lopinavir concentration-time plot
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We found no signiﬁ cant correlation between body weight and lopinavir exposure in 
our patients. In six out of twenty (30%) patients, a lopinavir Ctrough below the target 
threshold of 1.0 mg/L was observed. Four of these patients were naive patients, two 
of them were experienced. Th ese six patients were eligible for a dose modiﬁ cation. 
From the two non-naive patients no follow-up sample was available. After an increase 
in the lopinavir/ritonavir dosage to 7 capsules QD (933/233 mg), none of the other 
4 patients met the target lopinavir Ctrough level of 1.0 mg/L. Th ree patients received a 
further dose increase to 1066/266 mg of lopinavir/ritonavir (8 capsules), with only 1 
patient reaching a lopinavir plasma level above 1.0 mg/L (1.7 mg/L). 
Follow up lopinavir plasma concentrations were measured in nine of the 14 patients 
reaching a Ctrough level of 1.0 mg/L on the standard dose. Th e lopinavir plasma 
concentrations in these patients remained at the same level as compared to the 24-
hour curve at week 2. Lopinavir plasma concentrations were temporally lower in only 
one patient. 
Table 1. Lopinavir pharmacokinetic parameters
Antiviral activity and immunological results
From 10 naive patients follow up viral load and CD4 cell counts were available. At 
baseline 6 out 10 patients had a viral load (VL) >100,000 copies/ml, the other 4 
patients had viral loads between 19,100 and 95,900 copies/ml. After 48 weeks six 
of ten treatment naive patients had reached undetectable plasma HIV-RNA levels 
(<50 copies/ml). One patient had a viral load of 106 copies/ml and three patients 
discontinued the study. Mean CD4 cell count in the 10 naive patients at baseline was 
183 cells/µl. An increase in CD4 cell counts towards 295 cells/µl was observed by 4 
Parametera Present studyb (n=20) Literature datab(n=17)9 
AUC24 (h.mg/L) 197.9 r 64.5 164.9 r 67.5 
Cmax  (mg/L) 12.94 r 4.47 10.94 r 2.81 
Ctrough (mg/L) 2.94 r 2.48 2.46 r 2.63 
Tmax (h) 5.5 r 2.7 6.6 r 2.8 
T1/2 (h) 9.1 r 8.3 NA 
CL/F*kg (L/h*kg) 0.07 r 0.03 NA 
Vd/F*kg (L/kg) 0.73 r 0.59 NA 
 
Data are mean r standard deviation. NA = not available. 
a AUC24: the area under the plasma concentration-time curve from time 0 to 24 hours post-dose, Cmax: the 
maximum observed plasma concentration, Tmax: the time to Cmax, T1/2: the dosing interval or peak to trough half-
life, CL/F.kg: the apparent oral clearance value normalized for body weight, Vd/F.kg: volume of distribution 
corrected for body weight. 
b lopinavir/ritonavir 800/200 mg once daily. 
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weeks of treatment and stabilized at 388 cells/µl by week 12. At week 48 mean CD4 
cell counts were 366 cells/µl.
Adverse events and safety
Adverse events and safety data were available for the 10 naive patients. Th e lipid spectra 
(total cholesterol, low density lipoproteins (LDL), high density lipoproteins (HDL) 
and triglycerides) showed increases in time (Table 2). Th e blood samples were drawn 
without regard to food intake. However these increases were small and no concomitant 
medication or treatment interruption was necessary.
Adverse event data are summarized in Table 3. In one patient, with lopinavir/ritonavir 
dosage of 1066/266 mg QD, severe persisting diarrhoea was a reason to stop the study 
medication. Severe fatigue and somnolence occurred in one patient, however this was 
not a reason to stop study medication. 
Table 2. Summary of lipid proﬁ les in the 10 naive patients
Discussion
Th e main ﬁ nding of this study was that the pharmacokinetic proﬁ le of QD lopinavir/
ritonavir 800/200 mg in 20 HIV-infected patients was similar to data reported 
previously9. More importantly, the present study gives insight in the eﬀ ect of dose 
adjustment in naive patients that did not reach a predeﬁ ned lopinavir trough plasma 
concentration upon treatment with lopinavir/ritonavir 800/200 mg QD. Th is 
minimum concentration for antiviral activity has been proposed as 1.0 mg/L12. We 
found lopinavir Ctrough levels <1.0 mg/L in 6 out of 20 patients, as compared to 3 out 
of 18 patients previously reported9. Following dose adjustments only 1 out of these 
4 patients ﬁ nally reached a lopinavir Ctrough >1.0 mg/L. Th is is a rather poor success 
Week Total cholesterol Low density lipoproteins 
High density 
lipoproteins Triglycerides 
0 (n=10) 4.58 2.61 0.93 1.81 
4 (n=10) 5.37 2.73 0.96 3.19 
8 (n=10) 5.98 3.20 0.95 3.95 
12 (n=10) 6.19 2.94 1.22 3.30 
24 (n=8) 6.63 3.31 1.18 4.78 
36 (n=7) 6.86 4.61 1.24 2.77 
48 (n=7) 6.40 3.79 1.17 3.10 
 
Data given as mean values in mmol/L 
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Table 3. Adverse events in the 10 naive patients
rate and the reason why remains puzzling. It is recommended that lopinavir/ritonavir 
is taken with food to ensure absorption7. Diﬀ erences in food composition between 
studies might explain the diﬀ erences of the trough levels in both studies. In our study 
the medication was taken with a standard breakfast, whereas in the previous study 
possibly a meal with a higher amount of fat and a higher caloric value was used. In 
the present study patients with low plasma levels were reinforced to ensure their fed 
status before intake of lopinavir/ritonavir, to exclude the negative eﬀ ect of intake 
on an empty stomach. For the PI nelﬁ navir dosed at 1250 mg BID it has also been 
reported that dose adjustments in case of low nelﬁ navir plasma concentrations were 
only eﬀ ective in a minority of patients14. For nelﬁ navir the same applies with regard to 
food intake as for lopinavir, and the advice given to patients with low nelﬁ navir plasma 
concentrations. Th is observation indicates that dose adjustments may not have the 
desired eﬀ ect for other PIs as well. Another explanation could be that absorption from 
the gastrointestinal tract is limited. In some patients this limitation might result in a 
decreasing bioavailability of lopinavir at higher dosages. In a multiple dose escalating 
study, in healthy subjects, increasing lopinavir and/or ritonavir doses provided less than 
dose proportional increases in lopinavir concentrations15. Although the mechanism 
of this remains unclear, the occurrence of diarrhoea at higher dosages could be an 
important factor.
In the present study 3 out of the 4 patients that did not reach a lopinavir Ctrough >1.0 
mg/L, stopped the study medication, one of them because of virological failure. Th e 
Description Numbera
Diarrhoeab 8 
Fatigue and somnolenceb 8 
Skin reactions 6 
Headache 5 
Peripheral paresthesias 5 
Asthenia 5 
Flatulence 3 
Insomnia 3 
Per oral paresthesia 3 
Abdominal pain 3 
Nightmares 3 
Taste perversions 2 
 
a Number represents number of patients that experienced a specific adverse event at least once during 48 weeks 
follow up. Numbers reflect mild to moderate adverse events, unless stated otherwise. 
b These data include 1 case of severe diarrhoea and 1 case of severe fatigue and somnolence. 
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fourth patient had an undetectable VL from week 12 on. In an ITT analysis of the 
once daily versus twice daily study 74% of 19 patients had an undetectable viral load 
at 48 and 72 weeks9,10. Five patients did not reach an undetectable viral load by that 
moment. At week 72, two patients had dropped out of the study for reasons of adverse 
events and site closure. It would have been interesting to know whether the three 
remaining patients were the patients with the lowest lopinavir Ctrough as well. 
Lopinavir/ritonavir dosed as 800/200 mg QD was well tolerated by the patients in 
our study. One patient stopped therapy for reasons of severe diarrhoea. In comparison 
to lopinavir/ritonavir 400/100 mg BID the occurrence of diarrhoea might be more 
frequent after QD intake of lopinavir/ritonavir 800/200 mg. In the previous study, 
diarrhoea was reported more frequent in the QD group than in the BID group (5/19 
versus 3/19) as well9.
Our study had its limitations. Firstly, since a control group with another non-lopinavir 
based QD regimen or a lopinavir based BID regimen was not included, no direct 
comparisons with regard to antiviral activity and adverse events could be made. 
Secondly, eﬃ  cacy and adverse events were only descriptive in the follow up from the 
10 naive patients. A third limitation was the entrance of both naive and non-naive 
patients to the study, making the study population heterogeneous. Furthermore, the 
study was too small to investigate the correlations between pharmacokinetic parameters 
and sustained virological suppression. Certainly, based on our data such correlations 
cannot be ruled out. Large studies are needed to address this question.
In conclusion, lopinavir dosed as 800/200 mg QD together with nucleosides given once 
daily is a safe combination with respect to side eﬀ ects and viral suppression. However, 
attention should be paid to the occurrence of lopinavir Ctrough levels that are below 1.0 
mg/L. Th erapeutic drug monitoring is necessary to detect these likely subtherapeutic 
plasma levels. Dose modiﬁ cation, as ﬁ rst line intervention, in patients with Ctrough 
levels <1.0 mg/L, is not likely to result in higher plasma levels. Also, dose escalation 
might induce more side eﬀ ects, higher pill burden and subsequent non-compliance. For 
these patients, switching to BID lopinavir/ritonavir or replacing lopinavir/ritonavir 
for another drug might be better alternatives. Further studies are needed that address 
the question to what extend lopinavir pharmacokinetic parameters, i.e. Ctrough, are 
predictors of sustained virological suppression.
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Abstract
Didanosine enteric-coated (EC) should be taken on an empty stomach, but the once 
daily (QD) combination of indinavir/ritonavir can be taken with food. Because these 
drugs are frequently included in 1 regimen, the food eﬀ ects on the pharmacokinetics 
were evaluated. Th is was a randomized, 4 way crossover study of single doses of 
didanosine EC 400 mg and indinavir/ritonavir 1200/400 mg in 8 healthy subjects. 
Th e following regimens were given: didanosine EC 2 hours after breakfast (reference 
regimen A), indinavir/ritonavir with breakfast (reference regimen B), didanosine EC 
+ indinavir/ritonavir 2 hours after breakfast (test regimen C), and didanosine EC 
+ indinavir/ritonavir with breakfast (test regimen D). Breakfast was 550 kcal, 28% 
fat. Blood samples were drawn before and up to 24 hours after ingestion. Statistical 
comparisons of test regimens C and D with reference regimens A and B were made 
using the equivalence approach for indinavir and didanosine AUC and Cmax (0.80-
1.25). Eight subjects (5 men, 3 women) were enrolled and completed the study. 
Indinavir AUCs were bioequivalent in test regimens C and D compared to reference 
regimen B. A 14% increased Cmax was observed in test regimen C. Didanosine AUC in 
test regimen D was 4% lower and suggestive of bioequivalence compared to reference 
regimen A. However, regimen C didanosine AUC was 23% lower and bioinequivalent 
compared to reference regimen A. Didanosine Cmax decreased 42% and 46% in test 
regimens C and D, respectively, in comparison to reference regimen A. In this study, 
dosing didanosine EC 400 mg QD + indinavir/ritonavir 1200/400 mg QD with 
breakfast indicated no decrease in the amount of absorption for either didanosine and 
indinavir and that this regimen could be administered with food. 
Indinavir/ritonavir plus didanosine enteric-coated
69
Introduction
Th e treatment of HIV-infected persons with highly active antiretroviral therapy 
(HAART) has greatly improved the prognosis of patients. A high rate (>95%) 
of adherence to therapy is important to maintain long-term viral suppression1. 
Unfortunately, due to the complexity of the HAART regimens, compliance is low 
because both dose frequency and restrictions on concomitant food intake must be 
followed2,3. To make HAART regimens less complex, eﬀ orts are being focused 
on designing combination regimens suitable for once daily use, regardless of food 
restrictions. Th e protease inhibitor indinavir is approved for 800 mg thrice daily4. 
However, the combination with ritonavir, another protease inhibitor, allows decreased 
dosing frequency to twice-a-day (BID) dosage due to inhibition of cytochrome P450 
3A enzymes by ritonavir, which are responsible for the metabolism of indinavir5-7. In 
addition, once daily indinavir with ritonavir was studied in healthy subjects8, showing 
that 1200 mg indinavir with 400 mg ritonavir resulted in pharmacokinetic parameters 
that were promising for the once daily treatment of patients. Th e combination 
was best taken with food to avoid high peak plasma levels that are associated with 
nephrotoxicity. Th e preliminary results of a study investigating this combination 
in patients showed good virological and immunological response9. Didanosine, a 
nucleoside reverse transcriptase inhibitor (NRTI), has a recommended dose of 400 mg 
once daily. Didanosine decomposes in an acid environment and therefore is unstable in 
the acid environment of the stomach10. To protect didanosine from decomposition, it 
was previously formulated in tablets with a buﬀ er to increase gastric pH after intake. 
However, this formulation of didanosine was not well tolerated due to the buﬀ er 
included in the tablets. A new formulation of didanosine has become available with 
encapsulated enteric-coated (EC) beads. Th e EC formulation dissolves once the low 
gastric pH is neutralized in the gut lumen. Th e EC capsules are much better tolerated 
and are approved for intake on an empty stomach, deﬁ ned as at least 2 hours before 
or after a meal10. Combining indinavir/ritonavir with didanosine EC in a once daily 
regimen yields problems with regard to food intake. To take full advantage of a once 
daily regimen, it is important that all drugs involved can be taken at the same time. 
Th is study was undertaken to characterize the pharmacokinetics of both indinavir and 
didanosine when given together with or without food. 
Methods 
Study design 
Th is was a randomized, 4-way, crossover, single-dose pharmacokinetic study in 
8 healthy subjects. Four diﬀ erent drug regimens were randomly assigned to the 
subjects, using a Latin square design. Th e diﬀ erent drug regimens were as follows: 
didanosine EC 400 mg 2 hours after breakfast (reference regimen A), indinavir 1200 
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mg + ritonavir 400 mg with breakfast (reference regimen B), didanosine EC 400 mg 
+ indinavir 1200 mg + ritonavir 400 mg 2 hours after breakfast (test regimen C), 
and didanosine EC 400 mg + indinavir 1200 mg + ritonavir 400 mg with breakfast 
(test regimen D). A washout period of 3 or 4 days was implemented between the 
4 regimens. In preparation for study days, participants had to remain fasted for 8 
hours. Beverages containing alcohol were prohibited from 15 hours before the start 
of each study day. Medication was administered with 420 mL of tap water. After 
intake of medication, blood and urine samples were collected for 24 hours. On study 
days, participants received a standardized breakfast (550 kcal; 28% fat) at the clinical 
research unit. Lunch (4 hours after breakfast) and dinner (9 hours after breakfast) 
were also standardized and provided at the clinical research unit. For up to 12 hours 
after administration, participants had to drink 2.5 L of ﬂ uid, according to a prescribed 
schedule. Th e intake of grapefruit ( juice) was prohibited throughout the whole 
study period. 
Selection of subjects 
Subjects were eligible for inclusion if they met the following inclusion criteria: aged 
18 years or older and healthy (ie, not suﬀ ering from an acute or chronic illness and 
not using medications). Subjects meeting any of the following criteria were excluded: 
documented hypersensitivity to indinavir, ritonavir, or didanosine; positive HIV test; 
pregnancy; history of pancreatitis; history of alcohol abuse; or 1 or more prespeciﬁ ed 
laboratory abnormalities. Written informed consent was obtained from all subjects, 
and the Regional Ethical Review Board approved the study. Th e study was conducted 
at the Department of Clinical Pharmacy of the University Medical Centre, St. Radboud 
Nijmegen, in collaboration with the Department of General Medicine. 
Blood and urine sampling procedures 
On study days, 10 mL blood samples were collected in heparinized tubes by an 
indwelling catheter or venipuncture. Th e ﬁ rst sample was collected immediately 
before dosing; the other samples were taken at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 
6.0, 8.0, 10.0, 12.0, and 24.0 hours after ingestion. Plasma for the determination of 
indinavir, ritonavir, and didanosine was transferred to labeled polypropylene tubes 
and stored at –20°C. 
Urine samples were collected predose and during intervals from 2.0, 4.0, 6.0, 8.0, 
10.0, 12.0, and 24.0 hours after administration of medication. Total urine volume was 
measured for each interval. Urine samples (5.0 mL) for the determination of indinavir 
and ritonavir were transferred to labeled polypropylene tubes and stored at –20°C. 
Urine samples (1.00 mL) for the determination of didanosine were transferred to 
labeled polypropylene tubes containing 2.00 mL phosphate buﬀ er (0.2 M, pH 8.0) 
and stored at –20°C. 
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Bioanalysis
Indinavir and ritonavir were analyzed in plasma using a previously described high-
performance liquid chromatography (HPLC) method11. For indinavir, accuracy ranged 
from 104% to 108%, depending on the concentration level, and intraday and interday 
precision ranged from 2.1% to 7.5% and 0.4% to 3.5%, respectively. 
For ritonavir, accuracy ranged from 102% to 108%, and intraday and interday precision 
ranged from 2.0% to 8.1% and 0.4% to 3.5%, respectively. For the analysis of indinavir 
urine levels, a modiﬁ cation of the method used for plasma was used, as described 
elsewhere12. For this method, the accuracy ranged from 92% to 101%, and intraday and 
interday precision ranged from 0.3% to 1.1% and 0.5% to 4.4%, respectively. Didanosine 
plasma levels were measured using solid-phase extraction followed by reversed-phase 
HPLC with ultraviolet detection. Solid-phase extraction was performed with Waters 
Oasis MAX columns (Waters, Etten-Leur, Th e Netherlands). Th e columns were 
washed with 500 µL of methanol followed by 250 µL of water. Th en, 500 µL of the 
plasma sample was loaded on the column together with 500 µL of HPLC-analyzed 
water (Baker, Deventer, Th e Netherlands). After loading the sample, the column was 
ﬂ ushed twice with 150 µL HPLC-analyzed water (Baker, Deventer, Th e Netherlands) 
and vacuumed to dryness. Elution was performed by adding 0.5 mL of a mixture of 
methanol and water (80/20 vol/vol). Th e eluate was vaporized under a gentle stream 
of nitrogen at 37°C and reconstituted in 0.2 mL 95/5 vol/vol water/acetonitrile. Th en, 
50 µL of this solution was injected into the HPLC system. Chromatographic analysis 
was performed at ambient temperature on a Symmetry Shield RP18 3.5-µm analytical 
column (150 × 4.6 mm i.d., Waters, Etten-Leur, Th e Netherlands), protected by a 
Symmetry Shield RP18 3.5-µm column (3.9 × 20 mm i.d., Waters, Etten-Leur, Th e 
Netherlands). Mobile phase was a mixture of 0.020 M acetate buﬀ er (pH 4.6) (94%) 
and acetonitrile (6%) vol/vol. From 10 to 24 minutes, the composition of the mobile 
phase gradually changed to 74% acetate buﬀ er with 26% acetonitrile. Th e gradient 
was back to the original values by 26 minutes. Th e ﬂ ow rate was set at 1 mL/min, and 
the wavelength for ultraviolet detection was 260 nm. Didanosine retention time was 
6 minutes. Th e didanosine calibration curve was linear over a range of 0.017 to 5.58 
mg/L. Recovery after extraction from plasma was 97%. Accuracy ranged from 100% 
to 102%, and intraday and interday precision ranged from 1.8% to 2.1% and 1.5% to 
2.4%, respectively. 
Didanosine urine levels were measured using solid-phase extraction followed 
by reversed-phase HPLC with ultraviolet detection. Solid-phase extraction was 
performed with Waters Oasis MAX columns (Waters, Etten-Leur, Th e Netherlands), 
which were pretreated with 100 µL of methanol followed by 100 µL of water. Th en, 
1 mL 0.1 M ammonium hydroxide was loaded on the column together with 200 µL 
of the urine sample. After loading the sample to the column, it was ﬂ ushed with 1 mL 
0.02 M ammonium hydroxide and 1 mL methanol and vacuumed to dryness. Elution 
was performed with 0.5 mL 2% acetic acid in methanol in 15-mL glass tubes. Th e 
eluate was vaporized under nitrogen at 37°C and resolved in 0.5 mL 0.2 M disodium 
monohydrogen phosphate (pH 8.0), and 20 µL of this solution was used for injection to 
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the HPLC system. Chromatographic analysis was performed on a Platinum EPS C18 
300 A 5-µ analytical column (150 × 4.6 mm i.d., Alltech, Breda, Th e Netherlands), 
protected by a Platinum EPS C18 300 A5-µ All-Guard column (7.5 × 4.6 mm i.d., 
Alltech, Breda, the Netherlands). Mobile phase was a mixture of 0.025M potassium 
dihydrogenphosphate (97%) and acetonitrile (3%) vol/vol. Th e ﬂ ow rate was 1 mL/
min, and the wavelength for ultraviolet detection was 250 nm. Didanosine retention 
time was 10.5 minutes. Th e didanosine calibration curve was linear over a range of 
1.56 to 467 mg/L. Recovery after extraction from urine was 100.3%. Accuracy ranged 
from 101% to 105%, and intraday and interday precision ranged from 3.1% to 4.0% 
and 0% to 0.6%, respectively. 
Safety monitoring and laboratory measurements 
Twenty-four hours after administration, the clinical laboratory tests performed during 
screening were repeated on each study day. Adverse events were recorded and graded 
as mild, moderate, or severe according to World Health Organization (WHO) 
grading scales. 
Pharmacokinetic analysis 
Th e pharmacokinetic parameters of indinavir, ritonavir and didanosine were calculated 
by noncompartmental methods using Excel version 2000 (Microsoft Corporation 
1985-1999). Th e highest observed plasma concentration was deﬁ ned as Cmax, with 
the corresponding sampling time as Tmax. Cmin was the concentration at 24 hours after 
ingestion of the drugs. Th e terminal, log-linear period (log C versus t) was deﬁ ned 
by visual inspection of the last data points (n ≥ 3). Th e absolute value of the slope 
(β/2.303) was calculated by least squares linear regression analysis (β is the ﬁ rst-
order elimination rate constant). Th e elimination half-life (T1/2) was calculated by 
the equation 0.693/β. Th e area under the concentration versus time curve (AUC) 
was calculated using the trapezoidal rule from 0 to 24 hours. Th e AUC0–∞ value was 
calculated by extrapolating to inﬁ nity by the addition of the last measured plasma 
concentration divided by β. Th e apparent clearance (CL/F, where F is bioavailability) 
was calculated by dividing dose (D) by AUC, and apparent volume of distribution 
(Vd/F) was obtained by dividing CL/F by β. Clearance and volume of distribution 
were corrected for weight of the subject by dividing these parameters by the subject’s 
body weight in kilograms. For this purpose, body weight was measured on each 
study day. 
Th e cumulative renal excretion of indinavir and didanosine (Ae) was approximated 
by the total amount of indinavir and didanosine that was excreted unchanged in the 
urine during the dosing interval; Ae = S (volume urine x concentration indinavir or 
didanosine in urine). Renal clearance (CLR) was calculated using the formula Ae/
AUC. Th e fraction of the total amount excreted unchanged (fe) was calculated using 
the following formula: fe x F =Ae/D = CLR/CL. 
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Statistical analysis 
All statistical evaluations were performed with SPSS for Windows, version 10 
(SPSS, Inc, Chicago). Prior to statistical analysis, the pharmacokinetic parameters 
of indinavir, ritonavir, and didanosine were logarithmically transformed. Geometric 
means were calculated for all transformed pharmacokinetic parameters. Tmax values 
were summarized as medians and ranges and compared by regimen using the Wilcoxon 
signed rank test. A P value ≤ 0.05 was considered to be signiﬁ cant in all analyses. AUC 
and Cmax were tested for bioequivalence over the diﬀ erent regimens. For indinavir, 
AUC and Cmax of test regimens C and D were compared to the AUC and Cmax of 
reference regimen B. For didanosine, AUC and Cmax of test regimens C and D were 
compared to the AUC and Cmax of reference regimen A. A general linear method was 
used to calculate the geometric mean ratios of the AUC and Cmax of test regimens 
over the reference regimen. Conclusions with regard to bioequivalence were drawn 
as described by Williams et al13. Th e 90% conﬁ dence intervals of the geometric mean 
ratios were compared to the predeﬁ ned range of 0.80 to 1.25. Bioequivalence was 
concluded when the geometric mean ratio and the 90% conﬁ dence interval fell within 
the limits of 0.80 to 1.25. Bioequivalence was suggested if the geometric mean ratio 
fell within the limits of 0.80 to 1.25, but either the lower or the upper limit of the 90% 
conﬁ dence interval failed the limits of 0.80 to 1.25. Bioinequivalence was concluded if 
the geometric mean ratio and the 90% conﬁ dence interval fell outside the limits of 0.80 
to 1.25. Bioinequivalence was suggested if the geometric mean ratio fell outside the 
range of 0.80 to 1.25, but one of the limits of the 90% conﬁ dence interval fell within 
the limits of 0.80 to 1.25. 
A power calculation was performed in the development phase of the study. Th e 
calculation, based on indinavir Cmin, indicated that data of 6 subjects were needed to 
detect a 50% diﬀ erence. As a low dropout rate was assumed, 8 subjects were included 
in the study. 
Results 
Subjects 
Eight subjects(5 men, 3 women) were enrolled and could be evaluated. Th ere were no 
dropouts in this study. Th eir median age was 33 years (range = 19–57 years), and their 
median weight was 73.6 kg (range = 66.7–106 kg). All subjects were Caucasians. 
Adverse events and laboratory measurements 
Two out of 8 subjects did not experience any adverse events at all. Th e single doses given 
in this study were well tolerated by the subjects. No serious adverse events occurred. 
During the study, no clinically signiﬁ cant changes were observed in biochemical and 
hematological parameters. 
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Pharmacokinetics 
Th e indinavir pharmacokinetic parameters are listed in Table 1. Indinavir plasma 
concentration versus time proﬁ les based on median values for the reference regimen 
B and the test regimens C and D are shown in Figure 1. Note that data are presented 
as geometric means in the table, which may read diﬀ erently from the medians used in 
Figure 1. Test regimens C and D relative to reference regimen B showed bioequivalence, 
with the exception of indinavir Cmax in test regimen C, in which bioequivalence 
was only suggested. Th e 14% higher observed indinavir Cmax, when combined with 
didanosine 2 hours after breakfast, was accompanied by a statistically nonsigniﬁ cant 
(P= 0.12) decreased median indinavir Tmax of 1.3 hours when compared to reference 
regimen B. Reference regimen B (indinavir/ritonavir with breakfast) resulted in a Tmax 
of 2.3 hours. Test regimen D, in which indinavir/ritonavir and didanosine were given 
simultaneously with breakfast, showed a Tmax of 2.0 hours. No statistically signiﬁ cant 
diﬀ erences were observed in indinavir renal excretion. 
Figure 1. Indinavir plasma concentration-time proﬁ les
Curves are median values of 8 subjects
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Didanosine plasma concentration-time proﬁ les can be found in Figure 2, with 
pharmacokinetic parameters listed in Table 2. Note that data are presented as geometric 
means in the table, whereas medians were used in Figure 2. For didanosine, it was 
not possible to determine a reliable Cmin value because no subjects had detectable 
didanosine levels in plasma more than 12 hours after intake. Th e didanosine AUC 
in test regimen D was 4% lower and suggestive of bioequivalence compared to 
reference regimen A. However, didanosine AUC in test regimen C was suggestive of 
bioinequivalence compared to reference regimen A (geometric mean ratio and 90% 
conﬁ dence interval = 0.77 [0.60–0.98]). Didanosine Cmax was not bioequivalent in 
both test regimens C and D relative to reference regimen A. For Cmax, geometric mean 
ratios and 90% conﬁ dence intervals were 0.58 [0.40–0.83] for test regimen C and 0.54 
[0.36–0.81] for test regimen D. As such, there was a signiﬁ cant average decrease in 
Cmax of 42% and 46% for the respective test regimen relative to the reference regimen. 
A statistically signiﬁ cant increase for Tmax was observed for both test regimens as 
well. Other didanosine pharmacokinetic parameters did not show any statistically 
signiﬁ cant changes. Th e total renal excretion was signiﬁ cantly (P = 0.04) decreased in 
test regimen C (48.9 versus 64.7 mg in reference regimen A). 
Figure 2. Didanosine plasma concentration-time proﬁ les
Curves are median values of 8 subjects
Time (hours)
0 2 4 6 8 10 12
C
on
ce
nt
ra
tio
n 
(m
g/
L)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Reference regimen A, didanosine EC 2 hours after breakfast
Test regimen C, didanosine EC + indinavir/ritonavir 2 hours after breakfast
Test regimen D, didanosine EC + indinavir/ritonavir with breakfast
Indinavir/ritonavir plus didanosine enteric-coated
77
G
eo
m
et
ri
c 
m
ea
n 
an
d 
ra
ng
e 
G
eo
m
et
ri
c 
m
ea
n 
ra
ti
o 
an
d 
90
%
 C
I 
P
ar
am
et
er
 
R
eg
im
en
 A
†  
R
eg
im
en
 C
‡  
R
eg
im
en
 D
#  
R
eg
im
en
 C
/A
 
P-
va
lu
e 
R
eg
im
en
 D
/A
 
P-
va
lu
e 
A
U
C
 (h
.m
g/
L)
 
2.
01
 (1
.1
1-
3.
15
) 
1.
55
 (0
.5
2-
3.
11
) 
1.
93
 (1
.1
6-
4.
93
) 
0.
77
 [0
.6
0-
0.
98
] 
0.
08
 
0.
96
 [0
.7
9-
1.
17
] 
0.
69
 
C
m
in
 (m
g/
L)
 
nd
 
nd
 
nd
 
 
 
 
 
C
m
ax
 (m
g/
L)
 
0.
90
 (0
.3
9-
1.
49
) 
0.
52
 (0
.1
0-
1.
13
) 
0.
48
 (0
.1
4-
2.
26
) 
0.
58
 [0
.4
0-
0.
83
] 
0.
02
 
0.
54
 [0
.3
6-
0.
81
] 
0.
02
 
T
m
ax
 (h
)*  
2.
5 
(1
.0
-3
.0
) 
3.
0 
(2
.5
-8
.0
) 
4.
0 
(2
.5
-5
.0
) 
- 
0.
02
 
- 
0.
03
 
T
1/
2 (
h)
 
1.
3 
(0
.6
-2
.0
) 
1.
8 
(0
.9
-3
.7
) 
1.
8 
(0
.9
-4
.5
) 
 
 
 
 
C
L/
F.
kg
 (L
/h
.k
g)
 
2.
6 
(1
.6
-3
.4
) 
3.
3 
(1
.6
-7
.2
) 
27
 (1
.0
-3
.8
) 
 
 
 
 
V
d/
F.
kg
 (L
/k
g)
 
4.
7 
(2
.7
-9
.3
) 
8.
5 
(3
.7
-3
8.
6)
 
6.
8 
(1
.8
-1
8.
9)
 
 
 
 
 
A
e 
(m
g)
 
64
.7
 (4
4.
8-
98
.5
) 
48
.9
 (2
7.
2-
82
.5
) 
53
.4
 (3
0.
9-
95
.1
) 
 
 
 
 
C
L R
/F
.k
g 
(L
/h
.k
g)
 
0.
41
 (0
.1
8-
0.
67
) 
0.
41
 (0
.2
4-
0.
52
) 
0.
36
 (0
.2
3-
0.
52
) 
 
 
 
 
Fe
.F
 
0.
16
 (0
.1
1-
0.
25
) 
0.
13
 (0
.0
7-
0.
21
) 
0.
15
 (0
.0
8-
0.
24
) 
 
 
 
 
 C
I, 
C
on
fid
en
ce
 in
te
rv
al
; A
U
C
, a
re
a 
un
de
r t
he
 c
on
ce
nt
ra
tio
n-
tim
e 
cu
rv
e;
 C
m
in
, t
ro
ug
h 
co
nc
en
tr
at
io
n 
at
 2
4 
ho
ur
s;
 C
m
ax
, h
ig
he
st
 o
bs
er
ve
d 
pl
as
m
a 
co
nc
en
tr
at
io
n;
 T
m
ax
, s
am
pl
in
g 
tim
e 
fo
r 
C
m
ax
; C
L/
F.
kg
, t
ot
al
 c
le
ar
an
ce
 c
or
re
ct
ed
 fo
r w
ei
gh
t; 
V
d/
F.
kg
, v
ol
um
e 
of
 d
is
tr
ib
ut
io
n 
co
rr
ec
te
d 
fo
r w
ei
gh
t; 
T
1/
2, 
el
im
in
at
io
n 
ha
lf-
lif
e;
 F
, b
io
av
ai
la
bi
lit
y;
 A
e,
 to
ta
l a
m
ou
nt
 e
xc
re
te
d 
w
ith
 
ur
in
e;
 C
L R
/F
.k
g,
 re
na
l c
le
ar
an
ce
 c
or
re
ct
ed
 fo
r w
ei
gh
t; 
Fe
.F
, f
ra
ct
io
n 
ex
cr
et
ed
 b
y 
ur
in
e 
* 
M
ed
ia
n 
an
d 
ra
ng
e;
 W
ilc
ox
on
-s
ig
ne
d 
ra
nk
 te
st
 
†  4
00
 m
g 
di
da
no
si
ne
 2
 h
ou
rs
 a
ft
er
 b
re
ak
fa
st
 
‡  C
om
bi
na
tio
n 
of
 1
20
0 
m
g 
in
di
na
vi
r a
nd
 4
00
 m
g 
ri
to
na
vi
r a
nd
 4
00
 m
g 
di
da
no
si
ne
 2
 h
ou
rs
 a
ft
er
 b
re
ak
fa
st
 
#  C
om
bi
na
tio
n 
of
 1
20
0 
m
g 
in
di
na
vi
r a
nd
 4
00
 m
g 
ri
to
na
vi
r a
nd
 4
00
 m
g 
di
da
no
si
ne
 w
ith
 b
re
ak
fa
st
 
$  G
eo
m
et
ri
c 
m
ea
n 
ra
tio
 p
lu
s 9
0%
 C
I f
or
 re
gi
m
en
 C
 v
er
su
s A
 
&
 G
eo
m
et
ri
c 
m
ea
n 
ra
tio
 p
lu
s 9
0%
 C
I f
or
 re
gi
m
en
 D
 v
er
su
s A
 
  T
ab
le
 2
. S
um
m
ar
y 
of
 d
id
an
os
in
e 
ph
ar
m
ac
ok
in
et
ic
 p
ar
am
et
er
s (
n=
8)
Chapter 4
78
Ritonavir pharmacokinetic parameters are displayed in Table 3. Apart from a decreased 
Tmax in regimen C (P = 0.04), all regimens (C and D) were bioequivalent to reference 
A for ritonavir pharmacokinetic parameters. 
Table 3. Summary of ritonavir pharmacokinetic parameters (n=8)
Discussion
In the current study, we investigated the utility of the combination of indinavir/ritonavir 
with didanosine EC for once daily use in healthy subjects. Th e combination of these 
3 drugs was given together with or 2 hours after breakfast to investigate possible food 
eﬀ ects on the pharmacokinetics of indinavir and didanosine. Th ese test regimens were 
compared to reference regimens of indinavir/ritonavir administered with breakfast or 
didanosine administered 2 hours after breakfast, respectively. Indinavir exposure (both 
AUC and Cmax), when administered with didanosine and breakfast, was bioequivalent to 
reference regimen B. However, when indinavir was given with didanosine 2 hours after 
breakfast, Cmax was 14% higher but still suggestive of bioequivalence in comparison to 
reference regimen B. From this study, it becomes apparent that the intake of indinavir/
ritonavir with breakfast lowers the indinavir Cmax. Th is is a desirable eﬀ ect as indinavir 
toxicity is at least partly related to the magnitude of Cmax14. Lowered indinavir Cmax 
in the fed state has been reported by others as well5,7,15. Food is also known to delay 
 
Geometric mean and range Parameter 
Regimen B† Regimen C‡ Regimen D#
AUC (h.mg/L) 66.1 (27.5-119.3) 66.2 (36.4-116.3) 58.7 (31.0-119.4) 
Cmin (mg/L) 0.42 (0.09-1.50) 0.32 (0.12-1.40) 0.27 (0.03-1.43) 
Cmax (mg/L) 6.2 (3.8-11.2) 6.9 (4.6-10.5) 5.9 (2.8-11.5) 
Tmax (h)* 4.0 (4.0-10.0) 2.5 (1.5-8.0) 4.0 (2.0-8.1) 
T1/2 (h) 4.4 (3.3-7.2) 4.3 (3.6-6.4) 4.4 (2.4-6.8) 
CL/F.kg (L/h.kg) 0.08 (0.05-0.20) 0.08 (0.05-0.15) 0.09 (0.05-0.17) 
Vd/F.kg (L/kg) 0.50 (0.35-1.16) 0.48 (0.35-0.88) 0.56 (0.40-1.28) 
 
CI, Confidence interval; AUC, area under the concentration-time curve; Cmin, trough concentration at 24 hours;  
Cmax, highest observed plasma concentration; Tmax, sampling time for Cmax; CL/F.kg, total clearance corrected for 
 weight; Vd/F.kg, volume of distribution corrected for weight; T1/2, elimination half-life; F, bioavailability 
* Median and range; Wilcoxon-signed rank test 
† Combination of 1200 mg indinavir and 400 mg ritonavir with breakfast 
‡ Combination of 1200 mg indinavir and 400 mg ritonavir and 400 mg didanosine 2 hours after breakfast 
# Combination of 1200 mg indinavir and 400 mg ritonavir and 400 mg didanosine with breakfast 
Indinavir/ritonavir plus didanosine enteric-coated
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the absorption of indinavir, resulting in a delayed Tmax5,7,15. Th e observed diﬀ erences 
in indinavir pharmacokinetics following the diﬀ erent study regimens in the current 
study show that there were diﬀ erences in the fed state of the subjects following the 
regimens of being dosed 2 hours after breakfast or together with breakfast. Combining 
indinavir/ritonavir with didanosine with breakfast did not change indinavir AUC or 
Cmax relative to the same combination without didanosine, suggesting that there is 
no pharmacokinetic eﬀ ect of didanosine on indinavir exposure. A lack of such eﬀ ect 
has previously been reported16. When didanosine is given with breakfast, as in test 
regimen D, a decreased Cmax and an increased Tmax can be expected17. Given 2 hours 
after breakfast (regimen C), didanosine exposure decreased, indicating an interaction 
between absence of food and concomitant indinavir/ritonavir administration on 
didanosine absorption. However, such an eﬀ ect has not been reported elsewhere. 
No statistical comparisons were made between regimens C and D. Nevertheless, 
didanosine AUC in regimen D is favorable over that in regimen C, derived from 
the statistical comparison with regimen A. Didanosine Cmax, however, seems to be 
of the same magnitude in regimens C and D. Decreased absorption with regimen 
C in comparison to regimen A was further supported by the decrease in total renal 
excretion in regimen C (48.9 versus 64.7 mg in reference regimen A). In a previous 
study18 comparing didanosine buﬀ ered tablets with enteric-coated didanosine in 
both healthy subjects and patients, a decreased Cmax was observed for enteric-coated 
didanosine. However, AUC showed bioequivalence for both formulations, indicating 
that the absorption rate was slower, but total absorption remained constant. In this 
study, data from regimen D show the most favorable didanosine pharmacokinetics in 
that AUC values were similar to the reference regimen. Although this study was not 
conducted to investigate possible diﬀ erences in ritonavir pharmacokinetics, the only 
statistical signiﬁ cant change observed was a decreased Tmax in regimen C (P= 0.04), 
indicating faster absorption. Th ese data indicate that the use of didanosine has no 
eﬀ ect on ritonavir pharmacokinetics. 
Th is study had its limitations; ﬁ rst, the sample size was small, with only 8 subjects. 
In addition, considerable variability in pharmacokinetic parameters was observed. 
Second, we cannot draw conclusions for a steady-state situation. However, the studied 
eﬀ ects here mainly concern the absorption phase of the drugs, and these are not likely 
to be diﬀ erent when steady-state conditions apply. Th ird, at the time we conducted this 
study, no analytical assay to analyze intracellular triphosphate levels of didanosine was 
available. Didanosine needs to be converted intracellularly to the active triphosphate. 
To date, no data are available relating plasma didanosine levels to their intracellular 
triphosphate levels. 
In conclusion, didanosine EC + indinavir/ritonavir with breakfast (test regimen D) 
shows the most favorable pharmacokinetics and could serve as the basis of a HAART 
regime. Didanosine exposure was slightly lower in test regimens C and D. However, 
the conﬁ dence intervals for the didanosine AUC ratios (regimens D and A) were 
within 1% of the bioequivalence range, suggesting that a large sample size may have 
demonstrated bioequivalence. Indinavir exposure was bioequivalent for the 2 fed 
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conditions compared to reference, with the exception of Cmax in test regimen C. Th ese 
results indicate that this HAART regimen could be administered with food without 
decreased bioavailability. 
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Abstract
Objective: To assess the pharmacokinetics and tolerability of reduced dosages of twice 
daily indinavir boosted by low-dose ritonavir in healthy volunteers. 
Methods: Pharmacokinetics and tolerability of indinavir/ritonavir twice daily 
(600/100 mg and 400/100 mg) were assessed in a randomized crossover design in 
16 healthy volunteers. Each dosage was taken twice daily for 2 weeks before 12 h 
pharmacokinetics were obtained. 
Results: Sixteen subjects were included, with a mean age ±SD of 30 ±4 years; seven 
female, nine male. Fifteen subjects completed the study. After dose reduction of 
indinavir AUC, Cmax and Cmin decreased signiﬁ cantly. In the 400 mg group three out of 
15 subjects had indinavir levels below 0.10 mg/L versus none in the 600 mg group. 
All subjects reported mild to moderate side eﬀ ects throughout the study period, which 
were more severe in the 600 mg group (mostly renal, dry skin/lips, paresthesias/oral 
discomfort). In the 600 mg group four subjects reported dysuria and one subject 
discontinued because of ﬂ ank pain, whereas two subjects reported dysuria and no 
subject discontinued in the 400 mg group, respectively. Eight subjects developed 
crystalluria without a signiﬁ cant diﬀ erence between both groups. No signiﬁ cant 
change in serum creatinine was observed.
Conclusions: indinavir/ritonavir 400/100 mg twice daily resulted in signiﬁ cant lower 
indinavir exposure, with three out of 15 subjects revealing Cmin values below the 
recommended threshold for wild-type virus of 0.10 mg/L. Tolerability, however, was 
lower in the 600 mg indinavir group. Th erapeutic drug monitoring in the individual 
patient appears to be necessary to guarantee appropriate drug levels and simultaneously 
minimize toxicity.
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Introduction
Th e introduction of highly active antiretroviral therapy has markedly improved the 
treatment of HIV infection. Although drug therapy may have reached near maximal 
eﬃ  cacy, toxicity and adherence issues are the most important obstacles to long-term 
treatment, which is a lifelong treatment at the moment. In addition, most HIV-positive 
patients in the world do not have access to current treatments due to the high costs 
of antiretroviral drugs. Th erefore, it is important to explore drug regimens that are 
easier to adhere to, have less toxicity than current regimens and are made cheaper by 
reducing the amount of pills necessary, while the antiviral activity is preserved. 
Th is pharmacokinetic study focuses on protease inhibitor combinations of indinavir 
and ritonavir. Combinations of these two protease inhibitors are widely used in clinical 
practice1,2. Th e two most common regimens are indinavir/ritonavir 400/400 mg and 
800/100 mg twice daily, respectively3,4. Th e latter combination has the advantage 
of fewer pills and less ritonavir toxicity, which might be beneﬁ cial in the long term. 
However, a shortcoming of this combination is a higher rate of nephrotoxicity due 
to the development of kidney stones as compared to the indinavir monotherapy or 
the 400/400 mg twice daily combination5. Th erefore, a dose reduction of indinavir 
might mitigate the rate and severity of side eﬀ ects, on top of that reducing the costs 
of antiretroviral treatment. Preliminary clinical data with combinations of indinavir/
ritonavir of 600/100 mg and 400/100 mg twice daily suggest that such a dose reduction 
will not aﬀ ect the antiviral potency of the combination6-8. However, pharmacokinetic 
data on these particular indinavir/ritonavir combinations do not exist in detail so far 
and indinavir cannot simply be reduced in the indinavir/ritonavir combination, since 
it cannot be excluded that dose reduction may result in subtherapeutic plasma levels of 
indinavir. Th erefore, we studied the steady state pharmacokinetics of the 600/100 mg 
and 400/100 mg twice daily indinavir/ritonavir combinations in healthy volunteers.
Methods
Subjects and treatment
Sixteen healthy volunteers were recruited for this study. All volunteers were HIV-
negative, had not received any antiretroviral treatment before and had no known 
underlying disease. All volunteers gave written informed consent. All study procedures 
were done in accordance with the current revision of the Helsinki declaration of 1975, 
and the Ethics committee of the University of Bonn, Faculty of Medicine, Bonn, 
Germany approved the study. 
Following a crossover design, volunteers were randomly assigned to start either with 
a dose of 400 mg indinavir twice daily boosted by baby-dose ritonavir (100 mg twice 
daily; treatment 1) or with a dose of 600 mg indinavir twice daily boosted by baby-dose 
ritonavir (treatment 2). Th ey were instructed to ingest the drugs in the morning and 
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in the evening at 12-h intervals together with a light meal9. Furthermore, participants 
had to drink 1.5 l of water in addition to their normal daily ﬂ uid intake to prevent 
possible nephrotoxicity. After 2 weeks a complete 12-h pharmacokinetic assessment 
was done, and volunteers switched to the other dose regimen for another 2 weeks.
Th e study was conducted on an outpatient basis at the Medizinische Klinik, University 
of Bonn, Germany. On days 4, 8, 14, 18, 22 and 28, drug administration was performed 
under staﬀ  supervision. Compliance with study medication at home was evaluated 
at every study visit by inspection of drug-taking diaries, counting of capsules and 
measurement of plasma drug concentrations. 
Intensive blood and urine sampling was performed during days 14 and 28 after an 
overnight fast. Subjects had taken the last dose of indinavir and ritonavir the preceding 
evening. A pre-dose blood sample was taken, and subjects then ingested indinavir and 
ritonavir with a standardized medium-fat medium-calorie breakfast (610 kcal in total, 
16% of which was attributable to protein and 33 and 51% to fat and carbohydrates, 
respectively). Serial plasma sampling was performed at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 
5.0, 6.0, 8.0, 10.0 and 12.0 h after drug administration. In four randomly selected 
participants urine samples were collected after initial voiding of the bladder at 2-
h intervals up to 12 h after ingestion of the drugs. Standard meals were served at 
lunchtime (4 h after ingestion of the drugs) and dinnertime (10 h after ingestion of 
the drugs). Blood samples were processed within 6 h after drawing. Plasma and urine 
samples were stored at –70°C until analysis. 
Safety and tolerability
Safety and tolerability were assessed by a self-developed questionnaire that presented 
17 possible adverse events that may occur during treatment with indinavir or ritonavir. 
Th e volunteers were questioned six times (on days 4, 8, 14, 18, 22 and 28). Th ey could 
also mention adverse events that were not on the list. Participants were asked to grade 
every complaint as mild (symptoms do not interfere with daily activities), moderate 
(symptoms may interfere with daily activities) or severe (symptoms interrupt daily 
activities). Subjects were physically examined on every study visit and questioned 
about the reported adverse events in order to validate the self-reporting. On the same 
6 study days an extensive blood chemistry and haematology screen, and urine analysis 
were performed. 
Bioanalysis of indinavir and ritonavir
Plasma samples were analysed simultaneously for indinavir and ritonavir, and urine 
samples for indinavir concentrations. A validated reversed-phase HPLC method 
was used for determination of indinavir and ritonavir plasma levels10. Urine samples 
were analysed for indinavir with another HPLC method that has been described 
previously11, but with a modiﬁ ed sample pre-treatment procedure that has been 
described elsewhere12. 
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Pharmacokinetic analysis 
Th e pharmacokinetic parameters of indinavir and ritonavir were calculated with 
standard non-compartmental methods13. Th e terminal, log-linear period (log C versus 
t) was deﬁ ned by visual inspection of the last data points (n ≥ 3). Th e absolute value of 
the slope (β/2.303) was calculated by least squares linear regression analysis (β is the 
ﬁ rst-order elimination rate constant). Th e elimination half-life (T1/2) was calculated 
by the equation 0.693/β. Th e area under the concentration-versus-time curve (AUC) 
– calculated using the trapezoidal rule – was extrapolated to inﬁ nity by adding Cmin/β 
and was corrected for the contribution of the predose AUC by subtraction of C0/β, in 
which C0 is initial plasma drug concentration. Th e apparent clearance (CL/F, where F 
is bioavailability) was calculated by dividing dose (D) by AUC, and apparent volume 
of distribution (V/F) was obtained by dividing CL/F by β. 
Th e cumulative renal excretion of indinavir (Ae) was approximated by the total 
amount of indinavir that was excreted unchanged in the urine during the dosing 
interval; Ae=Σ (volume urine x concentration indinavir in urine). Renal clearance 
(CLR) of indinavir was calculated using the formula Ae/AUC. Th e fraction of the 
total amount of indinavir excreted unchanged (fe) was calculated using the formula: fe 
x F=Ae/D=CLR/CL.
Data analysis
All statistical evaluations were performed with SPSS for Windows, version 10 (SPSS, 
Inc., Chicago, Ill., USA) and the SAS software package. Prior to statistical analysis, 
the pharmacokinetic parameters of indinavir and ritonavir (apart from Tmax) were 
logarithmically transformed. Th e eﬀ ect of dose-reduction of indinavir on the steady-
state pharmacokinetics of indinavir and ritonavir was evaluated by comparison of the 
pharmacokinetic parameters of days 14 and 28 with the use of the two-sided Student 
t test for paired samples. Furthermore, geometric mean ratios with 95% conﬁ dence 
intervals were calculated for every comparison, and the model used included 
adjustment for the treatment sequence. Th e values for Cmax sampling time (Tmax) were 
not transformed and were compared with the Wilcoxon signed-rank test. A P-value ≤ 
0.05 was considered to be signiﬁ cant in all analyses. 
Th e incidence of adverse events was calculated separately for the ﬁ rst and second study 
period according to both dosages. It was expressed as the percentage of participants 
that reported a particular adverse event at least one time during the six consecutive 
reporting times in every study period. Statistical signiﬁ cance between groups was 
tested with the McNemar-Test for dichotomized paired samples. Consequently, every 
reported mild, moderate or severe adverse event was ascribed a severity score of 1, 
2 or 3 points, respectively. All scores were added up for every participant and were 
divided by the number of reporting times. In this way the mean toxicity scores for 
both dose groups were obtained for all individual participants. Diﬀ erences in toxicity 
scores between groups were calculated with the use of the Wilcoxon test for paired 
samples. Correlation between parameters was calculated with the Pearson correlation 
coeﬃ  cient (r) or Spearman’s correlation coeﬃ  cient (rs). 
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Results
Study subjects
Sixteen subjects were included in the study (seven female, nine male); 15 of those 
completed both study periods. One participant had to be withdrawn after switching 
to the higher indinavir dose due to an adverse event (ﬂ ank pain and crystalluria). 
Accordingly, this subject was included into the analysis of safety and tolerability, but 
was excluded from the calculation of pharmacokinetic parameters. Th e mean age of 
subjects was 30 years (age range, 24–41 years) and mean weight was 71 kg (weight range, 
49–90 kg). Th e combination of methods for measurement of compliance allowed for a 
reliable estimation of adherence to study medication. Compliance was excellent in all 
volunteers. Th ere were no reported doses missed. Th ree subjects reported a deviation 
in time of drug intake (one deviation each); two subjects reported two deviations each. 
None of these time deviations occurred prior to 3 days before study days 14 and 28. 
Figure 1. Indinavir steady-state plasma concentration-time proﬁ les
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Pharmacokinetics of indinavir
Dose reduction of indinavir resulted in a decrease in indinavir AUC0–∞, Cmax and 
Cmin (Table 1, Figures 1 and 2). 
Indinavir AUC0–∞ decreased in all subjects; Cmax decreased in all but one subject, 
in whom it increased from 4.82 to 5.28 mg/L despite dose reduction of indinavir; 
similarly, Cmin decreased in all but one subject, in whom it increased from 0.28 to 0.35 
mg/L. After dose reduction three out of 15 subjects in the 400 mg group had Cmin 
values below the recommended threshold of 0.10 mg/L (Figure 2). 
Figure 2. Indinavir minimum plasma concentration
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variability in Cmin values narrowed after dose reduction of indinavir. 
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Cmin above 0.675 mg/L7, whereas all subjects with treatment 1 (400 mg indinavir twice 
daily) had Cmin values below those thresholds. In the 600 mg indinavir group there 
were two subjects with indinavir Cmax values above 8 mg/L1. No subject in this group 
had indinavir Cmax values above 10 mg/L15, as all subjects in the 400 mg indinavir 
group had Cmax values below those thresholds. 
Total clearance increased signiﬁ cantly after dose reduction of indinavir. However, no 
signiﬁ cant changes were seen in either renal clearance of indinavir or the fraction of 
indinavir excreted unchanged with urine. Th e cumulative renal excretion of indinavir 
was higher in the 600 mg twice daily group than in the 400 mg twice daily group.
Table 1. Summary of steady-state pharmacokinetic parameters of indinavir (n=15)
Geometric mean and range  Parameter 
Treatment 1† Treatment 2‡ 
geometric mean ratio 
(treatment 1 /treatment 2) 
[95% CI] 
P value#
AUC0-infinity (h.mg/L) 16.18 (9.98-29.63) 30.15 (17.47-56.52) 0.54 [0.48-0.61] <0.001 
Cmin (mg/L) 0.19 (0.08-0.36) 0.49 (0.16-1.82) 0.38 [0.28-0.54] 0.002 
Cmax (mg/L) 3.84 (2.68-5.28) 6.03 (4.82-8.42) 0.63 [0.56-0.71] <0.001 
Tmax (h)* 1.75 (0.50-4.0) 2.0 (1.0-4.0)  0.094 
CL/F (L/h) 24.42 (13.75-39.97) 19.93 (11.13-34.94)  0.001 
CL/F.kg (L/h.kg) 0.34 (0.20-0.46) 0.28 (0.19-0.43)   
Vd (L) 74.88 (43.58-124.79) 68.12 (45.95-110.65)   
Vd/F.kg (L/kg) 1.07 (0.63-1.85) 0.96 (0.72-1.27)   
T1/2 (h) 2.20 (1.68-2.79) 2.41 (1.94-3.64)   
Ae (mg)$ 211 (152-229) 313 (249-345)   
CLR/F.kg (L/h.kg)$ 0.18 (0.16-0.26) 0.16 (0.15-0.23)   
Fe.F$ 0.53 (0.38-0.57) 0.52 (0.42-0.57)   
 
CI, Confidence interval; AUC, area under the concentration-time curve; Cmin, trough concentration at 12 hours; 
Cmax, highest observed plasma concentration; Tmax, sampling time for Cmax; CL, total clearance; CL/F.kg, total 
clearance corrected for weight; Vd (L), volume of distribution; Vd/F.kg (L/kg), volume of distribution corrected 
for weight; T1/2, elimination half-life; F, bioavailability 
* Median and range; Wilcoxon-signed rank test 
# P value for the difference between PK parameters in the two study periods; 2-sided t-test for paired data 
† Combination of 400 mg indinavir and 100 mg ritonavir twice a day 
‡ Combination of 600 mg indinavir and 100 mg ritonavir twice a day 
$ Median and range; based on data of 4 subjects 
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Pharmacokinetics of ritonavir 
Dose reduction of indinavir resulted in a signiﬁ cant decrease of ritonavir Cmin and 
Tmax (Table 2). Th ere was a trend to a lower AUC0–∞ of ritonavir, which, however, 
did not reach statistical signiﬁ cance. Ritonavir Cmax remained unchanged after dose 
modiﬁ cation of indinavir. Th ere was a signiﬁ cant correlation of Cmin concentrations 
of ritonavir and indinavir in both dosage groups (600 mg group: Pharmacokinetics 
of indinavir/ritonavir in reduced dose rs=0.864, P<0.001; 400 mg group: rs=0.788, 
P<0.001) as well as of the AUC of both substances (600 mg group: rs=0.827, P<0.001; 
400 mg group: rs=0.836, P<0.001). 
Table 2. Summary of steady-state pharmacokinetic parameters of ritonavir (n=15)
Safety and tolerability
One subject discontinued medication after switching to the higher indinavir dose of 
600 mg twice daily because of ﬂ ank pain and crystalluria. When taking the 400 mg 
indinavir dosage Cmax and AUC values for indinavir were not signiﬁ cantly higher in 
this subject than in the other subjects (Cmax 4.3 mg/L, geometric mean for the other 15 
subjects was 3.9 mg/L; AUC 22.8 mg/L, geometric mean 17.5 mg/L). Th e Cmin value 
of this subject was 0.34 mg/L. Th ere were two other adverse events grade 3 (diarrhoea, 
taste disturbance) that occurred in two subjects after beginning medication with the 
Geometric mean and range 
 
 Parameter 
Treatment 1† Treatment 2‡ P value# 
AUC0-infinity (h.mg/L) 9.25 (4.37-21.47) 11.47 (5.75-27.02) 0.06 
Cmin (mg/L) 0.23 (0.09-0.67) 0.42 (0.16-1.72) <0.001 
Cmax (mg/L) 1.55 (0.67-3.64) 1.66 (0.78-5.04) 0.62 
Tmax (h) * 1.50 (0.50-5.00) 4.08 (1.00-6.00) 0.009 
CL/F (L/h) 11.68 (4.82-26.66) 9.49 (3.60-24.54)  
CL/F.kg (L/h.kg) 0.16 (0.07-0.32) 0.13 (0.06-0.40)  
Vd (L) 54.99 (17.57-140.80) 45.84 (9.33-219.23)  
Vd/F.kg (L/kg) 0.77 (0.25-2.23) 0.64 (0.16-3.59)  
T1/2 (h) 3.26 (2.51-5.50) 3.35 (1.80-6.52)  
 
CI, Confidence interval; AUC, area under the concentration-time curve; Cmin, trough concentration at 12 hours; 
Cmax, highest observed plasma concentration; Tmax, sampling time for Cmax; CL, total clearance; CL/F.kg, total 
clearance corrected for weight; Vd (L), volume of distribution; Vd/F.kg (L/kg), volume of distribution corrected 
for weight; T1/2, elimination half-life; F, bioavailability 
* Median and range; Wilcoxon-signed rank test 
# P value for the difference between PK parameters in the two study periods; 2-sided t-test for paired data 
† Combination of 400 mg indinavir and 100 mg ritonavir twice a day 
‡ Combination of 600 mg indinavir and 100 mg ritonavir twice a day 
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lower indinavir dose of 400 mg twice daily. Both did not lead to discontinuation and 
resolved within a few days without intervention. 
Th e incidence of adverse events as assessed by repeated questioning of the participants 
is summarized in Table 3. Th e mean toxicity score for treatment 1 (400 mg indinavir 
twice daily) was 2.5 (range, 0–10). In 14 of 16 subjects the severity score increased 
with the higher dose of indinavir (600 mg twice daily) during treatment 2. Mean 
toxicity score for this treatment period was 4.2 (range, 0.3–10.3; P=0.008). In the 
600 mg group four subjects reported dysuria and one subject discontinued due to 
ﬂ ank pain as mentioned above. On the other hand, in the 400 mg group two subjects 
reported dysuria and no subject discontinued. Eight subjects developed crystalluria 
without a signiﬁ cant diﬀ erence between both dosage groups. Close examination of 
Table 3 and the corresponding toxicity scores revealed that not only did the incidence 
of kidney-related adverse events increase, but also the median toxicity score for 
kidney-related adverse events. Th e median toxicity score for all kidney-related adverse 
events (dysuria, ﬂ ank pain and/or crystalluria) increased from 0.35 to 0.44 (P=0.72). 
Primarily, an increase in the toxicity score for the clinical symptoms dysuria and 
ﬂ ank pain contributed to this deterioration (0.06–0.23; P=0.18). On the contrary, 
the median toxicity score for all adverse events related to the gastrointestinal system 
(nausea, abdominal pain, meteorism, vomiting, diarrhoea) was 1.50 for treatment 
1 and 1.56 for treatment 2, and did not diﬀ er signiﬁ cantly (P=0.82). Th ere was no 
clear correlation between indinavir AUC, Cmax or Cmin, and mean toxicity score or any 
organ-related toxicity score, respectively. 
Th e incidence and severity of dry skin and dry lips, which are usually regarded as 
adverse events related to indinavir, as well as of paresthesia, oral discomfort and taste 
disturbance, which are assumed to be related to ritonavir, were higher during the 
treatment with indinavir 600 mg twice daily. 
Analysis of laboratory parameters in all 16 subjects showed no signiﬁ cant diﬀ erences 
in laboratory parameters between groups at baseline apart from creatinine, which 
was not clinically signiﬁ cant (group 1: 1.1 ±0.1 mg/dl; group 2: 0.9 ±0.1 mg/dl; 
P=0.001; normal range for creatinine: <1.4 mg/dl). Clinically relevant changes in 
laboratory parameters were observed only for total bilirubin, fasting triglyceride and 
fasting cholesterol levels. Total bilirubin increased in all subjects from 0.57 ±0.32 mg/
dl (mean ±SD) at baseline to 1.34 ±0.60 mg/dl at the maximum (P=0.004, normal 
range for total bilirubin: 0.1–1.2 mg/dl). Fasting triglyceride levels increased from 88 
±46 mg/dl at baseline to 134 ±65 mg/dl at the maximum (P=0.001, normal range 
for fasting triglyceride: <200 mg/dl). Fasting cholesterol levels increased from 187 
±38 mg/dl at baseline to 229 ±49 mg/dl at the maximum (P<0.001, normal range for 
fasting cholesterol: <220 mg/dl). Th ere was a very small increase in creatinine values, 
which, however, was not clinically relevant (0.98 ±0.14 versus 1.06 ±0.15 mg/dl; 
P=0.004; normal range: 0.5–1.4 mg/dl). Th ere were no changes in serum GGT, ALT, 
AST, plasma glucose, total blood leukocytes, haemoglobin or thrombocytes. Th ere 
was no correlation between increases in bilirubin, cholesterol or triglyceride levels and 
any pharmacokinetic parameter of indinavir or ritonavir. 
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Table 3. Incidence of adverse events in % (n=16)
Adverse event Treatment 1† Treatment 2‡ P-value* 
Abdominal Pain 44 25 0.25 
Diarrhoea 56 56 1.0 
Meteorism 69 56 0.625 
Nausea 31 50 0.25 
Vomiting 0 13 0.5 
Total Gastro intestinal 40 40 1.0 
Crystalluria 38 31 1.0 
Dysuria 13 25 0.625 
Flank Pain 0 13 0.5 
Total Kidney-related 17 23 1.0 
Fever 0 0 1.0 
Headache 19 31 0.5 
Joint Pain 0 6 1.0 
Muscle Pain 13 13 1.0 
Oral discomfort 38 44 1.0 
Paresthesia 6 31 0.125 
Skin Abnormalities 38 50 0.625 
Taste disturbance 50 69 0.25 
Tiredness 38 44 1.0 
Weakness 31 38 1.0 
Not in the questionnaire:    
Dry lips 25 44 0.25 
Epigastric Pain 6 0 1.0 
Pimples 0 6 1.0 
Sweats 13 6 1.0 
Uric urge 6 6 1.0 
Vertigo 6 6 1.0 
 
† Combination of 400 mg indinavir and 100 mg ritonavir twice a day 
‡ Combination of 600 mg indinavir and 100 mg ritonavir twice a day 
*McNemar-Test for dichotomized paired samples 
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Conclusions
Th e results of this study describe steady-state pharmacokinetic data for two reduced 
dosages of twice daily combinations of indinavir and low-dose ritonavir in healthy 
volunteers. As expected, they show that exposure to indinavir is reduced after 
reduction of indinavir dose. Compared to reported pharmacokinetic parameters of 
indinavir when administered as indinavir/ritonavir 800/100 mg twice daily, indinavir 
exposure was even lower (reported values for Cmax: 6.8–8.7 mg/L; Cmin: 0.44–0.99 
mg/L; AUC: 37.7–44)9,10,16. 
It has been shown that antiviral eﬃ  cacy of indinavir is dependent on Cmin values, which 
should be kept above a certain threshold in order to obtain and maintain adequate 
suppression of viral replication17. Th ere are diﬀ erent thresholds for indinavir trough 
concentrations, but lately a threshold of 0.10 mg/L has been proposed to be adequate 
for indinavir in naive patients17,18, which we have taken for the analysis in this study. 
Th ere were no Cmin values in any of the subjects below this threshold in the 600 mg 
indinavir group. Even the lowest indinavir Cmin observed in this group (0.16 mg/L) 
was equivalent to the mean Cmin in the regimen of indinavir three times a day19, and 
it is safely above the presumed therapeutic threshold of 0.10 mg/L. However, after 
dose reduction of indinavir to 400 mg there were three subjects (20%) with Cmin 
values of indinavir below this threshold, thereby provoking the risk of possible viral 
replication and resistance development in case of HIV infection. Th us, indinavir dose 
cannot safely be lowered without controlling the resulting Cmin value of indinavir. All 
subjects with Cmin values below the 0.10 mg/L threshold were relatively heavy men. 
Accordingly, there was a linear correlation between Cmin values of indinavir and the 
body weight of the subjects. However, there were heavy men with adequate Cmin values 
also, and, therefore, it does not seem possible to predict the safety of dose reduction 
in an individual patient based on body weight. Th erapeutic drug monitoring (TDM) 
in the individual patient could overcome this uncertainty. A recent clinical study of 
indinavir/ritonavir 400/100 mg twice daily in HIV-infected patients showed that 
this dosage may be eﬀ ective in the treatment of HIV infection as compared to the 
traditional indinavir 800 mg three times a day dosage8. In contrast to our study, Cmin 
values were above the threshold of 0.10 mg/L in all compliant patients studied (lowest 
observed Cmin value 0.14 mg/L). Th ere are several explanations to this discrepancy. 
First, it is a study in HIV-infected patients and not healthy volunteers. Th ere 
might be diﬀ erences in tolerability that may be better in HIV-infected patients, or 
pharmacokinetics that contribute to the divergent results of our study and the study 
by Ghosn et al. Pharmacokinetics in HIV-infected patients may be signiﬁ cantly 
altered due to concomitant medication possibly interfering with indinavir or ritonavir 
metabolism, or underlying diseases such as chronic hepatitis. On the other hand, there 
might be a selection bias, as only patients virologically suppressed were included by 
Ghosn et al. Accordingly, patients in that study had relatively high Cmin values with the 
three times a day regimen. From our results we conclude that the indinavir/ritonavir 
400/100 mg twice daily regimen should not be administered without the use of TDM. 
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Nevertheless, the study by Ghosn et al. together with our data indicates that a reduced 
dose of ritonavir-boosted indinavir might be beneﬁ cial in the clinical setting.
Similar to indinavir, the exposure to ritonavir was reduced after reduction of indinavir 
dose. Th is ﬁ nding was not anticipated, but is not surprising as indinavir has an 
inhibiting eﬀ ect on the metabolism of ritonavir20. Accordingly, during treatment with 
the higher indinavir dose of 600 mg twice daily the metabolism of ritonavir possibly has 
a more pronounced inhibition than by the lower dose of 400 mg twice daily, resulting 
in increased ritonavir exposure. Interestingly, ritonavir levels in the 600 mg period 
resulted in a non-linear increase of indinavir levels after increase of indinavir dosage 
from 400 to 600 mg twice daily (data not shown). Th is also might be an explanation 
for the narrowing of indinavir Cmin concentrations after dose reduction of indinavir. 
Higher ritonavir levels are associated with higher indinavir levels than expected (this is 
supported by the ﬁ nding of signiﬁ cant correlations between Cmin values in both dosage 
groups). Th erefore, more inhibition of indinavir metabolism by ritonavir in the 600 mg 
group compared to the 400 mg group in general might lead to more variability in the 
600 mg group. However, the clinical consequence of pharmacokinetic changes have to 
be derived from indinavir pharmacokinetics rather than from ritonavir, because low-
dose ritonavir is meant only as a pharmacokinetic enhancer and will not contribute to 
the antiviral eﬀ ect of this indinavir/ritonavir combination. 
In contrast to antiviral eﬃ  cacy, it is assumed that the development of indinavir-
related toxicity depends on the height of plasma levels19. In particular, nephrotoxicity, 
which is caused by precipitation of indinavir-containing crystals in the urinary tract, 
seems to be dependent on the height of the plasma level5,15,21. Furthermore, there is 
anecdotal evidence that other indinavir-related side eﬀ ects (nausea, vomiting, skin 
abnormalities, hyperbilirubinaemia) are associated with higher peak plasma levels of 
indinavir, and that these side eﬀ ects disappear when plasma levels approach average 
population values. In general, indinavir plasma concentrations above 8 mg/L appear 
to be associated with severe side eﬀ ects1, although other thresholds have been deﬁ ned 
also7,14,15. Th is hypothesis appears to be conﬁ rmed in our study. Th e overall incidence 
and median toxicity score of adverse events are lower in the 400 mg than in the 600 
mg indinavir group. Although there was no clear statistical correlation to speciﬁ c 
pharmacokinetic parameters of indinavir, which is diﬃ  cult to draw, there is a clear 
association of indinavir dosage and severity of adverse events. Th e most limiting 
adverse event of indinavir is nephrotoxicity, clinically resulting in the development of 
ﬂ ank pain, dysuria and kidney stones. In our study, one subject had to be withdrawn 
because of severe ﬂ ank pain and dysuria, although a kidney stone was not found. Th is 
particular subject had tolerated the lower indinavir dose of 400 mg quite well with 
minor dysuria, but had to discontinue after switching to the higher indinavir dose of 
600 mg. Of note, all subjects had to add an amount of 1.5 l water to their usual daily 
ﬂ uid intake19,22. Despite this measure, which was followed by this subject, severe ﬂ ank 
pain could not be avoided. Cmax and AUC values for indinavir were not signiﬁ cantly 
higher in this subject than in the other subjects, and the Cmin indinavir concentration 
of this subject was well below the recently deﬁ ned upper thresholds of 0.5 or 0.675 
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mg/L, which have been associated with higher indinavir toxicity7,14. 
It has to be taken into account that volunteers in this study were healthy volunteers 
not used to take medication regularly. It is not possible to transduce the results directly 
to HIV patients. On the contrary, compared to other studies with healthy volunteers 
the drop-out rate in this study is very low, thereby indicating the good tolerance of 
both indinavir/ritonavir combinations. Not all adverse events observed are necessarily 
linked to indinavir. Especially, perioral disturbances/oral discomfort and paresthesias 
are known to be speciﬁ c to ritonavir. Unexpectedly, the incidence and severity of 
these adverse events was higher in the indinavir 600 mg group also. Th e elevated 
AUC of ritonavir in this group best explains this, although Cmax values did not diﬀ er 
signiﬁ cantly between both dosage groups. However, it is known that these side eﬀ ects 
can resolve after a longer period of time, whereas our subjects took each dosage only 
for 2 weeks. 
In this study, there is no possibility to assess whether a reduced dose of indinavir will 
result in a reduced incidence or severity of long-term side eﬀ ects such as lipodystrophy/
lipoatrophy and associated changes. Interestingly, we found a signiﬁ cant change in 
fasting cholesterol and triglyceride levels, thereby indicating a metabolic inﬂ uence of 
indinavir/ritonavir already after the 2-week period. In general, these side eﬀ ects are 
considered to be long-term side eﬀ ects also. Despite hyperbilirubinaemia there was no 
other relevant change in laboratory parameters, especially liver transaminases. 
Th eoretically, the optimal way to use indinavir is to keep trough levels above the 
threshold for HIV suppression and to avoid high peak levels. Th e results of our 
study show that this goal can by achieved by dose reduction of indinavir/ritonavir 
combination as compared to the common dose of 800 mg indinavir twice daily boosted 
by low-dose ritonavir. However, with the dose of 600 mg indinavir twice daily some 
patients will still suﬀ er from indinavir-related toxicity, whereas lowering the indinavir 
dose to 400 mg bears the risk of insuﬃ  cient indinavir plasma levels. Th erefore, it seems 
to be mandatory to perform TDM in the individual patient to guide antiretroviral 
therapy of the indinavir/ritonavir twice daily combination. Th e clinical eﬀ ectiveness of 
this approach has to be evaluated in further prospective clinical trials.
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Abstract
Aims: A once daily (QD) nucleoside-sparing regimen can prevent mitochondrial 
toxicity, overcome viral resistance and improve compliance. In the present study the 
eﬀ ect of efavirenz on the pharmacokinetics and tolerability of once daily nelﬁnavir/
ritonavir was evaluated in healthy subjects. 
Methods: Th is was a multiple-dose, open-label, single-group, two-period study in 24 
healthy subjects. Each received from days 1–10 (period 1): 1875 mg nelﬁnavir plus 200 
mg ritonavir QD with a 300-kcal snack. During days 11–20 (period 2) efavirenz 600 
mg QD was added to the regimen. Blood samples were collected up to 24 h after dosing 
on days 10 (period 1) and 20 (period 2). High-performance liquid chromatography 
methods were used for the determination of the concentrations of all compounds. 
Th e main pharmacokinetic parameters were calculated using noncompartmental 
methods. 
Results: All subjects completed the study. After the ﬁrst period mean nelﬁnavir 
AUC0-24 h, Cmax and C24 were 49.6 h.mg/L, 5.0 mg/L and 0.37 mg/L, and the sum of 
nelﬁnavir plus its active metabolite M8 C24 was 0.83 mg/L. Th e relative bioavailability, 
expressed as a geometric mean ratio (90% conﬁdence interval) for nelﬁnavir 0-24 h, 
Cmax and C24 of period 2 compared with period 1 was: 1.30 (1.21, 1.40), 1.29 (1.19, 
1.40) and 1.48 (1.32, 1.66). Th e sum of nelﬁnavir and M8 C24 in period 2 was 0.99 
mg/L, an increase of 19%. No serious adverse events occurred. 
Conclusions: Th e studied regimens were well tolerated. Nelﬁnavir/ritonavir given 
together with efavirenz resulted in a 48% higher mean C24 for nelﬁnavir, and the sum 
of nelﬁnavir and M8 C24s was 0.99 mg/L. Efavirenz exposure in this study was similar 
to that reported previously, and therefore can be used eﬀ ectively in combination with 
ritonavir and nelﬁnavir. 
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Introduction 
Since the introduction of protease inhibitors (PIs) in the mid 1990s for the treatment 
of HIV infection, life expectancy has increased substantially1,2. Neverthe less, treatment 
with highly active antiretroviral therapy (HAART) can still be improved, as efﬁcacy is 
not 100%. Major concerns in treatment with HAART are the occur rence of adverse 
events3, failure of compliance4 and development of viral resistance3. To improve the 
treatment of HIV-infected persons these problems need to be overcome. A nucleoside-
sparing regimen can pre vent nucleoside reverse transcriptase inhibitor (NRTI)-
induced mitochondrial toxicity, prevent NRTI (cross-) resistance and/or lead to an 
increase in the susceptibility of HIV to non-nucleoside reverse transcriptase inhibitors 
(NNRTIs)5. To improve compliance, and thus viro logical outcome4, simpliﬁcation of 
antiretroviral dos ing regimens seems to be eﬀ ective6, 7. 
We have previously demonstrated that nelﬁnavir in combination with ritonavir 
can be given once daily, at optimal doses of 2000 mg and 200 mg, respectively8. As 
a potent inhibitor of the cytochrome P450 (CYP) enzyme CYP3A49, ritonavir is 
used in these circum stances to boost plasma nelﬁnavir concentrations to achieve a 
durable therapeutic response. CYP3A4 is mainly responsible for the metabolism of 
nelﬁnavir10. However, the formation of the virologically active11 metabolite nelﬁnavir-
hydroxy-t-butylamide (desig nated M8) is primarily dependent on CYP2C1912. M8 
is subsequently metabolized by CYP3A4 into inac tive metabolites12. Th erefore, the 
combination of nelﬁnavir with ritonavir will result in both increased nelﬁnavir and 
M8 concentrations13,14. 
In the current study nelﬁnavir was given in form of new 625-mg tablets instead of 
250-mg tablets. Th e new formulation was choosen for two reasons. It is expected to 
be marketed within a relative short period and enables the dosage of 1875 mg QD to 
be taken as three tablets only, which is more convenient for the patients. Ritonavir was 
dosed at 200 mg QD and efavirenz at 600 mg QD, once daily in the evening, to avoid 
potential neurological adverse events15. Nelﬁnavir should be given during the day and 
with food16. In the present study nelﬁnavir, ritonavir and efavirenz were all taken at 
bedtime (23.00 h) together with a snack of around 300 kcal. 
Th e primary objective of this study was to character ize the pharmacokinetics of 
nelﬁnavir boosted by ritonavir when administered once daily with efavirenz in healthy 
subjects. Th e secondary objective was to determine the inﬂuence of nelﬁnavir when 
combined with ritonavir on the pharmacokinetics of efavirenz. Tolerability of the 
once daily regimen was also studied, as well as the inﬂuence of giving nelﬁnavir in the 
evening as opposed to the morning. 
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Methods 
Study design 
Th is was a multiple-dose, open-label, single-group, two-period study in 24 healthy 
subjects (12 males). Subjects received the following treatments: period 1 (days 1–10), 
1875 mg nelﬁnavir plus 200 mg ritonavir to be taken once daily at 23.00 h with a 
light snack of around 300 kcal; period 2 (days 11–20), 1875 mg nelﬁnavir plus 200 
mg ritonavir and 600 mg efavirenz to be taken once daily at 23.00 h with a light snack 
(around 300 kcal). Blood samples were collected throughout a 24-h period on days 
10 and 20 following a light meal of 315 kcal. Th is consisted of one slice of bread with 
butter and cheese, or peanut butter, or two slices of sausage, together with a glass 
of semi skimmed milk (3.75% fat). All other meals eaten on the pharmacokinetic 
evaluation days were standardized (breakfast 485 kcal, lunch 656 kcal and dinner 
1231 kcal). Medication was swal lowed with 200 ml of noncarbonated water. 
Subject selection 
All subjects had to be in generally good health, appro priate for their age as established 
by medical history, physical examination, electrocardiography, blood pres sure, heart 
rate, and the results of biochemistry, haema tology and urinalysis performed within 
3 weeks before the ﬁrst dose. Subjects had to be between 18 and 65 years old. Body 
mass index had to be in the range of 18–30 kg/m2. Subjects were not allowed to 
smoke more than 10 cigarettes, two cigars or two pipes per day, for at least 3 months 
prior to the study. Th e protocol was explained comprehensively to all subjects, and 
written informed consent was obtained prior to screening. Exclusion criteria included 
a febrile illness within 3 days before the ﬁrst dose, exposure to any drug, except for 
paracetamol, hormonal contraceptives and lopera mid, participation in another drug 
trial and/or donation of blood within 60 days before the study, and hypersen sitivity 
to nelﬁnavir, ritonavir or efavirenz. In addition, counselling and conﬁrmation of using 
adequate contra ception were required for all females of child-bearing age. Pregnant or 
breast-feeding subjects were excluded. Th e study was approved by the Regional Ethics 
Review Board, located in Nijmegen, Th e Netherlands. 
Blood sampling 
Blood samples of 5 ml were collected in heparinized hard plastic tubes at the following 
time points: predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, and 24 h after 
drug intake on days 10 and 20, and at 9 h postdose on days 1, 4, 7, 14 and 17. Blood 
samples were centrifuged at 2500 g for 10 min at 4 °C. Plasma was stored at –18 °C 
within 2 h after collection. 
Clinical assessment 
Blood samples after fasting for serum biochemistry [including glucose, total bilirubin, 
direct bilirubin (in case total bilirubin was above normal range), aspartate amino 
transferase (ASAT), alanine amino transperase (ALAT), gamma glutamyl transferase 
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(GGT), alkaline phosphatase, creatinine kinase, amylase, total choles terol, high-
density lipoprotein (HDL), low-density lipo protein (LDL), triglycerides, creatinine 
and potassium], haematology and a urine sample for urinalysis were taken at days 1, 4, 
7, 11, 14, 17 and 21. In females of childbearing age an instant β-hCG urine pregnancy 
test was performed at each visit. A urine drug screen for tetrahydrocannabinol (THC), 
morphine, cocaine and amphetamines was performed on day 1 and at the start of 
study days 10 and 20, using the InstacheckTM Multi-Drug Screen panel (Forefront 
Diagnostics, San Diego, CA, USA). Blood pressure and heart rate were monitored 
throughout the study. Subjects were monitored for adverse events by the medical and 
nursing staﬀ  at the trial centre. Subjects also reported any adverse events in response 
to general questioning. For each adverse event the following infor mation was recorded: 
onset and resolution date and time, intensity, relationship to trial medication, action 
taken, and outcome. All adverse events occurring between the ﬁrst intake of the trial 
medication and 30 days after the end of the trial were reported. Adverse events were 
classiﬁed as unrelated, doubtful, possible and probable, and were assessed for intensity 
according to AIDS Clinical Trial Group (ACTG) classiﬁcations: mild (symptoms do 
not interfere with daily activities), moderate (symptoms interfere with daily activities), 
severe (symptoms markedly interrupt daily activities) or serious. Th e latter were deﬁned 
as those that at any dose resulted in death, were life threatening, required in patient 
hospitalization or prolongation of existing hos pitalization, resulted in a persistent or 
signiﬁcant disability/incapacity or were congenital anomalies/birth defects. 
Drug analysis 
A validated high-performance liquid chromatography (HPLC) method with ultra-
violet detection was used for the determination of nelﬁnavir, M8 and ritonavir con-
centrations in plasma as published previously17. Th e lower limit of quantiﬁcation was 
0.04 mg/L for nelﬁ navir and ritonavir, and 0.10 mg/L for M8. For nelﬁ navir, accuracy 
ranged from 96% to 100% depending on the concentration. Intraday and interday 
precision ranged from 2.1% to 7.5% and from 0.4% to 3.5%, respectively. For ritonavir, 
accuracy ranged from 102% to 108%, and intraday and interday precision from 2.0% 
to 8.1% and 0% to 2.4%, respectively. For M8, accuracy ranged from 93% to 108%, 
and intraday and interday precision from 2.8% to 4.3% and 2.0% to 3.0%, respectively. 
A HPLC method with ultraviolet detection was also used for the analysis of 
efavirenz18. Th e lower limit of quantiﬁcation was 0.20 mg/L. Accuracy ranged from 
99% to 101%, and intraday and interday precision from 1.8% to 2.6% and from 1.1% 
to 2.8%, respectively. 
Pharmacokinetic analysis 
Th e following pharmacokinetic parameters were calcu lated using noncompartmental 
analysis (Excel version 2000, Microsoft Corporation 1985–1999): AUC0–24 h (h.mg/
L), the area under the plasma concentration– time curve; Cmax (mg/L), the maximum 
plasma drug concentration; C24 (mg/L), the plasma drug concentra tion at 24 h after 
drug dosing; Tmax (h), the time to reach maximum plasma drug concentration; T1/2 
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(h), apparent elimination half-life; CL/F (l/h), apparent clearance; Vd/F (l), apparent 
volume of distribution. CL/F and Vd/F were not calculated for M8. If ritonavir 
plasma con centrations at the end of the 24-h dosing interval were lower than the 
quantiﬁcation limit of 0.04 mg/L, they were estimated from the last quantiﬁable 
plasma con centration and the elimination constant. 
Statistical analysis 
For AUC0–24h, Cmax and C24 results were presented for treatment period 1 and 
treatment period 2 together with the ratios period 2 : period 1. Th e geometric mean 
and min–max range corresponding to mean and min–max range in the logarithmically 
transformed domain were given for both periods. Th e parametric point estimate 
(ratio estimate) and 90% conﬁdence intervals were cal culated for the ratio period 
2 : period 1. Treatments were considered bioequivalent if the respective 90% classical 
conﬁdence intervals for the AUC0–24h, C24 and Cmax ratios were included within the 
range of 0.80–1.2519. Tmax, T1/2, CL/F and Vd/F were considered to be secondary 
characteristics, the analysis of which was explorative. Tmax data were not log-
transformed and were compared between treatment periods using a Wilcoxon signed 
ranks test. Pharmacokinetic parameters for efavirenz were com pared with historical 
controls derived from a previously published study in healthy subjects18. 
Data on adverse events were classiﬁed according to system organ class using MedDRA 
V 4.1 coding (Med-DRA MSSO, Reston, VA, USA). Frequencies and per centages 
of occurred adverse events were tabulated. Laboratory values were graded according 
to toxicity scales. For ALAT, ASAT and GGT Grade 1 was deﬁned as 1.25–2.5 
times upper limit of normal (ULN), Grade 2 was 2.6–5.0 times ULN. For amylase 
Grade 1 was 1.1–1.3 times ULN and Grade 2 was 1.4–2.0 times ULN. For total 
cholesterol Grade 2 was 6.19– 7.77 mmol/L
 
and Grade 3 was 7.77–10.35 mmol/L. 
Grade 1 cholesterol was not used as it overlapped with the laboratory normal ranges. 
For triglycerides Grade 2 was 4.52–8.47 mmol/L
 
and Grade 3 was 8.48– 13.55 
mmol/L. For creatinine and total bilirubin Grade 6.42–8.91 mmol/L. For creatine 
phosphokinase Grade 1 was 1.1–2.0 times ULN, Grade 2 was 2.1–4.0 times ULN 
and Grade 3 was 4.1–6.0 times ULN. For HDL- and LDL-cholesterol no toxicity 
grades were deﬁned. In addition, for each laboratory parameter the median change 
from the baseline value to the highest observed value was calculated as well as the 
median change from the baseline value to the last observed value in the study. 
Results 
Twenty-four subjects (12 males and 12 females) com pleted the study. All subjects were 
Caucasian except for one Black male. Th e mean age of the subjects was 45 years, mean 
weight 72 kg, and mean height 1.74 m. Pharmacokinetic results for nelﬁnavir, its active 
metabolite M8, ritonavir and efavirenz are presented in Table 1. 
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Table 1. Pharmacokinetic data for nelﬁ navir, M8, ritonavir and efavirenz (n=24)
 Geometric Mean (Range) 
 Period 1† Period 2‡ 
Relative Bioavailability& 
GMR (90% CI) 
P-value#
Nelfinavir     
AUC0-24 49.6 (22.6-94.6) 64.3 (30.0-106.6) 1.30 (1.21-1.40) <0.01 
Cmax 5.0 (2.4-8.2) 6.4 (3.5-10.7) 1.29 (1.19-1.40) <0.01 
C24 0.37 (0.12-1.33) 0.55 (0.14-1.26) 1.48 (1.32-1.66) <0.01 
Tmax* 4.0 (2.5-6.0) 4.0 (2.0-6.0)  0.64 
T1/2 5.4 (4.0-8.4) 5.7 (4.1-8.0)  0.02 
Cl/F 38.1 (20.9-83.5) 29.6 (17.5-66.0)  <0.01 
Vd/F 296.6 (181.4-590.2) 242.9 (164.3-461.9)  <0.01 
M8     
AUC0-24 39.0 (26.0-68.2) 36.1 (20.3-75.2) 0.93 (0.87-1.00) 0.09 
Cmax 3.4 (2.0-5.8) 3.0 (1.7-5.3) 0.87 (0.81-0.92) <0.01 
C24 0.46 (0.22-1.16) 0.44 (0.17-1.31) 0.96 (0.85-1.09) 0.59 
Tmax* 5.0 (4.0-6.0) 6.0 (4.0-8.1)  0.01 
T1/2 6.4 (4.5-8.9) 6.3 (4.7-9.1)  0.39 
Ritonavir     
AUC0-24 17.5 (7.8-31.8) 14.0 (4.7-28.4) 0.80 (0.72-0.88) <0.01 
Cmax 2.4 (1.2-5.1) 1.8 (0.59-3.2) 0.76 (0.67-0.85) <0.01 
C24 0.04 (0.00$-0.14) 0.04 (0.01$-0.10) 0.88 (0.73-1.06) 0.24 
Tmax* 4.0 (1.5-8.0) 3.5 (1.5-8.0)  0.96 
T1/2 3.3 (2.2-4.1) 3.5 (2.4-4.7)  0.02 
Cl/F 11.4 (6.3-25.5) 14.3 (7.1-41.9)  <0.01 
Vd/F 54.3 (29.2-100.8) 72.1 (31.0-231.5)  <0.01 
Efavirenz     
AUC0-24  64.0 (37.9-156.9)   
Cmax  4.7 (2.9-8.7)   
C24  2.0 (1.1-5.5)   
Tmax  2.5 (1.0-10.0)   
T1/2  30.4 (14.5-73.8)   
Cl/F  8.3 (2.9-14.0)   
Vd/F  365.3 (157.9-864.3)   
 
GMR, Geometric Mean Ratio; CI, Confidence interval; AUC0-24, (h.mg/L) area under the concentration-time 
curve; Cmax, (mg/L) highest observed plasma concentration; C24, (mg/L) trough concentration at 24 hours; Tmax, 
(h) sampling time for Cmax; T1/2, (h) elimination half-life; Cl/F, (L/h) apparent clearance; Vd/F, (L) volume of 
distribution 
* Median and range; Wilcoxon-signed rank test 
† Combination of 1875 mg nelfinavir and 200 mg ritonavir 
‡ Combination of 1875 mg nelfinavir and 200 mg ritonavir and 600 mg efavirenz 
& Relative bioavailability of period 2 (test) over period 1(reference) 
# P-Value based on a paired samples t-test with 95% confidence 
$ If ritonavir plasma concentrations at the end of the 24-hour dosing interval were lower than the quantification 
limit of 0.04 mg/L, the actual concentrations were calculated on the basis of the last quantifiable plasma 
concentration and the elimination constant. 
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Plasma concentration versus time plots are pre sented in Figure 1 for nelﬁnavir and in 
Figure 2 for the sum of nelﬁnavir and M8. An increase in AUC0–24h (+ 30%), Cmax 
(+ 29%) and C24 (+ 48%) for nelﬁnavir was seen when combined with efavirenz in 
period 2. As a result, these parameters were not bioequivalent over periods 1 and 
2. Nelﬁnavir C24 increased in 21 subjects, and decreased in three (by –38%, –12% 
and –5%). 
In contrast to the increased nelﬁnavir parameters, AUC0–24h , Cmax and C24 of the 
active metabolite M8 remained bioequivalent after the addition of efavirenz to the 
regimen. Decreases were observed in ritonavir AUC0–24h (–20%), Cmax (–24%) 
and C24 (–12%) after the addi tion of efavirenz to the regimen, resulting in a lack of 
bioequivalence over periods 1 and 2. 
Figure 1. Nelﬁ navir concentration-time proﬁ les for study days 10 and 20
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Data of 24 subjects, concentration-time profiles are mean values with standard 
deviation in error bars. From this figure is becomes clear that nelfinavir plasma 
concentrations are increased after the addition of efavirens to the regimen on 
day 20 in comparison to day 10.
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Figure 2. Nelﬁ navir plus M8 concentration-time proﬁ les for study days 10 and 20
All 24 subjects reported one or more adverse events out of a total of 225. Th e most 
frequently reported were diarrhoea (75.0%), dizziness (58.3%) and nausea (37.5%). 
Table 2 lists all adverse events that were suﬀ ered by two or more subjects and which 
were possibly or probably related to the study medication. Six of the 225 reported 
adverse events were unrelated, and were therefore not included in further analysis. 
One hundred and twenty-one adverse events were reported during treatment with 
nelﬁnavir/ritonavir (period 1), versus 98 when nelﬁnavir/ritonavir was given together 
with efavirenz (period 2). No serious adverse events were reported during either 
treatment period. One adverse event of lower abdominal pain was classiﬁed as being 
severe, and it occurred during period 1. Th e majority (85%) of all adverse events were 
mild. Th e causal rela tionship to study medication was reported to be doubtful for 
29%, possible for 41% and probable for 30% of adverse events. 
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Data of 24 subjects, concentration-time profiles are mean values. From this figure it 
becomes clear that M8 substantially contributes to the trough concentrations, but also 
to maximal concentrations on both study days 10 and 20.
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Table 2. Summary of adverse events occurring in two or more subjects throughout 
 the study, considered possibly or probably related to study drug by the
 investigator
 
System Organ Class# Description$
Whole Study&
frequency and 
percentage 
Period 1* 
frequency and 
percentage 
Period 2+ 
frequency and 
percentage 
Gastrointestinal disorders Abdominal discomfort 2 8.3 % 2 8.3 % 0 0 % 
 Diarrhoea 18 75.0 % 10 41.7 % 8 33.3 % 
 Dyspepsia 2 8.3 % 0 0 % 2 8.3 % 
 Flatulence 5 20.8 % 4 16.7 % 1 4.2 % 
 Loose stools 5 20.8 % 4 16.7 % 1 4.2 % 
 Nausea 9 37.5 % 8 33.3 % 1 4.2 % 
 Stomatitis 2 8.3 % 1 4.2 % 1 4.2 % 
Fatigue 7 29.2 % 5 20.8 % 2 8.3 % General disorders and 
administration site 
conditions        
Metabolism and nutrition  Anorexia 3 12.5 % 1 4.2 % 2 8.3 % 
disorders Hypercholesterolaemia 3 12.5 % 1 4.2 % 2 8.3 % 
Musculoskeletal and  Myalgia 5 20.8 % 4 16.7 % 1 4.2 % 
connective tissue disorders Sensation of heaviness 2 8.3 % 2 8.3 % 0 0 % 
Nervous system disorders Disturbance in attention 2 8.3 % 0 0 % 2 8.3 % 
 Dizziness 14 58.3 % 4 16.7 % 10 41.7 % 
 Headache 4 16.7 % 3 12.5 % 1 4.2 % 
 Paraesthesia 4 16.7 % 2 8.3 % 2 8.3 % 
 Paraesthesia circumoral 2 8.3 % 1 4.2 % 1 4.2 % 
 Somnolence 5 20.8 % 2 8.3 % 3 12.5 % 
Psychiatric disorders Abnormal dreams 5 20.8 % 1 4.2 % 4 16.7 % 
 Agitation 2 8.3 % 0 0 % 2 8.3 % 
 Apathy 2 8.3 % 1 4.2 % 1 4.2 % 
 Insomnia 3 12.5 % 1 4.2 % 2 8.3 % 
Skin and subcutaneous  Sweating increased 3 12.5 % 0 0 % 3 12.5 % 
tissue disorders        
 
# Adverse events were classified according to system organ class with MedDRA V4.1. 
$ Description of adverse events according to MedDRA V4.1 preferred terms.  
& Adverse events of both study period 1 and 2 together tabulated as frequencies and percentages (calculated as 
frequency divided by number of subjects (24) times 100). 
* Adverse events of study period 1 tabulated as frequencies and percentages (calculated as frequency divided by 
number of subjects (24) times 100). 
+ Adverse events of study period 2 tabulated as frequencies and percentages (calculated as frequency divided by 
number of subjects (24) times 100). 
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Th e occurrence of adverse events did not lead to temporary or permanent dis-
continuation of trial medication, nor to dose modiﬁcations. Five percent of the adverse 
events were treated with concomitant therapy. Although diarrhoea was reported 
frequently, the use of loperamide for its relief was indicated in only one subject 
during period 1 and in another subject during period 2. Gastrointestinal disorders 
were observed more fre quently during study period 1 than during period 2. Dizziness 
(41.7%) and psychiatric disorders such as abnormal dreaming (16.7%) and agitation 
(8.3%) were reported more frequently in period 2. 
Laboratory abnormalities were recorded in all sub jects. Th e results of laboratory safety 
analysis of bio chemistry parameters are summarized in Table 3. Total cholesterol 
resulted in Grade 2 values in six subjects and Grade 3 values in four subjects. However, 
seven of these 10 subjects had Grade 2 toxicity values for cholesterol at screening. For 
triglycerides one subject showed Grade 2 toxicity and one subject Grade 3 toxicity. Both 
sub jects had normal triglyceride values at screening. For haematology and urinalysis 
no clinically signiﬁcant abnormalities were found. 
Table 3. Laboratory measurements
 
 Normal ranges males (females)
Number (Grade) 
of subjects  
with toxicity&
Change to 
maximum 
median (range)#
Change to final 
median (range)$
Alanine amino transferase (U/L) 0-50 (0-40) 3 (I) 2 (0 - 70) -2.5 (-23 - 63) 
Aspartate amino transferase (U/L) 0-40 2 (I) 6.5 (0 - 28) 1 (-8 - 27) 
Alkaline phosphatase (U/L) 0-120 - 5 (0 - 34) -6.5 (-26 - 34) 
Gamma glutamyl transferase 
(U/L) 0-50 (0-35) 1 (II) 5 (0 - 69) 3.5 (-14 - 52) 
Amylase (U/L) 0-53 1 (I), 1 (II) 5.5 (0 - 63) -2 (-13 - 9) 
Total Cholesterol (mmol/L) 3.9-6.5 6 (II), 4 (III) 0.95 (0.1 - 3.2) 0.65 (-0.5 - 2.1) 
HDL cholesterol (mmol/L) 0.9-1.7 (1.2-2.3) Nd 0.1 (0 – 0.3) -0.2 (-0.6 – 0.2) 
LDL cholesterol (mmol/L) 3.5-4.5 Nd 0.9 (0.1 - 3.2) 0.55 (-0.2 - 2.5) 
Triglycerides (mmol/L) 0.8-2.0 1 (II), 1 (III) 1.05 (0 – 6.7) 0.5 (-1.9 – 1.7) 
Creatinine (µmol/L) 60-120 (53-100) 2 (I) 4.5 (0 - 26) -4 (-18 - 8) 
Total bilirubine (µmol/L) 3-17 1 (I) 6 (2 - 10) 1 (-4 - 5) 
Glucose (mmol/L) 4.0-6.0 1 (I) 0.1 (0 - 1.9) -0.3 (-1.4 - 1.5) 
Creatine phosphokinase (U/L) 0-200 (0-170) 4 (I), 2 (II), 1 (III) 21 (0 - 614) -23 (-157 - 84) 
 
Nd = not determined 
#Median and range of the individual changes of 24 subjects from baseline (day 1) to maximum values. If day 1 
was the maximum the result was 0.  
$Median and range of the individual changes of 24 subjects from baseline (day 1) to last observed values. If day 1 
was the maximum the result was a negative value. 
&Number of subjects with toxicity graded I, Grade 1; II, Grade 2; III, Grade 3. 
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Discussion 
In the current study the combination of nelﬁnavir/ritonavir plus efavirenz dosed 
once daily was tested in comparison with the same combination without efavirenz. 
Th e results obtained in 24 healthy subjects showed an increased nelﬁnavir 
AUC0–24h of 30%, Cmax of 29% and a C24 of 48% after addition of efavirenz. Expo sure 
to M8, the active metabolite of nelﬁnavir, was unaﬀ ected. Ritonavir concentrations 
decreased after addition of efavirenz to the regimen, but its boosting eﬀ ects were still 
present. Efavirenz is known to inhibit CYP2C1915, which catalyses the formation 
of M8, the active metabolite of nelﬁnavir10. For this reason one would expect the 
coadministration of nelﬁnavir and efavirenz to result in lower M8 concentrations, 
combined with higher nelﬁ navir exposure. In accordance with this, it has been reported 
that the combination of nelﬁnavir 750 mg three times daily and efavirenz 600 mg 
QD leads to a 20% increase in nelﬁnavir AUC and a 37% decrease in M8 AUC20. 
Somewhat contrasting data come from a study in patients receiving a dual NRTI 
regimen with either efavirenz 600 mg QD, or nelﬁnavir 1250 mg twice daily (BID), or 
the combination of efavirenz and nelﬁ navir21. In the latter study nelﬁnavir AUC0–12, 
Cmax and Cmin were lowered by 37%, 21% and 65%, respec tively, after the addition of 
efavirenz for 32 weeks. How ever, this study was an efﬁcacy and not a bioequivalence 
study. After the initial 4 weeks of treatment in 40 patients no signiﬁcant intra-
individual diﬀ erences in pharmaco kinetics were seen, except for Cmin, which was signiﬁ-
cantly lower after 32 weeks of treatment in 26 patients. No signiﬁcant diﬀ erences were 
noted in M8 exposure. A major diﬀ erence with the current study, apart from nelﬁnavir 
dose, was the presence of ritonavir in our regimen. Ritonavir is a potent inhibitor of 
CYP3A49, the enzyme responsible for further metabolism of M8 and of nelﬁnavir 
itself10,12. Th e inhibition of M8 metabolism by ritonavir probably compensated for 
the decreased formation of M8 as a result of CYP2C19 inhibition by efavirenz. Th e 
alternative metabolism of nelﬁnavir, mediated by CYP3A410, is also inhibited by 
ritonavir. Th is could explain the observed higher nelﬁnavir exposure combined with 
a bioequivalent M8 exposure over the diﬀ erent regimens in the current study. For 
nelﬁnavir a minimal trough concentration of 0.80 mg/L
 
has been proposed22. In the 
current study nelﬁnavir given with ritonavir but without efavirenz resulted in a C24 
of 0.37 mg/L, increasing to 0.55 mg/L
 
when efavirenz was added. Both these values 
are too low to ensure viral suppression. If nelﬁnavir is dosed at 1250 mg BID, plasma 
concentrations of M8 are 30% of those of nelﬁnavir itself23. Th us, the minimal trough 
concentration for nelﬁnavir and M8 together should be 1.0 mg/L. In the current study 
the sum of nelﬁnavir and M8 resulted in a C24 of 0.83 mg/L
 
with out efavirenz, which 
increased to 0.99 mg/L
 
when efavirenz was added. 
Th e observed decrease in ritonavir AUC0–24h of –20%, Cmax of –24% and C24 of 
–12% in the current study was unexpected, since a previous study found an increase in 
ritonavir exposure following efavirenz coadministration24. In the latter study ritonavir 
was dosed at 500 mg BID, which, on a daily basis, is ﬁve times the dose used in the 
current study. Efavirenz is reported to have both inhibitory and inducing eﬀ ects on 
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CYP3A425, and ritonavir depends mainly on CYP3A4 for its metabolism9. Th ese data 
suggest that efavirenz coadministration may accelerate the metabolism of ritonavir 
administered at a low dose, which has also been reported previously18. Although 
concentrations of ritonavir decreased, it was still capable of boosting nelﬁnavir 
metabolism. It is unknown precisely what ritonavir exposure is necessary to beneﬁt 
from its boosting eﬀ ects. 
Nelﬁnavir was not expected to aﬀ ect the pharmacok inetics of efavirenz26. Ritonavir 
at a dose of 500 mg has been shown to inhibit efavirenz metabolism, resulting in a 
21% increase in AUC24. However, it is unclear whether the same eﬀ ect would occur 
when ritonavir is used at the lower dose of 200 mg once daily. In a study of multiple 
doses of indinavir/ritonavir 800/100 mg BID in combination with efavirenz 600 mg, 
the AUC0–24h, Cmin and T1/2 of the latter were 56.2 h.mg/L, 1.6 mg/L
 
and 35.1 h18 
after intake in the fasting. In the present study these data were 64.0 h.mg/L, 2.0 mg/L
 
and 30.4 h. Although the comparison of efavirenz pharmacokinetics with historical 
controls did not reveal relevant diﬀ erences, in the current study efavirenz exposure was 
somewhat higher. Th is could be the result of the intake of efavirenz with food in the 
present study, which has been reported to give a 17% increase in bioavailability15. 
In a previous multiple-dose study, where nelﬁnavir/ritonavir 2000/200 mg was given 
once daily to eight healthy subjects, either with a 610-kcal breakfast or with a 271-
kcal breakfast8, nelﬁnavir AUC, Cmax and Cmin were 57.6 h.mg/L, 6.3 mg/L
 
and 0.59 
mg/L, M8 Cmin was 0.53 mg/L
 
following the 271-kcal breakfast. Nelﬁ navir exposure 
in this study was higher than that observed in our study after a 315-kcal snack in the 
evening. Th e lower nelﬁnavir concentrations in our study can partly be explained by a 
6.25% lower dose. However, it is not possible to prove whether the remaining part of 
the observed diﬀ erence results from the evening versus the morning intake, and/or the 
diﬀ erence in coadministered food. If the combination of nelﬁnavir/ritonavir is to be 
used with non-interacting NRTIs instead of efavirenz, it is preferable to administer 
the drugs in the morning with a 610-kcal breakfast, which has been reported to result 
in higher nelﬁnavir exposure8. 
In total, 225 adverse events were reported by the 24 healthy subjects in this study. 
However, the majority were mild in nature and none met the criteria for a serious 
adverse event. None led to withdrawal from the study, indicating that the medication 
was tolerated by the subjects. Th e most frequently reported adverse drug reaction 
was diarrhoea, which is a known side-eﬀ ect of both nelﬁnavir and ritonavir, and 
occurred in 75% of the subjects. Th is seems to be less than the previously reported 
value of 100% after treatment with nelﬁnavir/ ritonavir 2000/200 mg once daily8. Th e 
summary of product characteristics of nelﬁnavir states that 97.7% of mild to moderate 
severe diarrhoea occurs in patients treated with nelﬁnavir 750 mg thrice daily, without 
ritonavir16. It seems that the new formulation given at this dosage leads to less diarrhoea 
than the 250-mg tablets, notwithstanding the comedication with ritonavir. Treatment 
of diarrhoea with loperamid was only indi cated in two subjects, which underlines the 
mild nature of this adverse event. More gastrointestinal disorders were reported during 
the ﬁrst period of the study (nelﬁ navir plus ritonavir) than during the second period. 
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In the second period of the study, when efavirenz was introduced, dizziness, abnormal 
dreams and agitation occurred more frequently than in study period 1. Th ese are 
known adverse events for efavirenz. 
Increases in total cholesterol, leading to Grade 2 val ues in six subjects and Grade 3 
values in four subjects, were observed. However, seven of these subjects suﬀ ered from 
Grade 2 values at screening, indicating that only three subjects showed increased values 
following drug treatment. 
In conclusion, the studied regimens taken with a min imum amount of food at bedtime 
were tolerated well and thus considered safe to use in patients. Nelﬁnavir/ritonavir 
given together with efavirenz resulted in a 48% higher mean C24 concentration for 
nelﬁnavir, and the sum of nelﬁnavir and M8 C24 concentrations was 0.99 mg/L. From 
this study it became clear that not all subjects met the cut-oﬀ  Cmin of 1.0 mg/L
 
for 
nelﬁnavir and M8 together, which should be approached with great care. Efavirenz 
exposure in this study was similar to that reported previously, and it can therefore be 
used eﬀ ectively in combination with ritonavir and nelﬁnavir. 
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Abstract
Low nelﬁ navir plasma concentrations, resulting in concentration ratios (CR) <0.90, 
have been associated with failure of therapy. Nelﬁ navir CR <0.90 were observed in 
56 patients receiving 1250 mg BID. In 38 dose was adjusted to 1500 mg BID, in 18 
no adjustment was done. Dose adjustment to 1500 mg BID resulted in a CR >0.90 in 
only 45% of patients. For patients with an initial CR <0.52 this was 7%. In conclusion, 
dose adjustments were not always successful.
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Introduction
Failing nelﬁ navir therapy can largely be explained by low plasma levels. Patients with 
nelﬁ navir 1250 mg BID containing HAART have a 3 times higher risk for virological 
failure when the CR is <0.901. Th erapeutic drug monitoring (TDM) can help to 
detect patients with such low plasma concentrations2. Nevertheless, to prevent patients 
with a CR <0.90 from failing their therapy an intervention is necessary. Th e chosen 
intervention should lead to a CR >0.90. It was previously shown that TDM improves 
nelﬁ navir treatment response, in patients with CR <0.903. For patients treated with 
nelﬁ navir 1250 mg BID normally the ﬁ rst intervention is to ensure the intake with 
food. Th e second intervention is increasing nelﬁ navir dosage from 1250 mg BID 
to 1500 mg BID with food. We evaluated the pharmacokinetic eﬀ ect of increasing 
nelﬁ navir dosage from 1250 mg to 1500 mg BID in patients with a CR between 0.52 
and 0.90, and in patients with a CR <0.52.
Methods
Th is was a retrospective survey from our database of patients receiving 1250 mg BID 
nelﬁ navir. All patients were 18 years or older. Both males and females were included in 
the study. It was ensured that the patients took nelﬁ navir with enough food, and without 
other drugs known to interfere with nelﬁ navir metabolism. Th e database contained 
information on nelﬁ navir dosage and plasma nelﬁ navir concentrations, including time 
after intake of medicine. CR were calculated by dividing plasma concentrations by 
population data at the same time after intake of medication4.
Patients receiving 1250 mg nelﬁ navir BID with an initial nelﬁ navir CR <0.90 were 
selected. After this selection patients were divided in 2 groups according to whether 
dose adjustments were made or not. Group 1 consisted of patients receiving a dose 
adjustment to 1500 mg nelﬁ navir BID. Group 2 was the control group consisting of 
patients who did not receive dosage adjustment. Th e second nelﬁ navir CR, obtained 
after dosage adjustment in group 1 or no intervention in group 2 was compared to 
the ﬁ rst CR. Additionally subgroup analyses were performed in groups 1 and 2 for 
patients with a nelﬁ navir CR <0.52, and a CR between 0.52 and 0.90. 
Th e Mann Whitney test was performed to compare the CRs from groups 1 and 2 
from the ﬁ rst sample at baseline. Th e two-samples proportion test was used to test 
success rates between (sub)groups. P-values <0.05 were considered signiﬁ cant. 
Plasma nelﬁ navir concentrations were measured using a high performance liquid 
chromatography method that has been published previously5. 
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Results
In total 56 patients (38 in group 1 and 18 in group 2) were included in the analysis. 
Mean CR in group 1 and 2 at baseline was 0.61 and 0.64, respectively, the diﬀ erence 
was not statistically signiﬁ cant (P=0.81). In group 1 seventeen patients (45%) had a 
CR >0.90 after dosage adjustment. In group 2 four patients (22%) had a CR >0.90 
in the second sample. Th is diﬀ erence between groups 1 and 2 was not signiﬁ cant with 
P=0.10. Th e subgroup analysis of group 1 showed that out of 14 patients (subgroup 
1A) with an initial CR <0.52, one patient (7%) had a CR >0.90 after dosage adjustment. 
In subgroup 1B (24 patients) with an initial CR between 0.52 and 0.90, 16 patients 
(67%) had a CR >0.90 after dose adjustment. Th e diﬀ erence between subgroups 1A 
and 1B was signiﬁ cant (7% versus 67 %, P<0.001). 
Figure 1. Nelﬁ navir concentration ratio versus nelﬁ navir dose in group 1
Each line connects the two CRs, before and after dose adjustment, of each patient. 
The horizontal line represents the 0.90 cut off value for the CR.
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For group 2 this subgroup analysis learned that out of ﬁ ve patients in subgroup 2A 
with an initial CR <0.52, two (40%) had a CR >0.90 in the second sample. From the 
13 patients in subgroup 2B with an initial CR between 0.52 and 0.90, two (13%) had 
a CR >0.90 in the second sample. 
Th e diﬀ erence in success rates between subgroups 1B and 2B was signiﬁ cant (67% 
versus 15%, P<0.01), indicating that the observed higher success rate in subgroup 1B 
resulted from the dose adjustment.
In Figure 1 the nelﬁ navir CRs of individual patients in group 1 before and after the 
dose adjustment are displayed. Th e left graph shows group 1 as a total. In 28 out of 
38 (74%) patients the CR increases after the dose adjustment, in the remaining 10 
the second CR is lower than the ﬁ rst. Th e right graph (subgroup 1A) shows three 
patients with a lower CR in the second sample compared to the ﬁ rst. Eleven patients 
have an increased CR after the dose adjustment, however only one patient reaches a 
CR >0.90.
Conclusion
A nelﬁ navir dose adjustment from 1250 mg BID to 1500 mg BID in patients with an 
initial CR < 0.90 was eﬀ ective in 45%, which is consistent with previously reported 
data3. For patients receiving nelﬁ navir 1250 mg BID with a CR <0.52 dose adjustment 
to 1500 mg nelﬁ navir BID was not an eﬀ ective intervention, as the dose adjustment 
was eﬀ ective in only 1 out of 14 patients. Th e same intervention was eﬀ ective in 67% 
of patients with a CR between 0.52 and 0.90. 
Th e eﬀ ect of additional dose adjustments in patients with a CR <0.52 was not 
studied. Nelﬁ navir doses up to 1750 mg BID might help prevent patients from plasma 
concentrations that are low. Addition of ritonavir to the regimen is another option to 
prevent patients from low nelﬁ navir plasma concentrations. Ritonavir is an inhibitor 
of the Cytochrome P450 isoenzyme 3A4 and inhibits the metabolism of nelﬁ navir 
and its active metabolite M86,7, leading to higher plasma concentrations of both 
nelﬁ navir and M8. In the Athena study dose adjustment to 1750 mg nelﬁ navir BID or 
the addition of ritonavir was eﬀ ective in 4 out of 7 patients with a CR <0.903, however 
it is not reported how many of these patients had a CR <0.52. 
With the future marketing of the 625 mg tablet dose adjustment to 1875 mg BID will 
be easy, however, it is not said that the same eﬀ ects are to be expected.
Additional research is needed to deﬁ ne interventions for patients with a CR <0.52, 
leading to a CR >0.90. In the meanwhile, TDM can help physicians to evaluate the 
eﬀ ect of dose adjustments in clinical practice.
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Abstract
Introduction: Interpatient variability of nevirapine pharmacokinetics is a reason to 
perform Th erapeutic drug monitoring (TDM) for this drug. Th e literature suggests 
gender and ethnicity as possible causes for interpatient variability of pharmacokinetics. 
In this study the association of ethnicity, gender and other demographic factors with 
nevirapine plasma concentrations were evaluated.
Methods: Data were retrospectively collected from routine TDM samples for 
nevirapine. Th e ﬁ rst nevirapine plasma level of each patient that was measured in the 
year 2002 was used for data collection. Only patients that used nevirapine 200 mg 
BID were included.
Results: For nevirapine data were collected of 89 females and 215 males. Average 
plasma nevirapine concentrations were statistically higher in Caucasian females, 
compared to Caucasian males (6.30 versus 5.61 mg/L, P=0.029). Race and time 
after intake of nevirapine were signiﬁ cantly associated with nevirapine plasma levels, 
following a stepwise multiple regression model.
Conclusion: Higher nevirapine levels were seen in non-Caucasian versus Caucasian 
patients, and higher average nevirapine levels were observed in female Caucasians 
compared to male Caucasians. Physicians should be alert for a higher risk for toxicity 
when treating females or non-Caucasian patients with nevirapine.
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Introduction
Several studies describing a relationship between nevirapine plasma concentrations 
and antiviral eﬀ ect or toxicity have been published. Data from these studies show a 
large interpatient variability for nevirapine1-4. Th is interpatient variability might lead 
to unexpected high plasma levels in certain groups of patients, and low plasma levels 
in others. To prevent patients from unwanted under- or over-exposure to nevirapine, 
knowledge of factors causing this variability is necessary.
A review article on the inﬂ uence of gender on pharmacokinetics indicated that a great 
number of drugs show pharmacokinetic diﬀ erences between females and males5. 
Gender related pharmacokinetic diﬀ erences, presented as higher plasma levels in female 
patients, have been reported for the antiretroviral drugs indinavir6 and lopinavir7. Th ese 
diﬀ erences may have their implications on treatment outcome with regard to virological 
failure in males due to subtherapeutic plasma levels on one hand and toxicity in females 
due to toxic plasma levels on the other hand. Pharmacokinetic gender diﬀ erences have 
been reported for a number of drugs with a metabolism that is mediated through 
CYP3A5. Metabolism of nevirapine is mediated by CYP3A4 and to a lesser extent 
by CYP2B68. So far the only data that has been published showing pharmacokinetic 
diﬀ erences resulted from a population pharmacokinetic study reporting a 25% lower 
clearance of nevirapine in females9. For that reason pharmacokinetic gender diﬀ erences 
can be expected for nevirapine. 
Ethnicity has been described as a factor related to diﬀ erences in pharmacokinetics 
of drugs metabolized by CYP3A10-13. Th erefore it is not excluded that ethnicity can 
inﬂ uence nevirapine pharmacokinetics, although recently a study described the absence 
of an association between race and nevirapine pharmacokinetics14. In such cohort 
studies unequal distribution of gender and race can result in very small subgroups that 
are not powered to prove signiﬁ cance for diﬀ erences between subgroups.
We performed a retrospective cohort study to evaluate the inﬂ uence of gender, race 
and other demographic parameters on the pharmacokinetics of nevirapine.
Methods
Study population
Data were retrospectively collected from routine TDM samples for nevirapine. 
Th e ﬁ rst nevirapine plasma level of each patient, both females and males, that was 
measured in the year 2002 was used for data collection. Th is was done to avoid bias 
from patients being repeatedly sampled for reasons of subtherapy/virological failure 
or toxicity. Only patients that used the recommended dose of nevirapine (200 mg 
BID) were included. Data was collected from the form that accompanied the sample. 
Collected data concerned: gender, race, age, length, body weight, body mass index 
(BMI) (BMI is equal to weight [in kilograms]/height2 [in square meters]), indication 
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for TDM, concomitant medication, plasma level and time of blood draw after intake of 
medication. Indication for TDM could be: control, suspicion of interaction, suspicion 
of non-compliance, suspicion of subtherapy and suspicion of intoxication. In the case 
of a suspicion of non-compliance data were excluded. Th e reason for this exclusion was 
that these samples could show low plasma levels, without having a pharmacokinetic 
background for that. All data were captured in a Microsoft EXCEL 2000 database. 
Th e HIV Monitoring Foundation (SHM) follows all HIV-infected patients in the 
Netherlands as a national cohort and patients have given informed consent. Th is 
cohort protocol has been approved by all institutional review boards of the 22 Dutch 
treatment centers for HIV-infected patients.
Bioanalytical methods
Nevirapine was analyzed in plasma using a previously described high performance 
liquid chromatographic (HPLC) methods with ultraviolet detection15. Th e accuracy 
of this assay ranges from 91.5 to 102.6%. Th e intraday and interday precision ranges 
from 1.3% to 3.9% and from 1.9% to 3.0%, respectively. Preceding analysis plasma was 
separated from the blood sample and stored at a temperature lower than 20 degrees 
Celsius below zero. 
Statistical analysis
Diﬀ erences in population characteristics and plasma nevirapine concentrations between 
subgroups based on gender and race were analyzed using an independent samples t-
test and an analysis of variance (ANOVA), respectively. To determine variables that 
inﬂ uence plasma nevirapine concentrations a stepwise multiple regression model was 
used. A P-value <0.05 was considered signiﬁ cant in all analyses.
Results
Patient population
Data were collected of 304 patients; 89 females and 215 males. Th e distribution of 
males and females was diﬀ erent in the 3 races. Race was Caucasian in 207 patients 
(171 males and 36 females), Black in 88 patients (40 males and 48 females) and Asiatic 
in 9 patients (4 males and 5 females). Detailed information on demographic variables 
can be found in Table 1. Mean plasma nevirapine levels were higher in females than in 
males, 6.78 mg/L and 5.95 mg/L, respectively (P=0.042). Figure 1 is a reﬂ ection of all 
available plasma levels, grouped by gender. 
In Caucasians, Blacks and Asiatic plasma nevirapine levels were 5.73 mg/L, 6.98 mg/
L and 9.09 mg/L, respectively. Th e diﬀ erence between plasma levels of Caucasians 
and Blacks was statistically signiﬁ cant with P=0.027, however the diﬀ erence between 
Asiatics and Caucasians or Blacks was not statistically signiﬁ cant. In more detail, 
average plasma nevirapine concentrations were statistically higher in Caucasian
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Figure 1. Nevirapine plasma levels of 304 HIV-infected patients
females, compared to Caucasian males (6.30 versus 5.61 mg/L P=0.029). No such 
diﬀ erences were seen between males and females of the Black and Asiatic races. No 
statistically signiﬁ cant diﬀ erences were observed between subgroups, based on gender 
and race, with regard to: reason for TDM, concomitant medication and time of blood 
draw after intake of nevirapine. 
Factors inﬂ uencing plasma nevirapine concentrations
Th e variables age, weight, length, BMI, time after intake, gender and race were evaluated 
for association to nevirapine plasma concentration in a univariate regression model. A 
stepwise multiple regression model was performed to identify variables with inﬂ uence 
on plasma nevirapine levels. It appeared that race and time after last intake were the 
only two variables that were signiﬁ cantly associated with nevirapine exposure (P≤ 
0.001). Th e Asiatic race was relatively underrepresented in our data set, and therefore 
might lead to bias in the analysis. To eliminate this possible inﬂ uence, additional 
multiple regression analyses were performed. In the ﬁ rst additional analysis Asiatic 
race was excluded, in the second the Asiatic race was regrouped together with Blacks 
as non-Caucasian. In these two additional analyses race and time after last intake were 
again associated with plasma nevirapine concentrations (P≤ 0.001). 
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Table 1. Demographic data 
Th e multiple regression model was also repeated for the separate subgroups of females 
and males. Th is was done to further investigate the association between gender and 
nevirapine levels as found in the univariate regression analysis. It appeared that in 
both males and females the variables race and time after intake were predictive for 
nevirapine plasma levels.
  All caucasian  black  asiatic  
Numbera A 304 207 (68.1%)  88 (28.9%)  9 (3.0%)  
 M 215 (70.7%) 171 (79.5%)  40 (18.6%)  4 (1.9%)  
 F 89 (29.3%) 36 (40.1%)  48 (53.9%)  5 (5.6%)  
Level (mg/L) A 6.19±2.93 5.73±1.73  6.98±4.25  9.09±5.43  
 M 5.95±2.68 5.61±1.67  6.98±4.24  10.05±8.69  
 F 6.78±3.41 6.30±1.91  6.98±4.31  8.32±0.82  
Time (h) A 5.3±3.6 5.4±3.7  5.1±3.1  5.3±5.4  
 M 5.4±3.5 5.3±3.6  5.6±3.0  5.2±4.3  
 F 5.1±3.7 5.5±4.1  4.8±3.1  5.4±6.7  
Age (y) A 41.5±9.9 44.0±9.3  35.6±8.7  41.8±13.3  
 M 43.9±9.2 44.8±9.2  40.2±8.7  39.5±3.7  
 F 35.7±9.4 40.0±8.7  31.8±6.7  43.6±18.3  
Weight (kg) A 75.5±13.9 76.6±13.2  74.0±15.3  65.2±10.2  
 M 78.4±12.1 79.1±11.9  76.0±12.5  71.9±9.4  
 F 68.6±15.5 64.7±12.5  72.3±17.2  59.9±7.7  
Length (m) A 1.75±0.10 1.78±0.09  1.68±0.10  1.62±0.08  
 M 1.79±0.07 1.80±0.06  1.76±0.08  1.71±0.02  
 F 1.64±0.07 1.66±0.08  1.62±0.06  1.56±0.02  
BMI (kg/m2) A 24.7±4.1 24.2±3.6  26.1±5.0  24.0±2.2  
 M 24.3±3.2 24.3±3.3  24.2±2.8  23.1±0.9  
 F 25.6±5.5 23.4±4.4  27.5±5.8  24.5±2.7  
 
A = all patients, M = males, F = females 
Data are means ± standard deviation, unless stated otherwise 
a Data given as frequencies and percentages 
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Discussion
In this retrospective study we evaluated the inﬂ uence of several demographic factors 
on the pharmacokinetics of the antiretroviral agent nevirapine. In total 304 HIV-
1 positive patients using nevirapine 200 mg BID were included. Plasma nevirapine 
concentrations were signiﬁ cantly higher in non-Caucasians versus Caucasians, and in 
female versus male Caucasians. Race and time after intake of nevirapine are signiﬁ cantly 
associated with nevirapine plasma levels, following a multiple regression model. It 
may be evident that plasma nevirapine concentrations decrease with increasing time 
after intake. In our data time after intake of nevirapine was similar in subgroups 
based on gender and ethnicity, so there is no contribution of this variable to the 
observed diﬀ erences. 
Recently it was published that race was not signiﬁ cantly related to clearance of 
nevirapine in a population pharmacokinetic model14. Although not signiﬁ cant, a trend 
towards lower clearance of nevirapine was observed for Blacks and Asiatics in this 
model, compared to Caucasians. Clearance was 6.4% and 12.6% (P=0.14) lower for 
Blacks and Asiatics, respectively. Based on these data, de Maat et al. conclude that 
race is not a factor to take into consideration when treating patients with nevirapine. 
Our data do show a signiﬁ cant relationship between race and nevirapine plasma 
levels, which might be the result of a larger group of non-Caucasian patients. Th e 
observations from our study advocate the use of TDM in certain groups of patients to 
prevent them from high nevirapine plasma concentrations.
Body composition has been mentioned in the literature as a possible explanation 
for variability in pharmacokinetics16. In our study the BMI was not associated with 
plasma nevirapine concentrations, although a statistical signiﬁ cant higher BMI was 
seen in Black women compared to Caucasian women or Black males (P<0.01). Th is 
observation however, was not accompanied by a signiﬁ cant diﬀ erence in the average 
nevirapine levels in these three groups. 
Diﬀ erences were also present between age, body weight and length in several subgroups, 
nevertheless these variables were not associated with nevirapine concentrations. 
Th e information collected on co-medications used and the indication for TDM did 
not show any diﬀ erences between subgroups. Th erefore it was not expected that these 
variables were predictive for the occurrence of higher plasma levels in the subgroups. 
Although the current data collection did not show a diﬀ erence in the use of 
comedications between females and males and/or racial groups, there might be an 
underestimation of the use of oral contraceptives. For the data collection we were 
depending on the completeness and accuracy of the sampling forms. For that reason 
it cannot be excluded that the use of oral contraceptives had no inﬂ uence on plasma 
levels of nevirapine. However it has been shown that single doses of ethinyl estradiol 
and norethindrone did not aﬀ ect nevirapine pharmacokinetics17.
Diﬀ erences in hormonal status of females compared to males might also inﬂ uence 
pharmacokinetics of nevirapine, and within the group of females the menopausal 
status might be a factor of inﬂ uence as well18. As for the diﬀ erences in hormonal status 
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between females and males the current data collection has no additional information. 
With regard to the possibility of subgroups of pre- and postmenopausal females 
within the group of females, the used database did not contain information on the 
menopausal status of the females. However, based on the reported ages of the females 
with an average of 35.7 years, the number of postmenopausal females will be very 
limited. Th erefore it is not likely that the menopausal status of the females results in 
subgroups with diﬀ erent pharmacokinetics.
In pregnant females a number of physiologic changes can alter diﬀ erent pharmacokinetic 
processes, however the net total eﬀ ect is often small19. Data from some small studies did 
not show diﬀ erences in plasma nevirapine concentrations between pregnant and non-
pregnant females20. Th e database used in the current study contained no information 
on pregnancy. However, the use of nevirapine in pregnant females is less likely, as the 
antiretroviral drug of ﬁ rst choice in pregnancy in Th e Netherlands is nelﬁ navir. For 
these reasons pregnancy is not likely to interfere with our data. 
Our study is limited by the absence of clinical data in the database, especially with 
regard to the occurrence of toxicity. Th is makes it impossible to correlate the occurrence 
of adverse events to the plasma nevirapine concentrations. For this reason the objective 
of our study was limited to pharmacokinetics only. In the literature however, a higher 
incidence of nevirapine related toxicity such as rash in females as compared to males 
has been described21-23. Th e clinical observations from these studies support our 
pharmacokinetic ﬁ ndings in the current study. 
In conclusion, from our data, race and time after intake are predictors for plasma 
nevirapine concentrations. After correction for time after intake this results in higher 
mean plasma nevirapine concentrations in Blacks and Asiatics in comparison to 
Caucasians. Apart from that a signiﬁ cant higher average nevirapine level was observed 
in female Caucasians compared to male Caucasians. Th ese higher nevirapine levels 
might lead to more nevirapine related toxicity in these subgroups. Th erefore, physicians 
treating non-Caucasian patients or Caucasian females with nevirapine should use 
TDM to individualize dosages and prevent toxicity.
Acknowledgements
Minny Meeuwissen, Tessa Rooyaards and Piet van der Meulen are kindly thanked for 
their assistance in the collection of the data needed for this study.
Nevirapine pharmacokinetic interpatient variability
139
References
1.  Gonzalez de Requena, D., M. Nunez, I. Jimenez-Nacher, and V. Soriano. 2002. Liver toxicity 
caused by nevirapine. AIDS 16:290-291.
2.  Havlir, D., S. H. Cheeseman, M. McLaughlin, R. Murphy, A. Erice, S. A. Spector, T. C. 
Greenough, J. L. Sullivan, D. Hall, M. Myers, and . 1995. High-dose nevirapine: safety, 
pharmacokinetics, and antiviral eﬀ ect in patients with human immunodeﬁ ciency virus infection. J 
Infect.Dis. 171:537-545.
3.  Veldkamp, A. I., G. J. Weverling, J. M. A. Lange, J. S. G. Montaner, P. Reiss, D. A. Cooper, S. 
Vella, D. Hall, J. H. Beijnen, and R. M. W. Hoetelmans. 2001. High expossure to nevirapine in 
plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 
15:1089-1095.
4.  Vries-Sluijs, T. E., J. P. Dieleman, D. Arts, A. D. Huitema, J. H. Beijnen, M. Schutten, and M. 
E. Van Der Ende. 2003. Low nevirapine plasma concentrations predict virological failure in an 
unselected HIV-1-infected population. Clin.Pharmacokinet. 42:599-605.
5.  Schwartz, J. B. 2003. Th e inﬂ uence of sex on pharmacokinetics. Clin.Pharmacokinet. 42:107-121.
6.  Burger, D. M., M. C. Siebers, P. W. Hugen, R. E. Aarnoutse, Y. A. Hekster, and P. P. Koopmans. 
2002. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than 
men? J Acquir Immune Deﬁ c Syndr 29:101.
7.  Burger D.M., Muller R.J., van de Leur M.R., and la Porte C.J.L. Lopinavir plasma levels are 
signiﬁ cantly higher in female than in male HIV-1 infected patients. 3rd International Workshop on 
Clinical Pharmacology of HIV Th erapy, April 11-13, 2002, Washington DC, USA, 
abstract 6.5. 2002. 
8.  Erickson, D. A., G. Mather, W. F. Trager, R. H. Levy, and J. J. Keirns. 1999. Characterization of 
the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human 
hepatic cytochromes P-450. Drug Metab Dispos. 27:1488-1495.
9.  Zhou, X. J., L. B. Sheiner, R. T. D’Aquila, M. D. Hughes, M. S. Hirsch, M. A. Fischl, V. A. 
Johnson, M. Myers, and J. P. Sommadossi. 1999. Population pharmacokinetics of nevirapine, 
zidovudine, and didanosine in human immunodeﬁ ciency virus-infected patients. Th e National 
Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. 
Antimicrob.Agents Chemother. 43:121-128.
10.  Sowunmi, A., T. J. Rashid, O. O. Akinyinka, and A. G. Renwick. 1995. Ethnic diﬀ erences in 
nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br.J.Clin.
Pharmacol. 40:489-493.
11.  Wandel, C., J. S. Witte, J. M. Hall, C. M. Stein, A. J. Wood, and G. R. Wilkinson. 2000. CYP3A 
activity in African American and European American men: population diﬀ erences and functional 
eﬀ ect of the CYP3A4*1B5’-promoter region polymorphism. Clin.Pharmacol.Th er. 68:82-91.
12.  Kinirons, M. T., C. C. Lang, H. B. He, K. Ghebreselasie, S. Shay, D. W. Robin, and A. J. Wood. 
1996. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: 
ethnicity and CYP3A activity. Br.J.Clin.Pharmacol. 41:69-72.
13.  Mancinelli, L. M., L. Frassetto, L. C. Floren, D. Dressler, S. Carrier, I. Bekersky, L. Z. Benet, 
and U. Christians. 2001. Th e pharmacokinetics and metabolic disposition of tacrolimus: a 
comparison across ethnic groups. Clin.Pharmacol.Th er. 69:24-31.
14.  De Maat, M. M., J. F. Nellen, A. D. Huitema, F. W. Wit, J. W. Mulder, J. M. Prins, and J. H. 
Beijnen. 2004. Race Is Not Associated with Nevirapine Pharmacokinetics. Th er.Drug Monit. 
26:456-458.
15.  Hollanders, R. M. W., E. W. J. van Ewijk-Beneken Kolmer, D. M. Burger, E. W. Wuis, P. P. 
Koopmans, and Y. A. Hekster. 2000. Determination of nevirapine, an HIV-1 non-nucleoside 
reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid 
chromatography. Journal of Chromatography B Biomed Sci Appl 744:65-71.
16.  Meibohm, B., I. Beierle, and H. Derendorf. 2002. How important are gender diﬀ erences in 
pharmacokinetics? Clin.Pharmacokinet. 41:329-342.
Chapter 8
140
17.  Mildvan, D., R. Yarrish, A. Marshak, H. W. Hutman, M. McDonough, M. Lamson, and 
P. Robinson. 2002. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/
norethindrone when administered concurrently to HIV-infected women. J.Acquir.Immune.Deﬁ c.
Syndr. 29:471-477.
18.  Tanaka, E. 1999. Gender-related diﬀ erences in pharmacokinetics and their clinical signiﬁ cance. 
J.Clin.Pharm.Th er. 24:339-346.
19.  Loebstein, R., A. Lalkin, and G. Koren. 1997. Pharmacokinetic changes during pregnancy and 
their clinical relevance. Clin.Pharmacokinet. 33:328-343.
20.  Mirochnick, M., D. F. Clarke, and A. Dorenbaum. 2000. Nevirapine: pharmacokinetic 
considerations in children and pregnant women. Clin.Pharmacokinet. 39:281-293.
21.  Bersoﬀ -Matcha, S. J., W. C. Miller, J. A. Aberg, H. C. van Der, H. J. Hamrick Jr, W. G. 
Powderly, and L. M. Mundy. 2001. Sex diﬀ erences in nevirapine rash. Clin.Infect.Dis. 32:124-129.
22.  Mazhude, C., S. Jones, S. Murad, C. Taylor, and P. Easterbrook. 2002. Female sex but not 
ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 
16:1566-1568.
23.  Antinori, A., F. Baldini, E. Girardi, A. Cingolani, M. Zaccarelli, S. Di Giambenedetto, A. 
Barracchini, P. De Longis, R. Murri, V. Tozzi, A. Ammassari, M. G. Rizzo, G. Ippolito, and 
A. De Luca. 2001. Female sex and the use of anti-allergic agents increase the risk of developing 
cutaneous rash associated with nevirapine therapy. AIDS 15:1579-1581.
141

Chapter 9
Interpatient variability in 
the pharmacokinetics of the 
HIV non-nucleoside reverse 
transcriptase inhibitor efavirenz: 
the eﬀ ect of sex, race and genetics
D.M. Burger1,2, I. van der Heiden3, C.J.L. la Porte1,2, 
M.E. van der Ende3, P. Groeneveld4, C. Richter5, P.P. Koopmans1,2, 
F.P. Kroon6, H. Sprenger7, J. Lindemans3, P. Schenk3, R. van Schaik3
1 University Medical Center Nijmegen, Th e Netherlands.
2 Nijmegen University Center for infectious diseases, Th e Netherlands. 
3 Erasmus Medical Center Rotterdam, Th e Netherlands.
4 Isala Hospital Zwolle, Th e Netherlands.
5 Rijnstate Hospital Arnhem, Th e Netherlands.
6 Leiden University Medical Center, Th e Netherlands.
7 University Hospital Groningen, Th e Netherlands.
Submitted
Chapter 9
144
Abstract
Background: Th e pharmacokinetics of efavirenz is characterized by large interpatient 
variability. In a preliminary analysis of patients from our Th erapeutic drug monitoring 
(TDM) service, signiﬁ cantly higher efavirenz plasma levels were observed in females. 
Methods: All samples that were analysed for efavirenz in our TDM service in 2002 
and 2003 were reviewed. Information on sex, age, body weight, length, race, hormonal 
contraceptive use, and time between sampling and last intake was recorded. DNA 
was isolated from plasma of these patients, and PCR-restriction fragment length 
polymorphism analysis was performed to detect the cytochrome P450 2B6 (CYP2B6) 
C1459T single nucleotide polymorphism (SNP) which is associated with low 
CYP2B6 activity. 
Results: A total of 255 patients were included in this analysis. Th e median efavirenz 
plasma level was 2.50 (interquartile range: 1.85–3.55) mg/L. Out of these 255 patients, 
8 (3.1%) were considered to have a subtherapeutic efavirenz plasma level (< 1.0 mg/L) 
and 48 (18.9%) a toxic efavirenz level (> 4.0 mg/L). Sex, time after last intake, and 
race were the only factors that were signiﬁ cantly associated with the efavirenz plasma 
level in a multivariate analysis. No inﬂ uence was observed for body weight, hormonal 
contraceptive use, and the presence of the CYP2B6 C1459T SNP (*5 and *7 allele). 
Conclusions: Sex and race are important factors in determining the interpatient 
variability in efavirenz plasma levels. Th is eﬀ ect is not caused by low CYP2B6 activity 
as determined by SNP analysis. Physicians should primarily be alert for signs of 
efavirenz-induced toxicity in females and non-Caucasian patients.
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Introduction
Th e HIV non-nucleoside reverse transcriptase inhibitor (RTI) efavirenz is 
recommended as one the preferred agents, combined with two nucleoside RTIs, as 
initial treatment of patients with HIV infection1. Several studies have demonstrated 
the potent antiviral activity of efavirenz in this combination, leading to >80% of 
patients with an HIV-1 viral load below the detection limit of 50 copies/mL2-4.
Th e pharmacokinetics of efavirenz can be characterized by extensive protein binding 
(>99%), hepatic clearance through cytochrome P450 (CYP) 2B6 and 3A4 isozymes, 
and a long elimination half-life (40–55h)5. Interpatient variability in efavirenz 
pharmacokinetics is signiﬁ cant, as has repeatedly been demonstrated6-8. Th e clinical 
relevance of this interpatient variability is the translation into variable response in 
HIV-infected patients: patients with low exposure to efavirenz have an increased risk 
of virological failure6,7,9-11, while on the other hand those with high exposure suﬀ er 
from efavirenz-induced side eﬀ ects, mostly related to the central nervous system 9,12. 
Based on this information, a therapeutic range for efavirenz of 1.0–4.0 mg/L has 
been recommended13. Given the presence of a concentration-eﬀ ect relationship for 
efavirenz and the large interpatient variability in its pharmacokinetic parameters, one 
would beneﬁ t from more data on factors that inﬂ uence the pharmacokinetic behaviour 
of this agent. As a result, treatment with efavirenz could be more individualized, and 
treatment failure, either due to insuﬃ  cient virological response or (CNS-) toxicity, 
can be prevented. In a preliminary analysis of patients from our Th erapeutic drug 
monitoring (TDM) service, we found that female sex was a signiﬁ cant risk factor for 
the development of toxic efavirenz plasma levels14. In this study, we have extended 
our study group and investigated potential factors associated with abnormal efavirenz 
plasma levels in female patients.
Methods
Patients
Patients were selected on the basis of a plasma sample that was submitted to our 
national TDM service for efavirenz from six diﬀ erent sites in 2002 and 2003. Only 
the ﬁ rst sample from a patient was included to avoid potential bias from repeated 
sampling. Patients used the standard dose for efavirenz of 600 mg once daily. Subjects 
for whom a sample was submitted with a suspicion of nonadherence (indicated by the 
physician on the application form) and samples with an undetectable efavirenz plasma 
level (< 0.2 mg/L) were excluded from the analysis. Also, samples withdrawn more 
than 24h after the last dose intake were omitted. 
Demographic data were extracted from the application form or the patient’s medical 
records. All HIV-infected patients in Th e Netherlands are followed as a national 
cohort by the HIV Monitoring Foundation (SHM) and patients have given informed 
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consent. Th is cohort protocol has been approved by all institutional review boards of 
the 22 Dutch treatment centers for HIV-infected patients.
Efavirenz plasma levels
Efavirenz plasma levels were determined by a validated high-performance liquid 
chromatographic assay, as previously prescribed15. Accuracy of this assay ranges 
from 99.0 to 100.5%; maximum intra- and interday precision are 2.6% and 2.8%, 
respectively. Efavirenz plasma levels were deﬁ ned as either subtherapeutic (< 1.0 mg/
L), therapeutic (1.0–4.0 mg/L), or toxic (> 4.0 mg/L)13.
Genetic analysis
Th e CYP2B6 C1459T single nucleotide polymorphism (SNP) was selected for 
genotyping following the previously reported reduced protein expression in human liver 
samples containing this SNP16. Our hypothesis was that this SNP could be related to 
increased exposure of the CYP2B6 substrate efavirenz. DNA was isolated from plasma
of all patients and PCR-restriction fragment length polymorphism analysis was per-
formed to detect the C1459T variant of the CYP2B6 gene, which is part of the CYP2B6*5 
and CYP2B6*7 haplotypes, and corresponds to the Arg487Cys amino acid change of 
the CYP2B6 isozyme. Th e method employed was a modiﬁ cation of the assay previously 
described by Lang et al.14 using forward primer 5’-CTGTTGCAGTGGACATTTG-
3’ and reverse primer 5’-ATCTCACTCCTGCACTCAC-3’. Th e absence or presence 
of the nucleotide change C1459T results in either wild-type CC (WT), heterozygous 
variant CT, or homozygous variant TT.
Statistical analysis
Diﬀ erences in efavirenz plasma levels between subgroups were compared by analysis 
of variance. Univariate and multivariate regression were applied to identify factors 
related to efavirenz plasma levels. Test results with a P-value < 0.05 were considered 
statistically signiﬁ cant.
Results
Patients
A total of 255 patients were selected from the six diﬀ erent study sites. Patient 
demographics are listed in Table 1. Th e median efavirenz plasma level was 2.50 mg/L 
with an interquartile range from 1.85 to 3.55 mg/L. Th e distribution of efavirenz 
plasma levels during the 24h dose interval is depicted in Figure 1. Out of these 255 
patients, 8 (3.1%) were considered to have a subtherapeutic efavirenz plasma level 
(< 1.0 mg/L) and 48 (18.9%) to have a toxic efavirenz level (> 4.0 mg/L). Consequently, 
the remaining 199 subjects (78.0%) had an efavirenz plasma level within the therapeutic 
range (1.0–4.0 mg/L).
Sex, race and genetics in efavirenz interpatient variability
147
Table 1. Demographics
Demographic factors inﬂ uencing efavirenz exposure
All demographic factors were entered in a univariate regression model for a potential 
relationship with the efavirenz plasma level. Subsequently, factors that were 
signiﬁ cantly associated with efavirenz exposure were stepwise added in a multivariate 
analysis. Results are depicted in Table 2. It appeared that sex, time after last intake, 
and race were the only factors that were signiﬁ cantly associated with the efavirenz 
plasma level. Th e eﬀ ect of sex and race are also presented in Figure 2. Th e average 
(± standard deviation (SD)) efavirenz plasma level in female patients was 4.0 (±3.2) 
mg/L versus 2.8 (± 1.7) mg/L in male patients (P < 0.001). Th ree diﬀ erent ethnic 
groups were present in our study population: Asians (n=10), blacks (n=84) and 
Caucasians (n=161). Th e average (± SD) efavirenz plasma levels in these ethnic 
groups were 3.3 (± 1.6), 3.8 (± 3.0) and 2.8 (± 1.6) mg/L, respectively (P=0.003).
An additional analysis of the inﬂ uence of body weight was conducted. As expected, 
female patients had a lower average body weight than male patients (65.0 versus 75.0 
kg); the same was true for non-Caucasians versus Caucasians: 68.1 versus 76.4 kg. Th us, 
a lower body weight in female and non-Caucasian patients could be an explanation for 
the association between sex and race with efavirenz plasma levels. In a multivariate 
analysis, however, body weight was no longer associated with higher efavirenz plasma 
levels when corrected for sex, time after intake, and race (P=0.355). 
 
Parameter (unit) % of patients Median Interquartile range 
Age (yr)  40 33-48 
Gender 
Male 
Female 
 
74.1% 
25.9% 
 
  
Weight (kg)  72 63-80 
Length (cm)  176 168-181 
Body surface area (m2)  1.85 1.73-2.00 
Time after intake (h)  13 12-16 
EFV plasma level (mg/L)  2.5 1.7-3.7 
Race 
Caucasian 
Black 
Asian 
 
63.5% 
32.5% 
3.9% 
  
CYP2B6 genotype at 
position 1459 
C/C 
C/T 
T/T 
 
N=228 
82.9% 
14.5% 
2.6% 
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Figure 1. Efavirenz plasma levels of 255 patients
Table 2. Univariate and multivariate regression analysis
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Efavirenz plasma levels of 255 patients
Therapeutic range for efavirenz (1.0 - 4.0 mg/L)
Univariate Multivariate Parameter 
R F P-value R F P-value 
Age 0.093 2.22 0.137    
Sex 0.238 15.18 <0.001 0.287 17.65 <0.001 
Body weight 0.217 12.15 0.001    
Body surface area 0.218 10.84 0.001    
Length 0.163 6.07 0.015    
Time after intake of 
medication 0.158 6.45 0.012 0.350
# 13.65# < 0.001#
Race 0.183 8.80 0.003 0.389## 11.56## < 0.001##
CYP2B6 Genotype 0.132 3.99 0.047    
 
#: in addition to gender; ##: in addition to gender and time after intake of medication. R = regression coefficient; F 
= Fischer’s exact test value. 
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Figure 2. Mean efavirenz plasma level (+ standard deviation) in the various 
 subgroups
Another possible explanation for the observed eﬀ ect of female sex on efavirenz plasma 
levels is the use of hormonal contraceptives in (part of ) the female subjects. We were 
able to track information on hormonal contraceptive use in 39 of the 66 female patients 
in our cohort. Eight of these 39 women used some kind of hormonal contraceptives, 
but hormonal contraceptive use was not associated with higher efavirenz plasma levels. 
In fact, an opposite trend was found towards higher efavirenz plasma levels in females 
who reported that they did not use hormonal contraceptives versus those who did: 
mean (± SD) values were 5.0 (± 3.7) versus 2.7 ± (1.1) mg/L, respectively (P=0.10).
Pharmacogenetic analysis
To investigate a possible genetic background for the observed diﬀ erences in efavirenz 
plasma levels between diﬀ erent ethnic groups, we have evaluated the C1459T 
polymorphism of CYP2B6 in 228 samples where DNA could be ampliﬁ ed. A 
large majority of the patients (82.9%) could be identiﬁ ed as wild type (CC), while 
heterozygous (CT) and homozygous (TT) variants could be found in 14.5 and 2.6% 
of the patients, respectively (Table 1). A signiﬁ cant diﬀ erence in the frequency of 
variant alleles (CT and TT combined) was observed between Caucasians (21.6%), 
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Blacks (8.2%) and Asians (0%) (P=0.033).Th is genetic polymorphism, however, could 
not be linked to diﬀ erences in efavirenz plasma levels: median values (+ IQR) were 2.6 
(1.8–3.7) mg/L, 2.1 (1.5–2.7) mg/L, and 2.1 (1.5–2.8) mg/L for CC, CT, and TT 
genotypes, respectively (P=0.074). 
Discussion
Our study is the largest interpatient comparison of efavirenz pharmacokinetics reported 
so far. Th e most important observations are the consistently higher plasma efavirenz 
levels in female patients as well as in non-Caucasian patients. In a post-hoc subgroup 
analysis, female non-Caucasian patients appeared to have a 60% higher efavirenz 
plasma level than male Caucasian patients (Figure 2). Th us, when treating patients 
with efavirenz, physicians should be aware of a higher risk for efavirenz-induced 
toxicity in females and non-Caucasian patients, as higher exposure to efavirenz has 
been linked to an increased risk of toxicity9,12.
Our data conﬁ rm the large interpatient variability in efavirenz plasma levels. Still, 
78% of patients had an efavirenz plasma level within the therapeutic range of 1.0–4.0 
mg/L, which is comparable to observations in other, smaller cohort studies6-9,11. Th is 
indicates that the observed interpatient variability in efavirenz exposure does not lead 
to unwanted eﬀ ects as long as they remain within this relatively narrow range. For the 
remaining 22% of the patients in this cohort, it appears that efavirenz treatment needs 
optimisation.
Remarkably, far less patients had subtherapeutic plasma levels of efavirenz (< 1.0 mg/
L) when compared to toxic levels (> 4.0 mg/L). Th is may have been caused by our 
exclusion criterion for non-adherent patients (based on a suspicion by the physician 
and/or the presence of an undetectable efavirenz level in the TDM sample). Including 
these samples would have confounded our investigations for factors associated with 
efavirenz plasma levels. Another explanation for the higher proportion of toxic 
efavirenz plasma levels may be a selection bias why physicians have sent a TDM 
sample for efavirenz. TDM of efavirenz is recommended in the Netherlands for all 
patients at week 4 and 24 after starting treatment with this agent, and when there 
is a suspicion of intoxication, suboptimal therapy, drug-drug interaction, or non-
adherence. Nevertheless, given the signiﬁ cant number of patients with toxic efavirenz 
plasma levels, it is important to investigate potential causative factors.
As reported earlier in a preliminary analysis of a smaller cohort in our TDM service, 
female patients had a signiﬁ cantly higher efavirenz plasma level than male patients 
(Figure 2). Th e consequence might be an increased risk for efavirenz-induced toxicity 
in female patients. Several cohort studies have demonstrated a 1.5–1.7 fold higher 
risk for adverse drug reactions in female patients using antiretroviral agents (reviewed 
by17), although details for those using efavirenz are not available. Recently, Spire et 
al. presented a cross-sectional study that identiﬁ ed characteristics associated with 
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an increased risk for discontinuation of efavirenz use18. Female patients had a 2.2 
times (95% conﬁ dence interval: 1.2–3.8) higher risk for discontinuation of efavirenz 
than males.
In addition, an eﬀ ect of race became apparent in our analyses, although this can 
partly be explained by a higher proportion of females among non-Caucasian (46.8%) 
versus Caucasian patients (13.7%). Nevertheless, the eﬀ ect of race was signiﬁ cant in 
a multivariate analysis when corrected for sex and time after intake (Table 2). It can 
also be observed in the post-hoc analysis presented in Figure 2 where non-Caucasian 
females and males displayed higher efavirenz plasma levels than in their respective 
Caucasian counter partners. Pﬁ ster et al. also observed a lower hepatic clearance rate 
of efavirenz in a combined group of African-Americans/Hispanics as compared to 
white non-Hispanics6.
We analysed several factors that could be the (partial) explanation for these sex and 
racial eﬀ ects. First, diﬀ erences in body weight, length, or body composition are present 
between females and males, and to some extent also between races. However, body 
weight (P=0.355), length (P=0.673) and body surface area (P=0.471) were not 
related to efavirenz plasma levels in the multivariate analysis when corrected for sex, 
race and time after intake of medication. Second, the use of hormonal contraceptives 
by a subgroup of female patients may be related to inhibition of efavirenz metabolism, 
as reported earlier for another CYP2B6 substrate, bupropion19. However, we could not 
conﬁ rm this association and even observed a trend toward lower efavirenz exposure 
in females using hormonal contraceptives. In addition, the Summary of Product 
Characteristics of Stocrin/Sustiva® describes that no eﬀ ect of a single dose of ethinyl 
oestradiol was observed on the steady-state pharmacokinetics of efavirenz20.
Th ird, we performed a pharmacogenetic analysis of the CYP2B6 C1459T 
polymorphism as a possible explanation of sex and/or racial eﬀ ects on exposure to the 
CYP2B6 substrate efavirenz. By ampliﬁ cation of DNA from plasma we were able to 
detect the CYP2B6 C1459T SNP in 17.1% of the subjects. Th is is comparable to what 
other groups have found, although the incidence of this SNP varies among races16,21-24. 
Although this SNP has been associated with low CYP2B6 protein expression, and 
thus low activity, in human liver samples16, we did not observe a relationship between 
this genotype and efavirenz plasma levels. Preliminary data from other groups suggest 
a relationship for the G516T SNP in CYP2B6 which is present in haplotypes 
CYP2B6*6 and CYP2B6*721,25. Th is G516T SNP was more frequently detected in 
African-Americans than in Caucasians in the ACTG study (20% versus 3%)25, which 
is in agreement with a higher risk for toxic efavirenz plasma levels in this subgroup. 
No information is currently available on any sex eﬀ ects observed in the AACTG 
study. In addition, it cannot be excluded that SNPs in CYP3A4 may play a role in 
efavirenz pharmacokinetics although the metabolism of efavirenz is predominantly 
handled by 2B626. 
Finally, diﬀ erences in co-medication between subjects may cause variability in exposure 
to efavirenz. However, information on co-medication is usually not provided on 
application forms for TDM samples. In addition, inhibitors of CYP450 enzymes such 
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as ritonavir, ketoconazole, and clarithromycin demonstrate none or minimal eﬀ ects 
on efavirenz plasma levels5,20, underscoring the limited contribution of CYP3A4 on 
efavirenz clearance.
In conclusion, this analysis of our TDM service database has demonstrated a signiﬁ cant 
eﬀ ect of sex and race on efavirenz plasma levels, which was independent of diﬀ erences 
in body composition, hormonal contraceptive use, or the C1459T SNP in CYP2B6. 
Physicians should be aware of an increased risk for efavirenz-induced toxicity in females 
and non-Caucasian patients. Further research, especially in developing countries 
where females dominate the HIV epidemic, is needed to determine potential factors 
inﬂ uencing efavirenz exposure. In this way, treatment with this highly potent drug can 
be further optimised.
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General Discussion
Th is thesis was written to gain more information on those drug interactions that play a 
role in the clinical pharmacology of antiretroviral agents. Dose optimizations of several 
antiretroviral regimens were studied to generate evidence for the implications of these 
dose adjustments in clinical practice. Studies on gender, race and pharmacogenetics 
learned us about their roles in variability of drug exposure between patients. Th is 
general discussion will connect the presented studies with their background, being 
antiretroviral treatment of HIV-infected patients. Additionally, attention will be paid 
to the roles of research ethics and research quality.
Drug interactions
Drug interactions of various backgrounds were studied in Chapters 1, 2, 4 and 6. 
Numerous studies on drug interactions involving antiretroviral agents have been 
published so far, and subsequently many reviews have summarized all these data. 
Nevertheless there are still new subjects where additional research needs to be done.
Th e treatment of HIV-infected patients, that suﬀ er from tuberculosis as well, is very 
complicated. As long as rifampin and rifabutin are part of the ﬁ rst-line treatment 
of tuberculosis, multiple potent drug interactions will occur with HAART1. Th is 
has been described in Chapter 1, where two diﬀ erent options for the combination 
of lopinavir/ritonavir with rifampin were studied. Tuberculosis is seen more often 
in HIV-infected persons in the developed countries than it was before2. We have to 
realize that in the developing countries the incidence of tuberculosis among HIV-
infected persons is dramatically higher3-5. When more combinations of tuberculostatic 
and antiretroviral agents are studied, more insight is gained in the treatment of this 
group of patients that suﬀ er from this double infection.
Multiple pre-treated patients are another group of patients where drug interactions 
can be expected more frequently. Th ese patients in general will use more medications 
for the treatment of HIV infection or concomitant disease than patients that just 
started HAART while still being in a relative good health condition. In Chapter 2 
a combination of two protease inhibitors, both boosted by ritonavir was studied in 
multiple pre-treated patients. Including the backbone therapy used by these patients 
at least ﬁ ve diﬀ erent agents were used to control HIV-infection. Apart from HAART 
most of these patients had impressive lists of concomitant drugs for the treatment of 
other diseases. For the medical team surrounding a patient it is very challenging to 
evaluate the occurrence of drug interactions, possibly leading to inactive therapy or 
extra toxicity. 
In Chapter 4 the inﬂ uence of food on the plasma concentrations of indinavir/ritonavir 
and didanosine was studied. Food-drug interactions are common in the treatment 
with antiretroviral agents. Some of the antiretrovirals need to be taken with food 
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to ensure complete absorption6,7. Others have to be taken on an empty stomach to 
avoid a long passage time with risk of decomposition of the drug by the acid from the 
stomach as a result8. Th e diﬀ erent requirements to food intake of the diﬀ erent drugs 
of the HAART regime contributes to more complex regimens, which on their turn 
contribute to lack of compliance9,10. Th erefore it is important to study the eﬀ ects of 
food and be able to make balanced decisions with complexity and compliance on one 
side and antiviral activity and toxicity on the other.
A once daily regimen including nelﬁ navir boosted by ritonavir in combination with 
efavirenz was studied in Chapter 6. Th is combination of drugs leads to complex 
drug interactions, and therefore plasma concentrations of the diﬀ erent drugs of this 
regimen were hard to predict. Th e result of this study is a regimen that might ﬁ nd its 
place among other user-friendly once daily regimens.
Dose optimization
Dose optimizations were studied in Chapters 1, 3, 5 and 7. In individual patients 
dose optimization following therapeutic drug monitoring is a common intervention 
when drug concentrations are outside the therapeutic window. In this way therapeutic 
drug monitoring helps to individualize drug dosages11. 
In several situations, like the occurrence of drug interactions, inactivity or toxicity, 
or when dose frequency is altered, data collection on dose optimization in a study 
is indicated. Th e reason for this is to prevent individual patients from the iterative 
process of dose adjustments following therapeutic drug montoring.
Drug interactions resulting in altered pharmacokinetic proﬁ les, compel for dose 
adjustment of the object drug. In Chapter 1 two diﬀ erent adjusted doses of lopinavir/
ritonavir were studied in combination with rifampin in healthy volunteers. Th e potent 
drug interaction between these drugs were already known, however no solution was 
available12. After the performance of this trial we can give advice with regard to plasma 
lopinavir concentrations and side eﬀ ects that are expected. 
Lower doses of indinavir were studied in healthy volunteers as described in Chapter 
5. Th is study provided pharmacokinetic data for a dose reduction that was already 
adopted in the treatment of patients experiencing toxicity13,14. Th e regimens studied 
here are currently being evaluated in patients, to diminish toxicity without turning 
in antiviral activity. An additional advantage of these dose reductions from 800/100 
mg indinavir/ritonavir BID to 600/100 mg BID or even 400/100 mg BID is the 
reduction of medication costs.
A dose adjustment from 1250 mg nelﬁ navir BID to 1500 mg BID is common in 
patients with low nelﬁ navir plasma levels. Nevertheless no data existed whether or not 
such a dose adjustment resulted in the desired eﬀ ect. Chapter 7 describes that this 
dose adjustment was successful in only a minority of patients. Th is illustrates that it is 
necessary to evaluate the eﬀ ect of dose adjustments in clinical practice. 
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Another example of this observation was found in the development of a once daily 
regimen containing lopinavir/ritonavir 800/200 mg, studied in Chapter 3. In this 
study in patients, a lower threshold for lopinavir trough concentrations was deﬁ ned to 
ensure antiviral activity. Subsequently, patients with plasma concentrations below this 
value were subjected to a dose increase. It was found that these dose adjustments were 
not likely to be successful. 
Gender, race and pharmacogenetics
Th ere are no two patients that are the same, which is important to realize in the search 
for diﬀ erences between groups of patients. Two studies in this thesis, described in 
Chapters 8 and 9, were undertaken to explain interpatient variability in nevirapine and 
efavirenz plasma concentrations. In these studies common parameters like gender, race 
and genetics were studied to group patients with plasma concentrations diﬀ erent from 
the mean. In clinical practice data from these studies can help to evaluate individual 
patients. Th e occurrence of toxicity or the absence of activity can then sometimes be 
anticipated, which eases clinical management of patients. 
Emergence of research questions 
Th e study of drugs in human beings is an interesting part of drug development. After 
the initial phases of synthesizing new compounds with possible pharmacological 
eﬀ ects in-vitro tests follow. Positive results in in-vitro tests will be followed by tests 
in animals and ﬁ nally the new compound is tested in humans. When this sequence 
of studies results in satisfying data the new drug will be registered in a certain dose 
regimen for a certain indication. 
Although this registration by the authorities is the result of a critical evaluation, 
questions may raise when the drug is used in practice in a patient population, that 
diﬀ ers from the study group. Th ese patient populations generally will diﬀ er from the 
study populations used to resemble data for registration, with regard to age, gender 
and co-morbidity and number of patients. When more patients are treated with the 
new drug, new properties will be discovered, that were unknown until then. Th ese 
properties can be related to eﬀ ectivity, drug interactions and adverse events. 
Th e combinations of several drugs in the treatment of HIV-infected persons make 
the chance to encounter problems even higher. Th e studies presented in this thesis 
originated from problems and questions encountered during the treatment of HIV-
infected persons, with already licensed drugs. 
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Objectives for clinical research
Questions derived from the treatment of patients with certain drugs are not yet ﬁ t for 
medical research. To be able to answer a certain question it is necessary to translate it 
into an objective for a study. It may be evident that this is a very crucial step in the early 
development of a new study. Performing a clinical study is an expensive and laborious 
process. It is very important to obtain as much information from the study as possible. 
On the other hand one should realize that answering multiple questions in one trial is 
challenging. Multiple objectives compel large study populations, sample sizes, which is 
sometimes hard to realize, for reasons of capacity and costs. 
Th e calculated sample size is a result of the anticipated eﬀ ect of the intervention studied 
and additional factors like precision of measurement and the desired precision of the 
answer. If the sample size is too small it will be impossible to answer the objectives 
with suﬃ  cient statistical power. 
In the study protocol, which describes the course of the study, the objectives should 
clearly be described. Th e objectives are primary or secondary according to the 
importance of the objective and the burden of proof the researcher expects to ﬁ nd. Th e 
objectives of the study will clearly direct the design of the study. For example, studies 
like in Chapters 2 and 3, evaluating long term activity of an antiretroviral regimen will 
not succeed when the follow up is limited to 4 weeks. Th e objectives of the study will 
also direct the choice for a study population.
Study population
When the objectives are clearly deﬁ ned time has come to select a proper study 
population. Th e study population included in clinical research can consist of patients 
or healthy volunteers. A well-deﬁ ned set of inclusion and exclusion criteria will always 
be needed to select a subgroup as necessary. 
If disease related parameters need to be studied like viral loads and CD4 cell counts or 
long-term adverse events, HIV-infected patients need to be studied. For these reasons 
patients were studied in Chapters 2 and 3. Data sets on larger groups of subjects 
as needed in Chapters 8 and 9 lead to the choice for patients as well. It would have 
been very aggravating to expose these numbers of healthy volunteers to the use of 
drugs. Short-term data collections were needed on pharmacokinetics of one or more 
(interacting) agents in Chapters 1, 4, 5 and 6, which could be studied best in healthy 
volunteers. Th ese studies technically could have been performed in patients as well, 
however we could not guarantee antiviral activity of the regimens studied.
Ethics in clinical research 
”Medical research involving human subjects should only be conducted if the 
importance of the objective outweighs the inherent risks and burdens to the subject. 
Th is is especially important when the human subjects are healthy volunteers” 15. 
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Th is is a statement from the Declaration of Helsinki and illuminates an important 
issue in the development of a clinical study with regard to the patients or healthy 
volunteers. Healthy volunteers, unlike patients will not obtain medical beneﬁ t from 
the treatment oﬀ ered in the study. We have to realize that study subjects are exposed 
to risks, for the potential beneﬁ t of other human beings. A risk-beneﬁ t assessment 
helps the researcher to ﬁ nd the optimum between the risks for the study subjects and 
the beneﬁ ts for society. 
Risk management in clinical research
Risks for participants to clinical research can be estimated by determining probability, 
magnitude and duration of harm. With knowledge of potential harms, risks must be 
minimized within the context of designing and conducting a valuable study. A way 
to minimize subject risks is the deﬁ nition of a set of inclusion and exclusion criteria 
that will rule out subjects that are at increased risk for harm to be expected from the 
study16. Such measures will result in less drop out of study subjects, which is a positive 
eﬀ ect for both study subjects and the study itself, as statistics will not be valuable if 
there are too few subjects left. 
Th e study described in Chapter 1 was a study in healthy volunteers. Th e subjects in 
this study were treated with lopinavir/ritonavir combined with rifampin in the second 
part of the study. Th e dosage of lopinavir/ritonavir was increased in the second part 
of the study. In total 12 of 32 subjects dropped out of the study due to adverse events 
and liver enzyme elevations. Although this high rate of adverse events occurred, risk 
management succeeded in this particular study. Study medication was stopped in 
those subjects that reached toxicity grades as pre-deﬁ ned in the study protocol. After 
study medication was discontinued in these subjects’ adverse events disappeared and 
liver enzymes normalized. In general, less adverse events or toxicities are accepted in 
a healthy volunteer study in comparison to the treatment of patients. Th is is due to 
the fact that healthy volunteers will not experience medical proﬁ t from the treatment. 
Patients suﬀ ering from adverse events can still experience medical proﬁ t, especially 
when there are no other treatment options left.
Another example of risk management in a healthy volunteer study is found in Chapter 
4. It was found that the objectives of this study could be answered by a single dose 
study. Th is meant that the subjects had to takes single dosages on four consecutive 
study days only. It may be evident that this resulted in less medication related risk 
compared to a two week multiple dose study.
In the development and execution of a clinical trial ﬁ ve diﬀ erent complementary 
actors, responsible for the risk management of study subjects, can be distinguished17. 
Each of these ﬁ ve actors has its own role and challenge in this risk management. First, 
the investigators need to make responsible decisions while developing or executing the 
study. Detailed knowledge helps the investigators to balance risk and beneﬁ t in these 
processes. In an undesirable situation the investigator may have conﬂ icts of interest of 
scientiﬁ c or ﬁ nancial nature, which should be avoided whenever possible. Secondly, 
Institutional Review Boards (IRBs) will evaluate the scientiﬁ c and ethical integrity of 
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the study protocol. It is important that the IRB has members that represent a broad 
spectrum of scientiﬁ c specialisms. Th irdly, there are bodies other than IRBs ensuring 
regulatory compliance and responsible research. Th ese bodies however fulﬁ l their 
function with more distance from the study protocol and the researcher. Th erefore 
these bodies evaluate the study protocols at a less detailed level, resulting in less 
power to recognize an unbalanced risk beneﬁ t ratio. Fourthly, research sponsors have 
a responsibility to evaluate and adjust the safety of the trial, but suﬀ er from ﬁ nancial 
conﬂ icts of interest. Fifthly, monitoring bodies and committees can assess the safety 
of the trial while being executed. Th ese bodies should operate independently under 
recognized guidelines and have the power to improve safety of the trial or in extreme 
situations of harm to stop a trial prematurely.
Quality in clinical research
Good clinical practice (GCP) is important in the performance of clinical studies. As 
pointed out above it is in the interest of both the participants of a study and society 
that is requesting a study, that quality of clinical research is guaranteed. Quality in 
clinical research was an important reason to explore diﬀ erent ways of working in the 
diﬀ erent studies in this thesis. We learned from our cooperation with a clinical research 
organisation and study monitors. In the case of the study presented in Chapter 1 the 
combined measures on quality control supported submission of the study report to the 
Food and Drug Administration (FDA).
Th e clinical research organisation
Th e healthy volunteer study presented in Chapter 1 and later the study presented 
in Chapter 6 were the ﬁ rst studies that we conducted in cooperation with a clinical 
research organisation (CRO). Th e CRO executed the practical part of these studies, 
including recruiting healthy volunteers, examining their medical status and admitting 
the healthy volunteers for drug administration and blood sampling. We developed the 
study protocols and measured the drug concentrations in blood samples obtained from 
the healthy volunteers in our own laboratory. Th is cooperation lead to substantial more 
professionalism in the conduct of those studies. Both these studies have numbers of 
participants that are larger than most of the studies we had performed before. At that 
time our own setting did not allow us to perform studies with 24 to 32 participants, as 
capacity was not big enough. 
Apart from being able to execute the study in one group with up to 32 healthy 
volunteers we learned from the collaboration with the clinical research organisation. 
We prepared trial documents, including study protocol, case report form (CRF), 
study report and several other documents, in collaboration with the CRO. Th ere is 
an important coherence between all these documents and it is important to recognize 
this coherence to be able to make them user-friendly. Th is coherence starts with the 
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uniform graphical design of the documents, but also includes the format of data entry 
in the diﬀ erent documents. Coherence also means that all documents have to be 
consistent with each other. Consistent documents help prevent errors possibly made 
by the diﬀ erent members of the team working on a study. Chain quality improves by 
such measures and therefore the results of the study are even more valuable. 
After performing the mentioned studies with the CRO more studies followed in this 
cooperation. However, as total study costs are higher in such cooperation there will be 
need to perform studies in our own setting as well. Nevertheless we will incorporate 
the knowledge from this fruitful cooperation in future research.
Study monitoring and audit
A third party in performing a clinical study can help control quality. We have experience 
with third parties in the form of study monitors and auditors, both contributing to 
quality control in their own way.
A study monitor was appointed by the sponsor of the studies presented in Chapters 
1 and 6. Th e study monitor is responsible for controlling data entry and visiting the 
study site. Th e study monitor raises questions comprising missing or invalid data from 
the case report forms. 
An internal audit is performed by the CRO to control for deviations from the study 
protocol and standard operating procedures while performing the study. Th e auditor 
pays attention to the procedures followed and their execution in practice by the 
personnel. Th e auditor reports deviations when necessary followed by feedback to 
prevent repetition of the deviation.
Future aspects
We have to keep in mind that a good study design, followed by a perfectly executed 
trial and a robust statistical analysis alone will not result in meaningful data, if 
knowledge and research philosophy, with regard to the research area, are lacking. Th e 
studies presented in this thesis may lead to better antiretroviral treatment in patients. 
Nevertheless ongoing research is necessary, as new antiretroviral agents will become 
available with their own characteristics. Th is will be an ongoing process as long as 
there is no cure for the infection with HIV. Since the beginning of the HIV pandemic, 
research has brought major improvements in the life expectancy of HIV-infected 
patients. Although this development gives hope, more than 90% of HIV-infected 
persons in the world are living in developing countries and still have no access to 
treatment. We have to realize that for our studies to be meaningful, global access to 
care is urgent. 
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Summary
In this thesis the clinical pharmacology of antiretroviral agents has been approached 
with a focus on drug interactions and dose optimization. Antiretroviral drugs are in 
use for the treatment of HIV-infected persons. Clinical pharmacology is the study of 
the relationship between concentration of the drugs in blood and their eﬃ  cacy and 
toxicity. Th is thesis comprises research with the diﬀ erent antiretroviral drugs.
In Part I of the thesis three studies with lopinavir are presented. In Chapter 1 blood 
concentrations of lopinavir after adjusted doses of lopinavir/ritonavir 800/200 mg or 
400/400 mg twice daily with rifampin and after normal doses of lopinavir/ritonavir 
400/100 mg twice daily alone were compared. Th e ﬁ rst choice tubercolustatic drug 
rifampin accelerates the breakdown, metabolism, of lopinavir. For this reason lopinavir 
combined with rifampin leads to plasma concentrations of lopinavir, which are too low 
to be antiretroviral eﬀ ective. Lopinavir is always combined with ritonavir as ritonavir 
positively inﬂ uences lopinavir plasma concentrations. It appeared that the higher doses 
of lopinavir/ritonavir may allow concomitant use of rifampin. Nevertheless plasma 
concentrations of lopinavir need to be checked in patients to assure eﬀ ective therapy. 
As described above, ritonavir is used to improve, to boost, plasma concentrations of 
lopinavir. Th is eﬀ ect can be used for other protease inhibitors like saquinavir, indinavir 
and nelﬁ navir as well. In Chapter 2 ritonavir was used to boost both lopinavir and 
saquinavir. Seven patients that failed several other antiretroviral cocktails were 
given lopinavir/ritonavir in a dose of 400/100 mg twice daily, together with 1000 
mg saquinavir twice daily. In addition several other drugs were used. Th e plasma 
concentrations of lopinavir and saquinavir were comparable with literature data. Th is 
indicated that ritonavir was capable to boost plasma concentrations of lopinavir and 
saquinavir simultaneously. Th e tolerability of the regimen was good and eﬃ  cacy was 
encouraging. In the treatment of HIV-infected persons there is an increasing interest 
in antiretroviral cocktails that can be dosed once daily rather than twice daily. For 
lopinavir/ritonavir, only sparse data are available on plasma concentrations and the 
diﬀ erences between patients after once daily administration. Chapter 3 presents a 
study in 20 HIV-infected persons treated with lopinavir/ritonavir 800/200 mg once 
daily. Plasma concentrations of lopinavir as well as the eﬀ ect of dose modiﬁ cations 
in case of ineﬀ ective plasma concentrations were studied. Once daily administration 
of lopinavir/ritonavir resulted in plasma concentrations of lopinavir, which were 
on average similar compared to twice-daily administration, with the exception of a 
somewhat lower plasma concentration just before the next dose was given. Th erapeutic 
drug monitoring may be helpful in identifying patients with lower-than-expected LPV 
exposure. However, dose modiﬁ cations did not lead to Ctrough levels above 1.0 mg/L in 
the majority of the patients in this study.
In Part II of this thesis two studies with the protease inhibitor indinavir are presented. 
In Chapter 4 the combination of indinavir/ritonavir with didanosine enteric-coated 
(EC) was studied. Didanosine EC should be taken on an empty stomach, but the once 
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daily combination of indinavir/ritonavir can best be taken with food. Because these 
drugs are frequently included in 1 regimen, the food eﬀ ects on the pharmacokinetics 
were evaluated. In this study, the regimen dosing didanosine EC 400 mg + indinavir/
ritonavir 1200/400 mg once daily with breakfast indicated no decrease in the amount 
of absorption for either didanosine and indinavir and that this regimen could be 
administered with food. Reduced dosages of twice daily indinavir boosted by low-dose 
ritonavir were studied in Chapter 5 to assess the pharmacokinetics and tolerability in 
healthy volunteers. Indinavir/ritonavir 400/100 mg twice daily resulted in signiﬁ cant 
lower indinavir exposure, with three out of 15 subjects revealing Cmin values below the 
recommended threshold for wild-type virus of 0.10 mg/l. Tolerability, however, was 
lower in the 600 mg indinavir group. Th erapeutic drug monitoring in the individual 
patient appears to be necessary to guarantee appropriate drug levels and simultaneously 
minimize toxicity.
Part III of the thesis presents two studies with the protease inhibitor nelﬁ navir. In 
Chapter 6 the eﬀ ect of efavirenz on the pharmacokinetics and tolerability of once 
daily nelﬁnavir/ritonavir was evaluated in healthy subjects. A once daily nucleoside-
sparing regimen can prevent mitochondrial toxicity, overcome viral resistance and 
improve compliance. Nelﬁnavir/ritonavir given together with efavirenz resulted in 
a 48% higher mean C24 concentration for nelﬁnavir, and the sum of nelﬁnavir and 
M8 C24 concentrations was 0.99 mg/L. Th e studied regimens were well tolerated. 
Efavirenz exposure in this study was similar to that reported previously, and therefore 
can be used eﬀ ectively in combination with ritonavir and nelﬁnavir. In Chapter 7 a 
nelﬁ navir concentration ratio (CR) <0.90 was observed in 56 patients receiving 1250 
mg twice daily. Such low nelﬁ navir plasma concentrations have been associated with 
failure of therapy. In 38 patients the dosage was adjusted to 1500 mg twice daily, in 18 
patients no adjustment was done. Dose adjustment to 1500 mg twice daily resulted in 
a CR >0.90 in only 45% of patients. For patients with an initial CR <0.52 this was 
7%. From this study it was concluded that dose adjustments were only successful in a 
minority of patients.
In Part IV non-nucleosides were the subject of research in two studies. In Chapter 8 
interpatient variability of nevirapine is subject of study. Th e literature suggests gender 
and ethnicity as possible causes for interpatient variability of pharmacokinetics. In 
this study the association of ethnicity, gender and other demographic factors with 
nevirapine plasma concentrations were evaluated. Higher nevirapine levels were seen 
in non-Caucasian versus Caucasian patients, and higher average nevirapine levels were 
observed in female Caucasians compared to male Caucasians. As a result physicians 
should be alert for a higher risk for toxicity when treating females or non-Caucasian 
patients with nevirapine. In Chapter 9 the eﬀ ects of gender and ethnicity on the 
pharmacokinetics of efavirenz were studied. Th e pharmacokinetics of efavirenz is 
characterized by large interpatient variability. In a preliminary analysis of patients 
from our Th erapeutic drug monitoring service, signiﬁ cantly higher efavirenz plasma 
levels were observed in females. Sex and race are important factors in determining 
the interpatient variability in efavirenz plasma levels. Th is eﬀ ect is not caused by 
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low CYP2B6 activity as determined by single nucleotide polymorphism analysis. 
Physicians should primarily be alert for signs of efavirenz-induced toxicity in females 
and non-Caucasian patients.
In the General Discussion a connection between the presented studies and their 
background, being antiretroviral treatment of HIV-infected patients, is made. 
Additionally, attention is paid to the roles of research ethics and research quality. Th e 
studies presented in this thesis may lead to better antiretroviral treatment in patients. 
Nevertheless ongoing research is necessary, as new antiretroviral agents will become 
available with their own characteristics. Th is will be an ongoing process as long as 
there is no cure for the infection with HIV. Since the beginning of the HIV-pandemic, 
research has brought major improvements in the life expectancy of HIV-infected 
patients. Although this development gives hope, more than 90% of HIV-infected 
persons in the world are living in developing countries and still have no access to 
treatment. We have to realize that for our studies to be meaningful, global access to 
care is urgent.
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Samenvatting
In dit proefschrift wordt de klinische farmacologie van antiretrovirale geneesmiddelen 
benaderd met een focus op geneesmiddelinteracties en dosisoptimalisatie. Anti-
retrovirale geneesmiddelen worden gebruikt voor de behandeling van patiënten die 
met HIV zijn geïnfecteerd. Klinische farmacologie is de studie naar de verbanden 
tussen concentraties van geneesmiddelen in het bloed en hun eﬀ ectiviteit en toxiciteit. 
Dit proefschrift omvat onderzoek met verschillende antiretrovirale geneesmiddelen.
In Deel I van het proefschrift worden drie studies met lopinavir gepresenteerd. In 
Hoofdstuk 1 worden plasma concentraties van lopinavir na aangepaste doseringen 
lopinavir/ritonavir 800/200 mg of 400/400 mg tweemaal daags met rifampicine 
en na normale doseringen lopinavir/ritonavir 400/100 mg tweemaal daags zonder 
rifampicine vergeleken. Het eerste keus geneesmiddel voor de behandeling van 
tuberculose, rifampicine, versnelt de afbraak, het metabolisme, van lopinavir. Om deze 
reden leidt de combinatie van lopinavir en rifampicine tot plasma concentraties van 
lopinavir, die te laag zijn om eﬀ ectief te zijn tegen HIV. Lopinavir wordt altijd gegeven 
in combinatie met ritonavir, omdat ritonavir de plasma concentraties van lopinavir 
positief beïnvloedt. Uit de studie bleek dat de hogere doseringen lopinavir/ritonavir 
het gebruik van rifampicine mogelijk maken. Desalniettemin zal het nodig zijn de 
lopinavir plasma concentraties te controleren om eﬀ ectieve therapie te verzekeren. 
Zoals hierboven beschreven, wordt ritonavir gebruikt om concentraties van lopinavir 
te verbeteren; te boosten. Dit eﬀ ect kan ook voor andere proteaseremmers zoals 
saquinavir, indinavir en nelﬁ navir gebruikt worden. In Hoofdstuk 2 wordt ritonavir 
gebruikt om zowel lopinavir als saquinavir te boosten. Zeven HIV-patiënten die 
gefaald hadden op eerdere antiretrovirale cocktails kregen lopinavir/ritonavir in een 
dosering van 400/100 mg tweemaal per dag, samen met 1000 mg saquinavir tweemaal 
per dag. Verder werden nog diverse andere geneesmiddelen gebruikt. De plasma 
concentraties van lopinavir en saquinavir waren vergelijkbaar met data uit de literatuur. 
Dit gaf aan dat ritonavir in staat is om de plasma concentraties van lopinavir en 
saquinavir gelijktijdig te boosten. De medicatie werd goed verdragen en de eﬀ ectiviteit 
was bemoedigend. Er is een groeiende belangstelling voor antiretrovirale cocktails die 
éénmaal daags ingenomen kunnen worden in plaats van tweemaal daags, vanwege het 
gemak voor de patient. Voor lopinavir/ritonavir zijn er beperkte data beschikbaar 
over de verschillen tussen patiënten na éénmaal daagse dosering. Hoofdstuk 3 
omvat een studie in 20 HIV-patiënten die behandeld werden met lopinavir/ritonavir 
800/200 mg éénmaal daags. Zowel de lopinavir plasma concentraties als het eﬀ ect van 
dosisaanpassingen in het geval van subtherapeutische plasma concentraties werden 
bestudeerd. Eenmaal daagse inname van lopinavir/ritonavir resulteerde in lopinavir 
plasma concentraties, die gemiddeld genomen vergelijkbaar waren met tweemaal 
daagse inname, uitgezonderd een iets lagere plasma concentratie op het moment net 
voor de volgende dosering. Th erapeutic drug monitoring kan behulpzaam zijn bij het 
identiﬁ ceren van patiënten met lopinavir plasma concentraties die lager zijn dan 
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verwacht. Desondanks leidde het aanpassen van de dosering in een meerderheid 
van de patiënten in deze studie niet tot een dalspiegel hoger dan 1,0 mg/l.
In Deel II van dit proefschrift worden twee studies met de proteaseremmer indinavir 
gepresenteerd. In Hoofdstuk 4 wordt de combinatie van indinavir/ritonavir met 
didanosine enteric-coated (EC) bestudeerd. Didanosine EC moet op een nuchtere 
maag ingenomen worden, terwijl de éénmaal daags te doseren combinatie van 
indinavir met ritonavir bij voorkeur met voedsel moet worden ingenomen. Omdat 
deze geneesmiddelen frequent worden gecombineerd in een cocktail, werden de 
voedseleﬀ ecten op de farmacokinetiek geëvalueerd. Deze studie laat zien dat de 
combinatie van didanosine EC 400 mg éénmaal daags + indinavir/ritonavir 1200/400 
mg éénmaal daags, gegeven met ontbijt, geen afname in de opname van didanosine 
en indinavir gaf. De medicatie kan dus met voedsel worden ingenomen. Lagere 
doseringen indinavir tweemaal daags samen met een lage dosering van het 
boosting ritonavir worden bestudeerd in Hoofdstuk 5 om de farmacokinetiek en 
verdraagbaarheid in gezonde vrijwilligers te testen. Indinavir/ritonavir 400/100 mg 
tweemaal daags gaf een signiﬁ cant lagere indinavir blootstelling, waarbij 3 van de 15 
deelnemers minimale plasmaconcentraties hadden die lager waren dan de aanbevolen 
grenswaarde van 0,10 mg/l. De verdraagbaarheid was echter lager na 600 mg indinavir. 
Th erapeutic drug monitoring lijkt nodig te zijn voor de individuele patiënt om goede 
bloedspiegels te kunnen garanderen en tegelijkertijd toxiciteit te minimaliseren.
Deel III van het proefschrift presenteert twee studies met de proteaseremmer 
nelﬁ navir. In Hoofdstuk 6 wordt het eﬀ ect van efavirenz op de farmacokinetiek 
van éénmaal daags nelﬁ navir/ritonavir geëvalueerd in gezonde vrijwilligers. Een 
éénmaal daags nucleoside-sparend regime kan mitochondriale toxiciteit voorkomen, 
virale resistentie doorbreken en therapietrouw verhogen. Nelﬁ navir/ritonavir samen 
met efavirenz resulteerde in een 48% hogere gemiddelde nelﬁ navir bloedspiegel 
24 uur na inname en de som van de nelﬁ navir en M8 24 uurs spiegels was 0,99 
mg/l. De bestudeerde regimes werden goed verdragen. Efavirenz-blootstelling 
was in deze studie vergelijkbaar met wat eerder gerapporteerd was en efavirenz 
kan daarom eﬀ ectief gebruikt worden in combinatie met ritonavir en nelﬁ navir. In 
Hoofdstuk 7 wordt in 56 patiënten die 1250 mg nelﬁ navir tweemaal daags kregen 
een concentratie ratio (CR) <0.90 gezien. Dergelijk lage nelﬁ navir plasmaspiegels zijn 
geassociëerd met therapie-falen. Bij 38 patiënten werd de dosering aangepast naar 
tweemaal daags 1500 mg en bij 18 patiënten werd geen aanpassing gedaan. De 
dosisaanpassingen naar 1500 mg tweemaal daags resulteerden in een CR >0.90 in slechts 
45% van de patiënten. Voor patiënten met een initiële CR <0.52 was dit 7%. Uit deze 
studie kan worden geconcludeerd dat dosisaanpassingen slechts in een minderheid van 
patiënten succesvol is.
In Deel IV zijn de non-nucleosides het onderwerp van onderzoek in twee studies. In 
Hoofdstuk 8 is de variabiliteit in farmacokinetiek van nevirapine tussen patiënten het 
onderwerp van het onderzoek. De literatuur laat geslacht en etniciteit zien als mogelijke 
oorzaken van variabiliteit. In deze studie werd de associatie tussen etniciteit, geslacht 
en andere demograﬁ sche factoren onderzocht. Hogere nevirapine-spiegels werden 
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gezien in niet-caucasische patiënten vergeleken met caucasische patiënten en hogere 
spiegels werden gezien in vrouwelijke caucasische patiënten vergeleken met mannelijke 
caucasische patiënten. Om deze reden zouden artsen zich ervan bewust moeten zijn 
dat er een hoger risico op toxiciteit is wanneer vrouwen of niet caucasische patiënten 
met nevirapine behandeld worden. In Hoofdstuk 9 worden de eﬀ ecten van geslacht 
en etniciteit op de farmacokinetiek van efavirenz bestudeerd. De farmacokinetiek 
van efavirenz wordt gekenmerkt door een grote variabiliteit tussen patiënten. In een 
preliminaire analyse van patiënten uit onze Th erapeutic drug monitoring service, 
werden signiﬁ cant hogere efavirenz plasmaspiegels gezien in vrouwen. Geslacht en 
ras zijn belangrijke factoren bij het bepalen van de variabiliteit van efavirenz tussen 
patiënten. Dit eﬀ ect wordt niet veroorzaakt door lage CYP2B6 activiteit zoals bepaald 
met single nucleotide polymorﬁ sme analyse. Artsen zouden oplettend moeten zijn 
voor tekenen van efavirenz geïnduceerde toxiciteit bij vrouwen en niet-caucasische 
patiënten.
In de Algemene Discussie wordt een verband gelegd tussen de gepresenteerde studies 
en hun achtergrond, namelijk de behandeling van HIV patiënten. Aanvullend wordt 
er aandacht besteed aan de rol van onderzoeksethiek en kwaliteit van onderzoek. 
De studies zoals gepresenteerd in dit proefschrift kunnen leiden tot een betere 
antiretrovirale behandeling van patiënten. Desalniettemin is verdergaand onderzoek 
nodig, omdat nieuwe antiretrovirale middelen, met hun eigen karakteristieken, 
beschikbaar zullen komen. Dit zal een voortdurend proces zijn zolang er geen 
echte genezing van HIV mogelijk is. Sinds het begin van de HIV-pandemie heeft 
onderzoek geleid tot grotere verbeteringen in de levensverwachtingen van HIV-
patiënten. Alhoewel deze ontwikkeling hoop geeft, leeft meer dan 90% van de HIV-
patiënten in ontwikkelingslanden, zonder toegang tot adequate behandeling. We 
moeten ons realiseren dat, om onze studies zinvol te laten zijn, wereldwijde toegang 
tot deze zorg urgent is.
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